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Synthesis of Novel Platinum Oxadiazoline Complexes with 
Potential Anti-tumour Activity.
Julien Saiju MRSC Supervisor, Dr G.S. Wagner.
Abstruct: in the framework of this project, a series of platinum 1,2,4-
oxadiazoline complexes was produced. These complexes were tested in vitro for anti- 
tumoui* effect and have been found to exhibit anti-tumoui* activity in ovarian, 
testicular and colon cell cultures. One complex, JS5, /ra«j'-dichlorobis{2-methyl-3- 
phenyl-5-(4-hydi’oxyphenyl)-A"^-1,2,4-oxadiazoline}platinum(II), 
^ra«5-[PtCl2{N=C(p-HO-C6H4)-0-N(Me)-CH(Ph)}2](product 45), proved to be twice 
as effective as carboplatin and also showed good activity in carboplatin resistant cell 
lines. Another complex JS6, ?raz7.y-dichloro(4-(2-methoxyethoxy)benzonitrile){2- 
methyl-3-phenyl-5-(4-(2-methoxyethoxy)phenyl)-A'^-l,2,4-oxadiazoline}platinum(II), 
/rfl«5-[PtCl2(p-Me0C2H40-C6H4CN){N=C(p-Me0C2H40-C6H4)-0-N(Me)-CH(Ph)}] 
(product 41), proved to be more effective in carboplatin resistant cell lines than 
platinum sensitive ones. This suggests a binding mode different to the accepted one 
exhibited by cisplatin, which is to the N7 nitrogen of guanine. The synthetic strategy 
employed was the [2+3] cycloaddition of platmum nitrile complexes to nitrones. This 
method was chosen as it is a straight forward route to the platinum heterocycles, using 
relatively mild conditions. Also, properties such as solubility of the platinum 
oxadiazoline in polar solvents can easily be modified by using starting nitrones and 
platinum nitriles that contain polar substituents. The starting reagents for these 
compormds are commercially available, simplifying the overall synthesis. In this way 
the ligand is constructed in the coordination sphere and subtle changes are effected 
without altering the basic skeleton of the complex.
Nitrones of the type RC6H4 CH=NOCH3 (R= OH, CO2H, 2 -CH3OC2H4 O, N(Me)2 , 
lSf(Me)3 , and sodium sulphonate salt), were prepared from the corresponding 
aldehydes via the condensation of an aldehyde with A-methyl-hydroxylamine method. 
Novel platinum complexes of the type PtX2 (RC6H4 CN)2 , (X= halogen, R = OH, 2- 
CH3 OC2 H4 O, were also prepar ed by a modification of the Kliarasch route.
Both mono and bis A'^ -1,2,4-oxadiazoline platinum complexes were produced that 
were more soluble in polar* solvents than previously known similar* complexes.
Substitution and oxidative addition reactions of the said oxadiazoline platinum 
complexes were also studied and are discussed. The synthesis of analogous ruthenium 
complexes was attempted, but ruthenium did not behave in the same way as platinum.
KcVW OVds: nitrones, cycloaddition, platinum complexes, anti-tumom*.
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1. Introduction.
Since the serendipitous discovery that cisplatin (cw-dichlorodiammine platinum(II)) 
inhibited the growth of bacteria by Rosenberg and co-workers some 40 years ago', 
research has been unrelenting in an effort to find anti-tumour platinum complexes. 
Barnett Rosenberg, shown in figure 1, was a biophysicist at the Michigan State 
University, and also had an interest in electrochemistry, so he had a broad scientific 
background. He had observed through his microscope that in bacterial cells 
undergoing mitotic division, the chromatids migrate to the polar regions of the cells. 
This reminded him of experiments he did as a schoolboy using bar magnets and iron 
filings. He tried to investigate this by applying an electric current with its associated 
magnetic field to bacterial soup. He used a platinum electrode which at that time was 
thought to be chemically inert. He found that the growth of the cells was inhibited, 
and with further investigation discovered cisplatin, and its tetrachloro platinum(IV) 
analogue, had been produced at the platinum electrode during the reaction, and that 
these were responsible for the observed inhibition^’^ .
© State University of Michigan 
Figure 1. Barnett Rosenberg; the founder of platinum chemotherapy.
Bacteria, like cancer cells, are rapidly dividing, and it was thought that if cisplatin 
inhibited the growth of one it would work for the other too. This was subsequently 
shown to be the case when Rosenberg’s team carried out experiments on mice bearing
Sarcoma 180 and Leukemia LIZIO^ '^" .^ In the wake of their research cisplatin entered 
phase 1 clinical trials in 1971* and received approval in 1978 for the treatment of 
testicular and ovarian cancer. Cisplatin is very effective at treating these cancers, but 
is also used in combination with other drugs in the treatment of oropharyngeal 
carcinoma, bronchogenic carcinoma, cervical carcinoma, bladder carcinoma, 
lymphoma, osteosarcoma, melanoma and neuroblastoma However, due to the 
toxicity of cisplatm and the Ihnited range of cancers treatable with it, the search has 
been on for platinum complexes that:
1 . are more selective (i.e. they selectively attack tumoirrs),
2 . attack a greater range of tumours,
3. have less severe side effects,
4. are more orally bioavailable.
It is thought that by making the complexes more selective in the tissues they attack, 
side effects will be reduced as a result. Oral broavailability is important as patients are 
less likely to be put off by a treatment not involving intravenous injections, and oral 
medicine could be administered as out-patient treatment without the need for long 
stays in hospital. Recent research has produced many water soluble platinum 
complexes, for example the platinum(IV) complexes of the type A2 PtCl2 (OH) 2  where 
A is a bidentate diamino ligand, made by E.J. Lee and co-workers in Korea in 1999'''. 
Whilst these complexes are water soluble, they ar e too polar to pass through the fatty 
stomach lining and ar e thus of no use as oral anti-tumour drugs as they never reach 
the site of action.
Whilst research has produced many thousands of platinum compounds over the last 
40 years, in the main cisplatm analogues, initially only one of these analogues 
received worldwide approval. This is carboplatin", and its structure and that of 
cisplatin are shown in figures 2  (b) and 2  (a) below.
o
C ,^  /C ,
/ \ NKH3 N
Figure 2. (a) Cisplatm
O
(b) Cai-boplatin.
Carboplatin is only useful on the same range of tumours as cisplatin; whilst it is 
slightly less active, it is also far less toxic with a daily dosage of 2 0 0 0  mg possible, 
compai'ed to 100 mg for c i s p l a t i n ^ A  third complex, oxaliplatin^ '^^  ^ (figuie 3(a)) 
has been granted a partial licence in some European countries for certain colorectal 
cancers, and more recently has been approved for metastatic colon cancer by the FDA 
in America. A similar complex nedaplatin (figure 3b) has received approval in 
Japan^ '^^^
,0
‘NH2
H.N. / O —  
H,N ^ o -
O
Figure 3. (a) Oxaliplatin (b) Nedaplatin.
The reason for this lack of progress is the constraints that were placed on researchers 
after the discovery of cisplatin’s anti-tmnour effect. Bearing in mind this was 
completely accidental, researchers went on to state that to be an effective anti-cancer 
agent, new platinum complexes should be:
1. Square planar cis complexes (trans complexes were believed to be inactive as 
initial tests on transplatin showed it to be inactive and more toxic than 
cisplatin).
2. Have two leaving groups (preferably anionic) such as chloride in the cis 
position.
3. Have two non-leaving ligands such as amino (preferably primary) in the other 
cis positions.
4. The complexes should be electronically neutral.
These structme activity rules were formalized by Cleare and Hoeschele in 
Better understanding of the mechanism of binding of platinum, and the chemistry of 
platmum(II) and platinum(IV) in general has led to a rethink in strategy, and now 
/ra«5 -platinum, platinum(IV) and polynuclear complexes are being studied^
The pmpose of this study is to produce platinum complexes that contain polar as well 
as non-polar moieties, making them orally bioavailable and able to pass through the 
stomach lining and other hpophilic tissues. Analogous ruthenium complexes will also 
be attempted, as similai' ruthenium complexes have been shown to possess anti­
tumour activity* '^^ ®, and also to have anti-bacterial effect, e.g. in the treatment of 
Chagas’ disease^^. Ruthenium has the advantage of being available in its two most 
common oxidation states, ruthenium(ÏI) and ruthenium(III). Ruthenium(III) is more 
inert towards substitution reactions than ruthenium(II) and allows the possibility of 
introduction into a biological system of inert complexes. These could be reduced in 
the reducing environment of the hypoxic tissue of tumouis to more active 
ruthenium(II) complexes^®. This may have special significance in the treatment of 
cancer especially with regards to side effects, as the ruthenium(II) complexes would 
tai’get cancer tissue DNA and not healthy tissue.
2. Background.
The vaiiety of cancer chemotherapy dings is laige, from the comparatively simple 
inorganic molecule cisplatin to the large and complex natural products such as 
vinblastme (figure 4). This was originally extracted from the Madagascan periwinkle 
plant^\ but has since been synthesized artificially in the laboratoiy.
MoOgC
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Figure 4. The structure of the anticancer drug vinblastine.
The mechanisms of action of these drugs aie dissimilar; cisplatin binds to DNA and 
prevents replication whereas vinblastine induces tubulin polymerization. Tubulin is a 
cytoplasmic protein which is responsible for carrying organelles such as mitochodria 
around the cell. When tubulin polymerises the cytoplasm becomes turbid and can 
nolonger fimction properly. Tubulin is important in mitotic cell division and when this 
is inhibited apoptosis is induced leading to cell death. The present project is primarily 
concerned with platinum complexes.
2.1 Binding of metallic drugs
Platinum complexes ai*e of importance in cancer treatment as they ai e able to interact 
with DNA, which is plentiful in the rapidly growing tissue of tumours. Interaction of 
platinum and transition metal complexes in general, with DNA impairs its ability to 
replicate and leads eventually to cell death. Platinum compounds are able to bind to 
DNA in several different ways, shown in figuie 6 (a):
1. Intercalation.
2. Outer sphere binding to the helix.
3. Inner sphere binding, either intrastrand or ioterstrand, to the helix.
4. Strand breakage.
Intercalation was originally proposed by Lerman ^  over 40 years ago. In simple terms 
a planai* molecule bonds by van der Waal’s forces between two base pahs of DNA in 
opposing helices. The molecule can be cairied to the site of action by platinum, as a 
ligand e.g. proflavme (figure 5).
Figuie 5. Proflavine.
This classical view of intercalation requires that the helix is locally extended and 
unwound. This alters the shape of the double helix and prevents replication and 
transcription. An alternative view of intercalation that involves bending of the helix 
was proposed twelve years later in 1973 by Gabbay and co-workers^^. This is shown 
in figure 6 (b).
INTERCALAI
OUTER-SPHERE
INTRASTRAND
STRAND BREAKAGE
INTERSTRAND
Figure 6 (a). The modes of interaction of metal complexes with DNA.
Mjrr/mn
Figuie 6 (b). The classical and alternative bending views of intercalation.
Outer sphere binding is possible because the outside of the helix is negatively 
charged. This stems from the structure of the backbone, i.e. sugar residues linked by 
phosphate diester bridges. The phosphate group caiTies a negative charge. There is the 
obvious possibility of coulombic attraction of positively charged metal species, 
phosphate oxygen attiaction between the helix and appropriate ligands and also the 
possibility of hydrogen bonding. Cobalt ammine complexes aie amongst the most 
studied in this area of binding to DNA. Cobalt hexa-ammine and its ethylene diamine 
analogue carry a 3+ charge, and the inert natuie of these species indicates an outer 
sphere attraction dominated by coulombic forces^ "^ . The binding of ruthenium ammine 
complexes has also been found to contain an electrostatic component. An example is 
[Ru(NH3)5(HzO)f
Of most importance to the binding of platinum in the treatment of cancer is inner 
sphere binding. This is a strong covalent attraction. Most studied aie the mixed chloro 
amines of platinum such as cisplatin. These will be expanded on later, so suffice to 
say here that complexes such as cisplatin bind to DNA bases. Binding can be of an 
inter- or intrastiand nature, interstrarid binding involves boriding to bases on opposite 
strands of the double helix. This would prevent the double helix from unraveling. 
Intrastrand binding occurs on bases of the same strand of the double helix, and 
although this does not prevent unraveling, it does prevent transcription and 
replication.
Lastly, strand breakage involves the cleaving of one or two of the helical backbones 
of the DNA skeleton. It is achieved by highly reactive species known as radicals. As 
long ago as fifty years this was done as a result of irradiation. The highly reactive 
hydroxyl radical was the product of irradiation and this breaks either a C-C bond in 
the sugai* skeleton, or a phosphate ester-sugar bond. Damage of this natui e prevents
transcription and replication, and has subsequently been achieved by chemical means, 
the Ru^  ^ ion being an example. This is made possible by the Ru^  ^ / Ru^^ redox 
reaction in the presence of a reductant, the electron transfer induces radical production 
and this is in contrast to the binding of platinum
2.2 Toxicity of Cisplatin
In 1978 cisplatin was approved for use in the treatment of testicular and ovaiian 
cancer, and later on for bladder cancer^. Cisplatin can also be administered in 
conjunction with other chemotherapeutic drugs such as bleomycin and 5-fluorouiacil, 
displaying synergic activity. What has been a major obstacle to the widespread use of 
cisplatin in the past and at present is the presence of major toxic side effects. The 
dose-limiting nephi'otoxicity is of a renal nature, and the damage is permanent. This 
can range fiom abnormal uriualyses to fatal renal dysfunction^^’^ .^
Cisplatin binds preferentially with cellular material rich in sulphur, which is in 
abundance in the tissue of the kidneys. Platinum has a special affinity for sulphur as 
platinum is a soft acid and prefers soft ligands such as sulphur. This can be partially 
overcome by re-hydration and the co-administration of a diuretic that flushes the 
kidneys If this problem had not been overcome cisplatin would have been dropped 
from clinical trials eaily in its life in 1973. More recently, since 1991, tests have been 
performed on cisplatin bound to sulphur containing protecting groups. This reduces 
the amomit of binding of cisplatin to kidney tissue^^. Safeguarding against kidney 
damage in this way is at the expense of the anti-tumour activity, and the right balance 
has to be struck between the benefits of effective anti-tumour action and the risk of 
renal damage to the patient. In effect, physicians do as much damage as they can 
without endangering the life of the patient in the short term, in order to achieve the 
maximum benefit in the long term.
Accumulative dosing of cisplatin can result in significant peripheral neurotoxicity. 
This improves with time after cessation of cisplatin. It takes the form of reduced 
sensation, impaired proprioception, and paraesthiae in the distal extremities^^. More 
rarely motor weakness can occur that can be severe enough to confine the patient to a
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wheelchair. From the eaiiy nineties to the present, extensive resear ch has been carried 
out on glutathione and other antioxidants to test their efficacy in reducing the 
neurotoxicity of cisplatin. The mechanism of platinum’s neurotoxicity is little 
understood but it is thought that because the damage is peripheral, perhaps platinum 
acts in cells of the dorsal root ganglia^*. It should be stressed that clinical resear ch 
into the use of small peptides such as glutathione for the pmpose of reducing the 
neurotoxicity of cisplatin must be exhaustive, as small peptides may act as tumour 
growth factors which would be most undesir able.
Ototoxicity is widespread in cisplatin treatment and is known to affect up to 50% of 
patients. It manifests itself initially by ultra-high frequency hear ing loss (9000 -  20 
000 Hz), followed by high frequency loss (4000 -  8000 Hz) and finally low frequency 
(250 -  4000 Hz) impairment
Less serious is cisplatin’s haematological toxicity. Normal doses of cisplatin produce 
myelosuppresion and anaemia though tlris is not serious in the majority of cases and is 
monitored and treated in a standard manner. Although little is known about the 
mechanism of this toxicity, suggestions that it is a side effect of renal toxicity have 
been discredited as carboplatin produces anaemia but is not renally toxic^ .^
Other less serious toxicities are vascular problems, nausea and vomiting, and hair loss. 
As hafr is constantly growing involving rapid cell growth and DNA, it is affected in 
the same way as rapidly growing cancer tissue, and inhibited. This hair loss is 
reversible after cessation of cisplatin^^, which is curious as one would hope that the 
damage to cancer cells was final. It is difficult to account for this apparent anomaly. 
One possibility is that as hair is rich in sulphur and presumably hair follicles and the 
bloodstream flowing to them are too, it is likely that the drug is substituted and the 
hafr loss is an effect of the resulting platinum complex. If the new complex does not 
bind with DNA in the follicle, then the follicle may survive to giow hafr another day 
when cisplatin treatment is discontinued.
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2.3 Tolerance and resistance to cisplatin.
It has been observed that some tumours do not respond to platinum drugs at all, 
possibly for reasons of pharmacokinetics or tumour architecture, wliile some respond 
initially but later on become re s is ta n tT h e  mechanisms of tolerance and resistance 
are not well understood, but one hypothesis is that platinum initially binds to DNA in 
tumour cells that are susceptible to attack, leaving behind platinum resistant cancer 
cells. An example of this is in hypoxic tissue. The tumour' cells closest to the blood 
supply are prone to attack from platinum which has a medium in which to travel 
within the tumour. Platinum caimot reach the cells further away fr om the blood supply 
so these cells are platinum resistant. Another theory is that the cells adapt and the 
DNA repair mechanism is able to work around the presence of certain levels of DNA 
damage within the cell.
The various mechanisms of tolerance and resistance fall into two categories, fh stly 
those that result in less of the active drug gaining access to and reacting with the 
tar get DNA, and secondly those that increase a cells ability to tolerate certain levels of 
DNA damage.
2.3.1 Reduced access of the drug to DNA
This could result from alterations in one or any of the following parameters:
1. Drug pharmacokinetics.
2. Tumour vasculature and / or tissue architectme.
3. Extracellular* factors which might inactivate the dr*ug within the tumom*.
4. Uptake into tumour* cells.
5. Intracellular factors which inactivate the drug such as binding to glutathione or* 
metallothioneins.
6 . Accessibility of the DNA or* of specific regions of the DNA.
Most of the evidence available from resear ch on resistant cell lines points to 4 and 5 
as the main cause of resistance^ '^^ .^
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2.3.2. Increased repair or tolerance of DNA damage.
It is not understood how DNA damage leads to cell death. At first it would appear 
obvious that binding of platinum inhibits transcription and replication, but as cells 
contain extensive enzymatic repair machinery, there may be more to it. It is possible 
that the cells pre-programmed self destruct mechanism called apoptosis may come 
into play in an effort to remove the damaged cell. In short, this means that platinum 
directly induces the cell to self destruct. It is proposed that in resistant tumours the 
cells do not have such an efficient apoptotic mecharrisrn and therefore do not die but 
tolerate the presence of platinum and DNA damage
2.4 The chemical nature of cisplatin binding with DNA.
Cisplatin contains two non-exchanging ammonia groups and two leaving chloride 
ligands. The binding of ammonia to platinum is strong and these groups should not 
easily be removed in vivo. It is reasonable to assume that platinum will bind well with 
nitrogens containing a lone pair such as amine groups, which are found in DNA. 
These bonds are strong and covalent in nature and cannot be broken even by the CN‘ 
ion. The platinum adducts formed can be isolated by chemical or enzymic means^ .^ 
Most research points to platinum binding with the N-7 of guanine on one strand of 
DNA and the guanine of the opposing strand (GG linkage), but guanine to adenine 
linkages (GA) ar e also known. The natme of the bhiding is thought to be mainly 
interstrand links. Research into this is contradictory and some researchers suggest the 
binding is of an intrastrand natur e. Linkages to pur ine are also known, and this can 
lead to a conformational switch of the sugar residues of the bound purine. This is 
thought to be important in the mechanism of cisplatin’s inhibition of DNA synthesis. 
It should be noted that the trans isomer also forms GG linkages but these do not 
produce a kink in the DNA like cisplatin and this is considered to be the reason the 
trans isomer has no anti-tumour* effect^ .^
With cisplatin the GG linkages reach a maximum after* approximately twelve hours, 
whereas in the case of the trans isomer* the maximum is reached after six hours. Three 
factors could be responsible for this, firstly, cisplatin is slower* at forming GG adducts
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for steric reasons, secondly, because it is kinetically more stable, or lastly, the DNA 
repail* mechanism is able to act more quickly in the case of the trans isomer. In any 
case, the trans isomer is cytotoxic like cisplatin.
2.5 The aqueous chemistry of cisplatin
Before cisplatin can bind with DNA it has to arrive at the site of action. Cisplatin is 
only sparingly soluble in water, and when injected intravenously is prevented from 
dissociating by the high blood plasma chloride ion concentration of 103 mmol. This 
hampers any binding that might have occurred between blood proteins and cisplatin. 
However, as 50% of cisplatin is eliminated from the body within 24 hours, binding of 
cisplatin in the bloodstream must occur in some way. In the cytoplasm the chloride 
concentration is only 4 mmol and hydrolysis occurs as shown in the figure 7 below.
^Cl Am Cl Am^ ^01
'P t
Am Cl Am Am OH
(') (ii) (iii)
Am^ ^H,0 Am w O Am OH
/P I  ; p (  '  > (
Am H;0 Am OH Am OH
(iv) (v) (vi)
Figure 7. The structures of the hydrolysis products of platinum -  amine (Am) 
complexes, at each stage of hydrolysis.
Tliis mechanism of transport of cisplatin across the cell membrane to its point of 
action can be either passive or active. Neutral species preferentially cross the 
membrane by the passive mode, i.e. from a point of high concentration to one of low 
concentration. Cisplatin can also cross a cell membrane by an active transport 
mechanism. This is where the drug is carried across the membrane by a carrier within 
the membrane. The passive mode is thought to be the main route of transport^^’
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2.6. Design of novel platinum anti-tumour drugs
In the last fifteen years or so, research has steered away fi*om the restrictive structure / 
activity rules which were written in stone in the early 1970s. The main reasons for tins 
are the lack of progress in developing drugs that are an improvement of cisplatin, and 
a better understanding of the pharmacology of platinum drugs. The driving force 
behind this is the deshe to find chemotherapeutic drugs that are effective on a wider 
range of cancers, are less toxic, non-tolerant and more orally bioavailable.
Novel research falls into the following categories:
1. Sterically hindered platinum complexes.
2. Platinum(IV) complexes.
3. Trans platinum complexes.
4. Multinucleai’ platinum complexes.
5. Diaminocyclohexane platinum complexes.
6 . Platinum compounds with carrier ligands.
7. Water soluble platinum complexes.
2.6.1. Sterically hindered platinum complexes
In recent years, knowledge of the mechanisms of tumoui* resistance to platinum has 
improved. Various factors affect the level of tolerance, the major contributing factors 
being impaired transport of the di’ug, cytoplasmic detoxification due to increased 
levels of glutathiones and metallothioneins, improved DNA repair, and DNA 
tolerance to platinum adducts.
The reasoning behind research into sterically hindered platinum complexes is that it is 
well known that axial steric hindrance reduces the rate of substitution reactions in 
square planar complexes. This means that the platinum complex is less susceptible to 
substitution by glutathione and metallothioneins found in cells. The importance of this 
is that resistance to the platinum complex is reduced as more of the drug reaches the 
site of action. With this in mind platinum complexes including ligands such as
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substituted pyi'idines have been designed^^. The steric hindrance occurs as the rmg 
bends down from the PtCbNi plane and the methyl substituent lies over the platinum, 
inhibiting axial substitution. Crystal structures have shown this to be the case. An 
example of this is cz>amminedichloro(3-methylpyridine) platinum(II) shown in figure
8 . The ring is tilted (rotation about the Pt-N) with respect to the squai*e plane by 48.9°. 
In the case of the 2-methyIpyridine analogue, the angle is 103°, and the methyl group 
lies directly over the platinum square plane.
Figure 8 . cw-amminedichloro(3-methylpyridine) platinum(II).
Clinical trials have shown the 2-methypyiidine analogue to be active in cisplatin 
resistant cell lines. However, the time for DNA platinum adducts to reach a maximum 
is significantly longer than for cisplatm, and this has implications regarding DNA 
repair that require more reseai'ch. This rationale is adopted in the current project.
2,6.2 Platinum(IV) cdthplexes.
Early studies by Rosenberg showed platinum(IV) complexes to have anti-tumour 
activity. This was largely ignored until fifteen yeais ago. Research into platmum(IV) 
has been fuelled by the desfre to find anticancer drugs that aie orally bioactive. This 
improves the quality of life of patients as few people enjoy injections, and it opens up 
the possibility of out patient treatment. Platinum(IV) compounds aie more inert to 
ligand substitution and it is thought that they aie reduced to platinum(II) by both 
extracellullar and intracellular agents prior to binding with DNA. The type of axial 
ligand determines the rate of reduction of platinum, and consequently the biological 
activity of the complex. Platinum(IV) opens up all sorts of possibilities of different 
ligands. An example of a platinum(IV) complex is Iproplatin synthesized by Tobe and 
co-workers*^ (figure 9), although clinical trials of this complex were abandoned due to
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lack of superior performance. The major obstacle to overcome is gastrointestinal 
absorbency. The complex has to be sufficiently polai* to be water soluble, but also 
lipophilic enough to pass through the stomach lining.
OH
NJH, !„c,
NHg
OH
Figure 9. Iproplatin.
More recently, research into platinum(IV) complexes has experienced a revival, after 
a tail off due to the poor performance of Iproplatin. Complexes containing ethylene 
diamino and caiboxy ligands have been produced. Absorbance is poor, between 20% 
and 37% of administered dose* .^ Another drawback is gastrointestinal problems 
caused by the drugs. Carboplatin for example resulted in severe problems and is 
administered intravenously, like cisplatin. However, the limited success has fuelled 
research using these types of ligands. Axial carboxy and equatorial amine ligands 
provide three sites for modification*^’^ *^, and this can reduce the rate of reduction from 
platinum(IV) to platinum(II) in the bloodstream. One of these complexes JM216, was 
the first orally active platinum complex to be designed*^. Its structure is similar* to that 
in frgme 10 except that it has axial acetate ligands instead of hydroxide. It is hoped 
this will enable more drug to reach the target. The activity of the platinum(IV) diugs 
is necessarily dependent on theii* platinum(II) analogues.
2.6.3 T ta n s  Platinum coinplexes
Transplatin is kinetically more reactive than cisplatin and therefore more susceptible 
to deactivation. This is one reason why it is not active as an anti-tumoui* complex. 
This kinetic reactivity may be reduced by the introduction of a ligand that sterically 
hinders the platinum. Research in this area has produced several complexes that do 
exhibit anti-tumour activity; in some cases it is greater than their cis 
counterparts*^’^ ’^^ *. An example of one of these is shown below in figure 10.
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Figure 10.
<^2 «^ ’,/rfl«5 ,/rfl/?.s-aminine(cyclohexylamine)dichlorodiliydi'oxy platinum(IV).
By having a large bulky ligand in a trans position there is also the possibility of 
forming platinum - DNA adducts of a completely different natur e compar ed to the GG 
adducts. This is important as one of the main mechanisms of resistance to cisplatin is 
the tolerance to, and / or removal of platinum - DNA adducts. This has been shown to 
be the case in a study of platinum iminoether complexes of the type 
PtCl2 (Æ’-immoether)2 (^^-/ra«5 ' complex), where platinum DNA mono adducts were 
isolated. These were formed at the N7 of guanine, and even after 48 hour s incubation 
at 37 °C only mono adducts were formed. This is in contrast to transplatin which 
forms bifiinctional adducts, and demonstrates that some transplatin analogues bind to 
DNA in a different way^ .^ This idea is continued in the next sub-section.
?' /H
® I \ \  
MeO
Figur e 11. A platinum(II) iminoether complex
Another important group of platinum(IV) compounds are the imidazole complexes. 
These are tetrachloro complexes with the imidazole in a trans position to another 
ligand such as DMSO or to another imidazole. Similar* ruthenium complexes have 
also been developed and display anti-tumour* activity. Analogous pyridine and 
thiazole complexes have also been developed, and all three classes show comparable 
activity to cisplatin in cisplatin resistant cell lines*^’*^ .
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Figure 12. Platinum imidazole complexes.
2.6.4. Multinuciear Platinum complexes.
Having bi- and trinuclear platinum complexes opens up the possibility of new binding 
sites on DNA, and consequently entirely new platinum - DNA adducts. Hopefully 
these adducts will be resistant to the DNA repair* mechanism. These complexes take 
the form of simple square planar platinum complexes joined by bridging linkers such 
as aliphatic diamines. An example of this is BBR3464*^’"*** (figure 13) and in 
preclinical tests it has exhibited a complete lack of cross resistance to cisplatin 
resistant cell lines'**. It is also more potent than cisplatin in vitro in an osteosarcoma 
cell line'*^ . This improvement in potency is due to increased DNA binding and cellular 
platmum uptake compar ed to cisplatin.
.NH,(CH,),H2 N NH3 H3 N ■
Pt P t
H3 N. Cl
or m . H M NH2(CH2)6HgN NK
Figure 13. The structure of BBR 3464.
The overall 4+ charge on the platinum complex facilitates binding in the minor* DNA 
groove which is negatively char ged. The minor groove of DNA is shown in figur e 14 
below.
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Mmor
Figure 14. Model of DNA showing the major and minor groove. 
© University of California, Berkeley.
2.6.5. Diaminocyclohexane platinum complexes(dach)
Since the first synthesis of this type of complex in the 1970s'*^ ’'*^ , many platinum(II) 
and platinum(IV) complexes of this type have been synthesized, the most famous 
being oxaliplatin*^’ They were found to be active in some cisplatin resistant cell 
lines. The new platinum(IV) complexes are analogues of oxaliplatin with axial 
carboxy ligands. Some of the complexes have the amines on the 1 and 2 positions, 
others on the 1 and 4. A complex of Pt(cw-l,4 -dach)Cl2 (figure 15) exhibited in vitro 
activity in Pt(l,2-dach) resistant cell lines. This could be for structural reasons but 
very little is understood on how Pt(l,4-dach) overcomes this resistance and more 
work is required'^.
Figure 15. Pt(cz5'-l,4 -dach)Cl2
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2.6.6. Complexes with biologically active carrier ligands.
Akeady mentioned in section 2.1 were the platinum proflavine complexes which ar e 
intercalators. The theory behind the research is that by attaching ligands to platinum 
that are known DNA intercalators, the concentration of platinum can be localized in 
the vicinity of the DNA, rather tlian being bound to tissue m the kidneys and 
metallothioneins in the bloodstream. In this way, toxicity can be reduced. Although 
plenty of research is ongoing in this area, so far the results of the platinum complexes 
are not an improvement on the carrier ligands alone, although some are an 
improvement on cisplatW^. Carrier ligands are also used that are not biologically 
active, such as sugars, amino acids, and polymer backbones. These are used to alter 
the properties of the platinum complex, such as solubility, absorbance across cell 
membranes, or the time the complex remains m the system before elimination.
2.6.7. Water soluble complexes
There are two main strategies in this approach, the first is to introduce polar moieties 
to ligands or to the platinum dhectly, and secondly to make a hydiosol colloid of an 
insoluble platinum complex, such as [(+l)-l,2-bis(4-fluorophenyl)ethylenediamine]- 
dichloro platinum^^’"^ .^ Both methods have yielded active complexes and an example 
of the former approach is shown in figure 16.
Figui’e 16. A water soluble anionic phosphono carboxylate complex of platinum13,46
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2.7. Ruthenium in chemotherapy
Searching the literature revealed many hits for ruthenium complexes to do with 
catalysis, but comparatively few for medical applications, though this situation is 
improvmg. This may be because research into ruthenium for anti-tumour effect is 
more recent than for platinum which has been ongoing for forty years. Initially 
ruthenium complexes were synthesized that were analogues of platinum compounds. 
As time passes and the research progresses, more publications will undoubtedly 
appear. Patent issues may delay the publication of results by researchers and 
pharmaceutical companies alike. The origin of funding and the motivation behind 
research also play a part. Research into platinum chemistry was common before the 
discovery of cisplatin’s anti-tumour activity, and platinum chemistry for research’s 
sake is still a major motivation. Another factor could be the heavy emphasis put on 
biological testmg and anti-tumour effect. Researchers may be reluctant to publish 
their work if the compounds made are less efficacious than cisplatin and car boplatin.
One of the groups of complexes in the public domain is ruthenium coordinated 
imidazoles an example of which is shown in figure 17 below.
O , 'V® Me^ 1 / ImH
Figure 17. A ruthenium tetrachloro(DMSO)(imrdazole) complex.
This complex is very similar to the platinum imidazole complexes shown in figure 12 
and both are important in current cancer research. This complex carries a negative 
charge, and if a protonated imidazole cation (ImH^ is used as the counter ion instead 
o fN a \ the molecule has greater chemical stability. This compound has been proposed
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for phase I and II clinical trials"^ .^ Another benefit of this complex is that it is less 
toxic than the analogous platinum complex.
Imidazoles are similar to the heterocycles of the present study, oxadiazoles, so it is 
reasonable to assume if imidazole complexes are active anti-tumour agents, then 
oxadiazoline complexes might be too. The other main aieas of ruthenium 
chemotherapeutic research are multinuciear ruthenium complexes, and complexes of 
ethylenediaminetetraacetic acid (EDTA) and phenyl hydroxamic acid. The latter are 
being investigated by the Royal College of Surgeons in Ireland, and the general 
structure of them is shown in figure 18. The EDTA is coordinated via the two 
nitrogens in a cis manner, and by two of the carboxylate groups in a trans manner.
( e d t a )  R U \  l l  
O ^ N H
Ph R
Figur e 18. The structure of a ruthenium(III) hydroxamato complex50
Of growing importance is the use of rritric oxide donors ligated to metal centres, 
particularly ruthenium. The above complex, figure 18, and figure 19 below are 
examples of nitric oxide donors. Tlris has a dual effect as nitric oxide inhibits tumom’ 
growth and hopefully the ruthenium complex does too. The nitric oxide is released in 
the reducing conditions of the tumom’ so it is a type of cari’ier ligand. Using this 
approach introduces a dual approach to cancer treatment.
+
01
Figme 19. Ruthenium nitric oxide complex51
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Summing up, despite platinum chemotherapy being approved for 28 years, the range 
of tumours treatable is still fairly limited, and problems of toxicity and tolerance 
remain. Plenty of scope remains for research into platinum and ruthenium complexes 
that may circumvent these problems. The present project adopts many of the above 
approaches to the design of novel platinum complexes, namely, trans complexes, 
sterically hindered complexes, introducing polar moieties, multinuciear complexes, 
water soluble complexes and ionic complexes. Hopefiilly complexes that have greater 
solubility in water, improved anti-cancer activity and reduced tolerance, will be 
designed.
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3.0 A brief overview of platinum chemistry.
The chemistry of platinum can be summar ised into thr ee distinct ar eas;
1 . electrochemistry,
2 . catalysis,
3. coordination chemistry.
Platinum is a typical transition element, characterised by its high melting point of 
1772 °C, high density of 21.45 g/crn  ^ and variable oxidation state^ .^ It is also 
chemically inert and has good electrical conductivity which is why it has historically 
been used in electrical cir cuitry, to make crucibles, and in electrodes. Indeed it was 
only its use as an electrode that led to the discovery that cisplatin inhibited the growth 
of bacteria \  So platinum was not quite as chemically inert as was thought at the time. 
Platinum is used in the hydrogen electrode which is the universal standard for 
measiu'ing half cell potentials.
3.1 Catalytic activity of platmum.
Platinum is well known for its catalytic activity, not least because of its use in the 
modern exhaust catalytic converter.
Pt/Rh
2  C= 0  +  2 N5 0  -------^  N=N +  2 O—C—O
Scheme 1. The conversion of noxious gases in automotive exhausts to more 
acceptable gases.
Platinum is also used in aroimd thirty industrial processes from the cracking of 
petroleum to the cur ing of silicones. It is probably most famous for its use in reductive 
hydrogenations. Platinum can be used as either homogeneous or heterogeneous 
catalysts. The catalytic converter is an example of a heterogeneous catalyst where the 
platinum is mounted on a solid support. This type of catalyst depends on high 
temperature and surface activity for its catalytic action. Platinum catalysts used for 
curing silicones such as siloxanes are examples of homogeneous catalysts. They 
dissolve in the reaction medium so are in the same phase as the reactants. Much lower 
concentrations of homogeneous platinum catalysts are required to achieve similar
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activity compared to heterogerreous catalysts in the production of silicones. More 
recently platinum nanoclusters have been used to catalyse the polymerisation of 
siloxanes^^-
3.2 Coordination chemistry of platinum.
Coordination chemistry involving platinum may be motivated by interest in medicinal 
chemistry, or just for chemistry’s sake. Chemists may be interested m a certain type of 
reaction and use platinum to make the reaction possible or make it easier. Platinum 
has made a significant contribution to organometallic chemistry. The &st 
organometallic compound described was Zeise’s salt in 1830^ "^ . This was nearly fifty 
year’s before the birth of Victor Grignard. The structure of Zeise’s salt is shown in 
figure 2 0  below.
H ^ H ç i
-P t-C I  i
H H01
Figure 20. The structure of Zeise’s salt.
Wliilst Zeise’s salt has no commercial value whatsoever, its palladium analogue is 
extremely important in the conversion of alkenes to carbonyl compounds. This is 
known as the Wacker process after the German scientist who invented it^ .^ The 
Wacker process was one of the fir’st large scale industrial applications of catalysis, 
utilizing readily available ethylene and converting it to ethanol via acetaldehyde.
Platmum is important in coordination chemistry because of its ability to bind to both 
saturated hydrocarbons and unsaturated systems such as arenes and alkenes. It is also 
able to bond with lone pah donors such as nitrogen, sulphur and phosphorus. Figure 
21 (a) below shows the a  bond in Zeise’s salt which involves electron donation from 
full 91 orbitals of ethylene to the empty <ix2 -y2  orbital of platinum.
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(a)
(b)
CI
C
Figure 21(a) The main orbitals involved in a  bonding in Zeise’s salt, (b) the main 
orbitals involved in n bonding in Zeise’s salt.
Figure 21(b) above shows the k bonding of Zeise’s salt which involves back donation 
from the electrons of the filled d  orbital of platinum to the empty antibonding orbitals 
of ethylene. The p  group elements such as nitrogen and sulphur are good a  donors 
through their lone pairs. However the strength of the bond can vary between 
compounds that contain the same donor element. An example of this is the difference 
in bond strength of nitriles and amines. This is due to the hybridisation of the nitrogen 
in each case. In a nitrile the lone pair is a sp hybrid so has 50% s character. This 
means the lone pair is more tightly bound to the nucleus than in the case of an amine, 
which has sp  ^ hybridisation. In this case the lone pair has 75% p  character and is not 
so tightly bound to the nucleus. The amine is able to bind more efficiently with 
platinum.
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3.2.1 The classification of hard and soft acids and bases.
The affinity of a ligand for platmum is governed by its Lewis basicity. Platinum is a 
soft Lewis acid and preferentially binds with soft Lewis bases^ .^ Soft Lewis acids are 
characterised by a large ionic radius, a low positive oxidation state, valence orbitals 
containing electron paii's and they are readily oxidised. Soft Lewis bases are 
chaiacterised by a large atoms of intermediate electronegativity (2.5-3.0 on the 
Pauling scale) and are readily polarised and oxidised. Platinum(II) meets the criteria 
for a soft Lewis acid while sulphur and phosphorus fall into the soft base category^^’^ ,^ 
depending on oxidation state and particulai- ligand. Nitrogen is in general classed as 
intermediate but again this depends on the particular ligand. Table 2 below 
summar ises some of these ligands.
Hard Lewis Base s o / -  PC /- NOs" NHj R-NH2
Intermediate Lewis Base SO;-'- NO2 - Pyiidine
Soft Lewis Base CN- PR] SR2
Table 2. Classification of various Lewis bases.
In the same way that bases are classified as hard or soft, so are Lewis acids. Pearson 
classified hard acids as those that formed theft strongest complexes with hard bases, 
and soft acids form theft strongest complexes with soft bases^ *". This is in agreement 
with Chatt’s theory of class ‘a’ and ‘b’ metal ions^^’^ .^ This stated that class ‘a’ metals 
prefer to complex with elements of lower atomic number within a group of the 
periodic table, whilst class ‘b’ metals prefer to complex with elements of higher 
atomic number within a group. So for platinum halide complexes the stability 
decreases fiom iodine to fluorine. This trend coincides with a reduction in the 
polarisability of the halogens going up the group, and Pearson used polarisability as a 
criterion for measuring hardness or softness. So the two theories of Pearson and Chatt 
are in overall agreement. Both the Gibb’s flee energy and enthalpy of formation of 
divalent tetralialoplatinate anions become less positive going fiom chlorine to iodine, 
indicating an increase in stability moving down the group^ .^ This is shown below in 
table 3.
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Halogen AGaq (kJ / mol) AHaq(kJ / mol
Chlorine 143.9 159.3
Bromine 133.1 111.3
Iodine 77.0 39.7
Table 3. The Gibb’s free energy and enthalpy of formation of divalent 
tetrahaloplatinate anions in aqueous solution.
Both these theories were devised by experimental observation of the reactions of 
different metals and anions and then applied to the periodic table as a whole.
3.2.2 Substitution reactions of platinum(II) complexes.
This affinity of different ligands for platinum is exploited in substitution reactions to 
synthesize new complexes. This method is employed in the present project. Platinum 
nitrile complexes are often used as starting materials for ligand exchange reactions as 
they are not tightly bound and are easily substituted. Important to these reactions is 
the rate of exchange of a ligand. Experimental observation of the rate of exchange of 
ligands on square planar platinum complexes was used to devise a series which is the 
approximate order of the decreasing labilising ability of ligands. This became known 
as the trans effect^^, and is a measure of the effect a ligand has on the rate of 
substitution of the ligand trans to it in the square planar complex. From its fir st 
conception, the order of the series has evolved to the following^^ although it is by no 
means exhaustive;
C2H4 - N O - C O -  CN- > RsSb > R3P > RgAs -  H' -  SC(NH3)2 > CH3- > CeUi > 
SCK > NO2 ' > r  > Br‘ > cr > NH3 > OH' > H2 O .
The fust thing to note is that the end of the series with the greater labilising effect is 
dominated by good n acceptors such as misaturated systems, arsines and phosphines, 
and the trans effect is most appropriate when the ligands involved are good n 
acceptors. Tlris is because they withdraw electron density fr om the platinum and this 
is translated to the bond trans to the ligand thus weakening it. At the other end of the 
series are the halogens and ammotria, and according to the trans effect, chlorine 
should labilise ammonia. This is understood not to be the case in the binding of
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cisplatin to DNA, where the chlorines are the leaving groups. Whilst chlorine and 
ammonia are adjacent in the series, and might be considered to be similar, ammonia is 
a difficult ligand to remove. This leads on to another effect which is called the trans 
influence. The difference between the two phenomena is that the trans effect is a 
kinetic property dealing with the rate of exchange, whereas the trans influence is a 
thermodynamic property dealing with bond strengths. The two effects are inextricably 
linked. As the platinum - ammonia bond is stronger than the platinum - chlorine bond 
the latter is substituted in cisplatin. This also explains why transplatin is more reactive 
than cisplatin with regar d to exchange of the chlorine. In the Cl-Pt-Cl the chlorines are 
more strongly labilised than in the Cl-Pt-NHs of cisplatin.
The main mechanism for the substitution of square planar* platinum complexes is 
thought to be associative. This is outlined in figure 26(b). This assumption is based on 
indirect evidence such as the rate of substitution decreasing as the degree of 
substitution of a ligand increases. This means that the ligand’s substituents sterically 
hinder substitution of the ligand, and the rate is consequently slower^ ®.
3.2.3. The oxidation states of platinum.
Platinum exhibits various oxidation states, the most common bemg 0, +2 and +4. The 
mean atomic radii have been measured experimentally for these oxidation states m a 
number of environments including triphenylphosphine and isocyanide, and are 
identical at 0.131 nanometres^^. The corresponding palladium atomic radii are the 
same. This feature is due to the contraction of the ionic radius caused by shielding 
from the nucleus of the valence d  electrons by the 4 /  subshell o f electrons. This is the 
so called lanthanide contraction effect and is common in second and third transition 
series. It is worth noting the covalent radii of platinum complexes where the platinum 
is in 0, +2 or +4 oxidation state, are also identical^^.
Ionisation potentials have also been measured and are summarised in table 4 below. 
Just a glance at the table shows the difficulty in achieving the higher oxidation states 
of platinum. The transition from tetravalent to pentavalent platinum requires 55 eV. 
Ionisation potentials are used in the calculation of lattice energies of ionic compounds.
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This application is of limited value in platinum chemistry as Bom-Haber lattice 
energies are based purely on coulombic attraction, and take no account of covalent 
bonding^^'^\ In platinum complexes there is a major contribution from covalent 
attraction.
Transition Ionisation potential (eV)
9.0
27.56
56.06
97.16
M" M'’* 152.16
Table 4. Ionisation potentials of platinum^^.
More relevant to the stability of platinum complexes in different oxidation states are 
oxidation-reduction potentials. Three of these relevant to the current project are 
shown in table 5.
Oxidation state 
change
Equilibrium Oxidation
potential(V)
Pt° Pt" Pt Pt24 2e • 1.2
Pt + 4CI- PtCl^ z- + 26 -0.75
Pt" ^ Ptiv PtCI/- + 2CI- PtClgZ- + 20 -0.77
Table 5. Selected redox potentials for the common oxidation states of platinum^^.
Platinum is described as a noble metal as it is not considered reactive, and this is 
reflected in the negative oxidation potential of the first transition in table 5. The 
reverse reaction is favourable in aqueous solution, i.e. Pt^  ^ is more likely to be 
reduced to elemental platinum than platinum being oxidised. This is immediately 
obvious on inspection of the Nernst equation;
AG,„® = -nFE®
A negative redox potential will give a positive Gibbs free energy which is 
unfavour able for a reaction. In fact the Gibbs fi*ee energy and enthalpy of formation of 
the second reaction in table 5 are 143.9 kJ / mol and 159.3 kJ / mol respectively. This
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renders the anion unstable in aqueous solution. This is demonstrated by the following 
equilibrium; the complex ion [PtCfl]^" is unstable in aqueous solution and 
disproportionates to elemental platinum and the platinum(IV) complex ion^ .^ 
However tliis is not a spontaneous process and does not occur under mild conditions 
of room temperature. This is amply demonstrated by the use of aqueous potassium 
tetrachloroplatinate as a nuclear magnetic resonance spectroscopy (NMR) reference 
standar d, which can be stored and used for year s.
2 [PtCIJ2- —  Pt(0) +  [PtCy2- +  2CI-
Scheme 2. The disproportionation of the divalent tetrachloroplatinate anion in 
aqueous solution.
Platinum(IV) species can be reduced to platinum(II), and platinum(II) oxidised to 
platinum(IV), by iron(II) and iron(III) respectively. These were originally thought to 
involve a platinum(III) intermediate^^, but this theory was subsequently thrown into 
doubt by an investigation on the reduction of platinum(IV) by chromium(II) which 
showed the rate determining step to involve a two electron transfer^ "*. Platinum(IV) is 
stable with regard to oxidation, which is why there are so few platinum(V) or 
platinum(VI) species known. This is due to the electr onic configuration of the valence 
orbitals of platinum(IV) species being S .  The low spin octahedral geometry results in 
full xy, xz and yz orbitals, which is a more stable state than having unpair ed electrons 
which would be the case in the platinum(V) or (VI) oxidation states.
3,2.4 Geometry of platinum complexes with varying oxidation state.
Platinum in different oxidation states displays varying coordination number and 
structure. The most common are summarised in table 6. By far* the most studied 
platinum (0) complexes are those of phosphines and arsines. They were used as 
models for the compounds formed when small molecules are chemisorbed onto the 
metal. This was believed to be at the heart of the metal’s catalytic action. Zerovalent 
platinum complexes ar e stabilised by ligands that are both strong a  donors and strong 
Tc acceptors. Amongst these are the two aforementioned and nitric oxide, ammonia, 
isocyanide and cyanide^^.
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Divalent platinum complexes with a coordination number of four aie always square 
planar in structure. Having square planar geometry leads to the possibility of cis and 
trans isomers for mixed ligand complexes. An obvious example is cisplatin and 
transplatin^^.
Oxidation state Coord. No. Structure Example
0 4 Tetrahedial [Pt{P(OR)3}4]
0 3 Planai* [Pt(PPh3)3]
0 2 lineal* [Pt(PPh3)2]
2+ 4 Square-planai* [PtCl2(NH3)2]
2+ 4 Tetrahedial None known
44- 6 Octahedral [PtCl4(NH3)2]
Table 6. The common oxidation states, coordination numbers and structuies of 
platinum complexes^^.
Platinum(IV) complexes exhibit solely octahedral geometry, and like platinum(II) 
complexes they are diamagnetic as the low spin crystal field splitting renders the 
and -y^ orbitals empty and the electrons of the n bonding orbitals all pafted. 
Platinum(II) and platinum(IV) complexes make up the bulk of platinum complexes 
studied.
Much less common are platinum complexes in oxidation states of one, three, five and 
six. The reason for the rarity of odd number oxidation states is that they would 
involve an unpaired valence shell electron which renders the complex unstable^^. In 
fact the only reports of univalent platinum complexes are clusters of more than one 
platinum complex sub-unit^^. This facilitates the lone electron being paired with a 
similai' electron on another platinum centre resulting in Pt-Pt bond involving an 
electron pair. Trivalent platinum compounds aie also rare. Some reaction 
intermediates have been claimed to be platinum(III)'^^, only to later be discredited 
Also claimed are some di-platinum(III) compounds such as PtiOs^ "^ , but these have 
later been found to be a combination of platinum(II) and platinum(IV)^^. This is 
concluded as the complexes aie diamagnetic, indicating there are solely electron pairs. 
Platinum(III) would be paramagnetic because of the unpaired electron. Platinum
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triiodide has also been claimed but again is diamagnetic. As the structure has been 
confirmed as octahedral by X-ray crystallography, it is thought to be Pt(II)Pt(IV)l6^^ 
which is consistent with its observed diamagnetism. Platinum trichloride^^ and 
tribromide^^ have also been claimed but their dark colours aie inconsistent with the 
claimed oxidation state, e.g. PtCh is yellow green and PtCU is red brown, however 
the claimed trichloride is black.
Of all the odd number oxidation states of platinum, platinum(V) is most common.
The complex ion [PtFe]' is the most well known pentavalent platinum complex, the 
bulk of the work being caiiied out by Baitlett et ah It is found in combination with 
alkali metals^ \  oxygen^^ and xenon^^. The alkali metal hexafluoroplatinates have been 
shown by X-ray diffraction to have the complex anion in an octahedral geometry. 
They aie also readily reduced to platinum(IV), the reaction in water being violent. 
This is also an indication of how difficult it is to oxidise platinum(IV) complexes, the 
ionisation potential of Pt (IV) -> Pt (V) is 55 eV which is very large. Xenon has a 
similar first ionisation potential to oxygen, being approximately 12 and 13 eV 
respectively. As a dioxygenyl hexafluorplatinate complex had been isolated and 
confu'med by X-ray diffraction, it was considered by Bartlett et al. that xenon might 
behave in the same way. The complex Xe’^ [F6Pt]' and the others mentioned have all 
been found to be paramagnetic, indicative of the unpaired valence electron of 
pentavalent platmum. These complexes are by no means easy to prepare and require 
either high temperatur es o f250-300 “C, or high temperatur es and high pressme.
The fluoride of platinum is the only hexavalent platinum compound known. It is made 
by electrically heating a platinum wire in fluorine close to a liquid nitrogen cooled 
surface^ "^ . It is a red black solid that melts at 61.3 °C and boils at 69.1 ”C. It is 
thermally unstable decomposing to form fluorine and platinum tetrafluoride. It is also 
extremely reactive, being a very strong oxidising agent. It has pure octahedral 
symmetry which is evident in its IR absorption spectrum.
Summing up, the chemistry of platinum is vast and it has only been possible to lightly 
scratch the surface. There are still many ar eas of platmum chemistry that warrant 
further investigation. The present project deals with a tiny area of platinum chemistry, 
namely platmum mediated cycloadditions, and this is expanded on in section 4.2.
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4.0 Previous work
The synthesis of classic platinum drugs such as cisplatin and carhoplatin is a lengthy 
process of ligand exchange involving several steps, and employing expensive silver 
reagents. The synthesis of cisplatin is outlined in scheme 3 below.
K^ Ptu N H r /I^Pt H,N "'I
AgNOgCaq) H3N ^OH 
H.N OH
+  Agi
Cl H3N, ,C1 
H3N Cl
Scheme 3. The outline synthesis of cisplatin75
The above synthesis begs the question, why not stop the synthesis at the dihydroxy 
stage? After all it has already been stated in the aqueous chemistry of cisplatin 
section, that it is thought cisplatm is converted to dftiydroxydichloro platinum(II) in 
the blood stream. The answer to this is that cisplatin and its full synthesis were known 
decades before any serious understanding of how it worked was postulated. In fact 
this synthesis was proposed some thirty years before it was discovered that cisplatin 
had any anti-tumour activity at all. More importantly, although the dihydroxy 
complex is thought to exist in aqueous solution, it has not been possible to isolate it as 
a solid.
The idea behind the present project is to construct the ligands directly in the platinum 
coordination sphere.
This approach has a number of advantages:
1. The stereochemistry surrounding the platinum centre should remain 
michanged by the process.
2. It facilitates a modular approach where substituents can be varied, easily 
building up a large bank of complexes ft om relatively few components.
3. This allows for a combinatorial chemistry approach.
In the past, the cycloaddition products A"^-l,2,4-oxadiazolines have proven difficult to 
prepare. The 1,3-dipolai* cycloaddition of nitrones to nitriles is essentially the only
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method of preparing them. This reaction works well with electron deficient nitriles^^’ 
but normal alkyl substituted nitriles are not reactive enough^^. Acetonitrile for 
example, does not react, even at high temperatures or pressmes^^. Microwave 
uTadiation does not induce a reaction This is why up until recently only a few A"^ -
1,2,4-oxadiazolines were known, and there was not a method for the enantio selective 
synthesis of these compounds.
A first improvement was achieved when it became apparent that platinum nitriles 
underwent cycloaddition with nitrones relatively easily compared to uncoordinated 
nitriles^ '^^ .^ Platinum(IV) activates nitriles more strongly than platinum(II), indicating 
that the metal acts as a Lewis acid and withdraws electron density fiom the CN triple 
bond.
Ph^ P h - ^ 0
\  \\ N -M eV .Cr C Me~N 11
Ph H 0 - ^ P h\ Ph
Scheme 4. Bis cycloaddition of platinum bis benzonitrile to a nitrone.
This effect is so marked that in the case of coordinated cinnamonitrile, cycloaddition 
occurs exclusively at the CN triple bond instead of the C=C double bond which is the 
preferred site for cycloaddition in uncoordinated cinnamonitrile^^. The reaction is 
also accelerated from days to hours, and the yield improved by microwave 
irradiation^^.
The mechanism of the 1,3-dipolar cycloaddition of nitrones to rritriles is thought to 
follow a classic cycloaddition reaction, i.e. a concerted one step mechanism with the 
ring bonds being formed simultaneously. A recent theoretical study by G. Wagner 
into the effect of Lewis acids on the mechanism has shown it is very likely that the 
metal mediated reaction follows a two step process with an intermediate*" .^ The Lewis 
acid, which is coordinated to the nitrile, does not alter the reactivity of the nitrile, it 
stabilises the intermediates, transition states and products. This is shown
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schematically below in figure 22. For both kinetic and thermodynamic reasons the A"^ -
1,2,4-oxadiazolines are preferred over the A"^ -1,2,5 regioisomer*" .^
H Me\  /C =  N +/  \Ph 0 -
L A  N;
LA = Lewis acid
Ph
Me
H
N:
LA \
Me
Ph O
LA
W hen LA coordinated, concerted  is 
unlikely to occur. W hen not LA 
coordinated, the reaction follows a 
concerted  pathway.
H\
Me
P h ^ - s ;  f
, N = C  
I R
Or two step . Preferred route.
Figure 22. The two step mechanism of the cycloaddition of Lewis acid coordinated 
nitriles to nitrones.
This reaction is quite general and PtCl2 (sulphoxide)(nitrile) complexes for example, 
undergo cycloaddition equally well (scheme 5)*^ . In addition, if a chiral sulphoxide is 
used, complexes with two chiral centres can be prepared. If the chiial sulphoxide is 
enantiomerically pure then two diastereoisomers will result* .^
K,PtCL DMSO
Cl—Pt—Cl
0 ^ 1  'Me Me
PhCN
Cl
Cl— Pt—N=C—Ph
''MeMe
RCH=NOMe a  \ /
---------------- Cl Pt N,
Me
Scheme 5. Outline synthesis of mixed nitrile DMSO platinum complexes. )
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4.1. Aims of the study.
The previous platmum A"^-l,2,4-oxadiazoline complexes produced proved to be only 
soluble in chlorinated organic solvents and it was not possible to test them for 
biological activity. They were also far- too apolar to be of much use as anti-cancer 
agents.
In the framework of this project, the main objective is the introduction of more polar 
oxadiazoline ligands onto the platinum centre. This should make the platinum 
complexes more soluble in polar and aqueous compatible solvent systems. In this way 
the previous synthetic methodologies will be improved and extended.
Both mono and bis oxadiazoline platinum complexes will be prepared. An analogous 
approach will be applied to ruthénium complexes.
The platinum oxadiazoline complexes produced will be biologically tested for anti­
tumour effect.
The reactivity of the platinum oxadiazoline complexes will be studied with regard to 
substitution at the metal centre, and oxidative addition, also at the metal centre. Little 
is known about the reactivity of this class of compound, and it is intended to elucidate 
this in a small way.
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4.2. General considerations about the synthetic strategy.
For the present study, platinum nitrile complexes were chosen as targets because it is 
loiown from previous experiments that nitriles (e.g. benzonitrile and cinnamonitrile), 
when coordinated to platinum(IV) or platinum(II), are activated to undergo [2+3] 
cycloadditions with nitrones* '^* '^* '^* .^ The expected reaction should also occur 
between more polar* platinum nitrile complexes and more polar nitrones.
4.2.1. Preparation of nitrones.
One way of making oxadiazolines more polar* is the mtroduction of polar groups on 
the phenyl ring of the nitrone. This was achieved using commercially available raw 
materials such as substituted benzaldehydes. Nitrones are one of the few dipolar* 
reagents that do not need to be used in situ but can be isolated, purified and stored. 
They can be prepared in many different ways, e.g. by oxidation of V,7V-dialkyl- 
hydroxylamines** ,^ oxidation of secondary amines*^ or* imines**, V-alkylation of 
oximes*^, or condensation o f car bonyl compounds or imines with hydroxylamines^^. 
These methods are shown in figur e 23. The condensation of aldehydes with iV-methyl- 
hydroxylamine^®, shown in scheme 6, has been shown to be a straight forward route, 
and was employed in this study.
NHR
R ^ R
NR
+
HONHR
RA HO \A
NRGH
Figure 23. Various ways of preparing nitrones.
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4 hrs reflux 
NaXO.,
HONHgMeCI---------------------------------------- ri H +  H^O
CHgClg
MeOH
R = H or Me
Scheme 6. The condensation of aldehydes with V-methyl-hydroxylamine.
The reaction conditions m scheme 6 are specific to R= H or Me. Different conditions 
are required when the substituent is: p-COOH, p-MeOCHiCHzO, p~
dimethylamino, p-N^(Me)3 , m-MeOCHiCHzO, o-MeOCHiCHzO, o-sodium 
sulphonate salt, m-OH and m-COOH, see section 8 (experimental section).
In the reaction, solid NaiCOg is applied as a base and methanol is used as co-solvent 
to dissolve the iV-methyl-hydr'oxylamme-hydrochloride and to facilitate its 
deprotonation. Unfortunately, it also dissolves other organic compounds, and that is 
why a two step evaporation-extraction procedure is used to isolate the product. All 
nitrones were made in this way unless otherwise stated in section 8.
4.2.2. Preparation of platinum nitrile complexes:
In order to produce results that are complementary to the previous studies, new 
platinum nitrile complexes of the general type [PtX2 (RC4H6 CN)2] (R= H, OH, 
COOH, 2-MeOCH2CH2P MezN and p- N(CH3)3^ CH3 SO4 , X= Cl, Br and I) were 
attempted. The reactions of those platinum nitrile complexes isolated puie, with 
valions nitrones were studied. The method of preparation of platinum(II) complexes 
was varied to produce mainly cis or mainly tram  complexes.
The thiee routes used were;
1. A variation on the Eysel et ah method^ ^ which is an aqueous route stalling 
with potassium tetrachloroplatinate. This is dissolved in water and 
acetonitrile and left to exchange at room temperature. The initial kinetic 
product is predominantly cis, but if left longer the thermodynamic tram  
product is produced as well. For reasons of symmetiy and polaiity it is 
believed the tt'am isomer crystallises out fiist. The cis isomer has a net
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dipole whereas the trans does not. The opposing dipole vectors cancel out in 
the trans case, this is shown in figure 24 below. Ligand exchange of 
acetonitrile with other nitriles, such as benzonitrile, was carried out in 
chloroform at 60 using a ten molar* excess of ligand, again producing a 
mixture of isomers.
5-ve ô-ve
P h C N ^  Cl P h C N ^  01
5+ve p t ( ^  S+ve P t ^
P h C N ^  Cl 01 NCPh
0-ve 5-ve
Figure 24. Symmetry and polar ity of cis and tt'ans platmum nitrile complexes.
2, To produce a predominantly trans product a variation on the Khar asch method
of direct ligand attachment to platinum was employed^^’^ ,^ using platinum 
dihalide and the desired ligand. A large excess of ligand was used and the 
platinum dihalide gradually stirred into the free ligand at 110 °C. 
Temperatur e was varied depending on the melting point of the ligand, and in 
some cases toluene was used as solvent.
3. To p ro d u ce  a  p red o m in a n tly  cis p ro d u ct, d irect lig a n d  su b stitu tio n  w a s  carTied
out at room temperature using the aqueous route^*, potassium 
tetr achloroplatinate, and the desir ed ligand in place of acetonitrile.
It has been mooted that a mixture of cis- and tj'ans-h\s nitrile platinum complexes can 
be converted to mainly trans by heating at 1 2 0  in the solid state, or in kerosene^^. 
Tliis was attempted using the present complexes. Thin layer cliromatography (TLC), 
NMR and IR spectroscopic studies performed before and after were used to determine 
which signals correspond to each isomer, and whether the method was successfiil in 
general. There are various possible mechanisms to explain this transition. The most 
simplistic is that with an input of energy the square planar cis complex assumes a 
tetrahedral airangement, and then relaxes back to square planar but with the similar 
ligands m a tratw position. This is shown in figur e 25.
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N
P t/ClAH
-  AH ck /NX
Figme 25. Solid state mechanism for conversion of a cis platinum to a trans 
platinum complex.
Another mechanism is that one of the ligands, most likely a nitrile becomes 
detached, it then attaches to the planai* three ligand platinum complex to give a 
mixtuie of cis and trans isomers. This is an example of a dissociative 
mechanism^^, shown in figme 26 (a).
/  V o ^ N : r - >  T
C l P t
D
Ptcr 'N,. + c r
Figme 26 (a). Dissociative mechanism for conversion of cis to trans platinum 
complexes.
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RCN
RCN
I
I
X '
/  I Pt-y -Cl
RCN
Figure 26 (b). SN2  type mechanism intermediate.
Another possibility is an SN2  type mechanism is where the bond between platinum 
and one benzonitrile ligand weakens as the bond between the incoming benzonitrile 
forms. The result is a five coordinate intermediate. Observation of figure 26 (b) shows 
that either a cis or trans isomer could form in contrast to the associative mechanism 
shown in figure 77. The other possibility is an associative mechanism outlined below 
in figure 26 (c)^ .^ This involves a five coordmate intermediate which would require 
the chlorine in the square plane to labilise the nitrile tt'ans to it. Most probably the 
transformation is effected by more than one mechanism.
RCN ^01 
RCN Cl
RCN RCN., ...Cl
^N C R
ClRCN
-RCN RCN^ Cl
cX NCR
Figme 26 (c). Associative mechanism for conversion of cis to trans platinum 
complexes.
4.2.3. Cycloaddition of nitrones to platinum nitrile complexes:
The cycloaddition of nitrones to platinum nitrile complexes creates a new centre of 
chirality which is situated at the N-CHR-N carbon atom in the heterocycle. We can 
expect the formation of two diastereomeric products, m different ratios.
Cycloadditions were initially attempted in an NMR tube which facilitated monitoring 
the progress of the reaction by proton NMR spectroscopy. If  successful they were 
scaled up. Nitrones and platinum nitriles were dissolved in a suitable deuterated
44
solvent in the molai* ratio of 2.2:1 for bis cycloadditions and 1:1 for mono. The NMR 
tube was placed m a heating block at 60 for up to 1 0  days for cycloaddition to both 
nitriles, or left at room temperature for a similar period for mono cycloaddition. 
Proton NMR spectroscopy was regularly performed to monitor the progress of the 
reactions. Appeaiance of a broad singlet at around 5.90 ppm and a doublet at 8.80- 
9.00 ppm in the proton NMR spectrum is indicative of cycloaddition. This is 
demonstrated by the proton NMR spectra of a niti*one, and a mono cycloaddition 
product shown below in figures 27 and 28 respectively. The HC==N proton of the 
nitrone appears in the aromatic region due in small part to ring cunent effects and its 
close proximity to the ring, but mainly to the electronic effect of the H-C=N and its 
associated magnetic field. After cycloaddition, the double bond is replaced by a H-C- 
N single bond, which does not have a large magnetic field compared to the double 
bond, and the proton signal moves out of the aromatic region. The position of the 
doublet at 9.05 ppm is an effect of the 5d%^ non-bonding orbital of platinum which 
effectively deshields the two equivalent ortho phenyl protons of the C=N~Ar ring. 
This is a consequence of the geometry of the molecule and the close proximity of the 
phenyl rings to the z axis.
cn kO to  CD «N I
A_ 1
— I------1— 1— I------1— I-----1— I----- 1— I— I-----r
6.5 6.0 5.5 ~r~5.0 —I—<- 4.5—T“ 8.0 —r—I—'—I—I—i—7.5 7.0 4.0 PPM
Figure. 27. Proton NMR spectiwi of JV-methyl-C-phenyl nitrone in CDCI3 including 
an expansion of the aromatic readmg.
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R =  4-( 2- CHjOCHïCHiCM
RC.H6 ' * 4 ' H PhCl V
”X j
C.H.R
yMe
jA A_J
Figure. 28. Proton NMR spectrum of a mono oxadiazoline platinum complex in 
CDCI3 with the main aromatic region expanded.
It is known that /raw,y-platinum nitrile complexes can form both mono and bis cyclo- 
adducts, whereas their cis counterparts can only form mono-adducts. This is thought 
to be due to the extreme steric hindrance that would result from having two 
oxadiazoline ligands in a cis positions. If  the mono oxadiazoline complex is not 
isolated and further reaction allowed to progress, the complex decomposes. This 
characteristic can be, and was, used to determine the stereochemistry of starting 
platinum nitrile complexes, where this could not be achieved by spectroscopic means.
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\5. Results and discussion
5.1. Production of nitrones.
Nitrones are more formally named benzylidene-methylamine-iV-oxides^'^. Nitrones 
were produced using accepted methods without much to report. The route used was 
the condensation of an aldehyde with A^-methyl-hydi'oxylamine^^. This method was 
chosen over the other methods outlined in the section 4 as it is a direct, one step route 
to the nitrone. The other methods such as oxidation of imines or alkylation of oximes 
would require the starting reagents to be made as a separate step. An additional 
problem with the oximes is that alkylation can occur at the nitrogen forming a nitrone, 
or the oxygen giving the oxime ether. This is dependent on the configuration of the 
oxime and reaction conditions'^, rtwrt-benzaldoximes yield nitrones while syn- 
benzaldoximes yield oxime ethers as shown in scheme 7.
R OH
RX + y = N  — ►
R"
Scheme 7. A mixture of syn and anti oximes yields a mixture of products.
Aldehydes were chosen over ketones as the aim of the project is to make complexes 
that are more polar and consequently more soluble in polar solvents and aqueous 
systems. The formyl proton is acidic, and a ketone, lacking this proton, would 
certainly result in a more lipophilic complex. Unless non-symmetrical ketones were 
chosen there would be no chiral centre in the resulting oxadiazoline. It is also unlikely 
that non-symmetrical ketones with a benzene ring containing various different polar 
substituents would be commercially available, and this would make the overall 
synthesis more complicated and less cost effective. Another problem with ketones is 
that the reaction compared to aldehydes is slow, due to the increased steric hmdiance 
at the cai'bonyl carbon. The water of condensation has to be removed to shift the 
equilibrium of the reaction to the right hand side. This requires a Dean-Stark 
apparatus. Also the products of the condensation of ketones are mixed cis and trans 
isomers. If one was significantly more reactive than the other this could affect the 
product of cycloaddition and yield. On the other hand, aldehydes only produce one
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product wliich is the isomer with the phenyl group and the oxygen on the same side of 
the double bond. This is confirmed by Nuclear Overhauser enliancement NMR 
spectroscopy (NOESY), where no correlation is visible between the N-Me and the 
ortho phenyl protons. This is shown in figui'e 29. In short, aldehydes are the first 
choice of reagent for making nitrones as they are cheap, off the shelf starting 
materials, and produce one nitrone only. Using aldehydes with a variety of electron 
withdrawing and donating functionalities facilitates the rapid production of a bank of 
nitrones with similar but shghtly different properties. For example, the pKg of 
benzaldehydes with an hydroxy group show the meta-suhstitaent to contain a less 
acidic proton than the ortho or para. This is due to the electron withdrawing formyl 
group wliich affects the ortho and para positions but not the meta position. In this 
way a family of platinum oxadiazoline complexes can he produced and studied, and 
valid comparisons drawn.
Figme 29. Two of the resonance forms of benzylidene-methylamine-N-oxides.
In the left hand structme of figure 29 there is free rotation about the CH-N bond and 
this eliminates the stereochemistry associated with the right hand structme. Attack 
comes fi-om both sides and the products are a mixture of geometric isomers. If it was 
the case that the nitrones existed in two stereoisomeric forms, namely cis and ti'ans, 
this would still have no effect on the resulting oxadiazoline. According to the 
proposed two step mechanism*"  ^ the double bond breaks in the intermediate, again 
facilitating free rotation and the end result is a mixture of enantiomers.
To produce more polar nitrones, benzaldehydes with polar substituents such as 
amino, carboxy and hydroxy were chosen. It was hoped that this would impart 
polarity in the platinum oxadiazoline end products and make them more soluble in a 
greater range of organic solvents and possibly aqueous systems as well.
The following nitrones were made (product numbers in brackets).
HONHjMeCl-
Me
N +
R
H ,0
R=H(1) and para- OH (4), COOH (9), Z-MeOCz^O (7), (Me)2N (11), (Me)3N'"(12), 
meta- OH (3), COOH (8), Z-MeOCzH^O (6),
Ortho- OH (Z), Z-MeOCzHtO (5), SOaXlO),
Scheme 8. Production of nitrones.
A dinitrone^^ (13) was also made from the dialdehyde terephthlaldehyde with the 
intention of producmg a multinuclear platinum compomid. Specific reaction 
conditions and yields aie contained in section 8.
+ 2 H2O2 HONH,MeCiH
O
H
+ N\Me
Scheme 9. Production of a diniti'one.
By usmg electron withdrawing and donating substituents in ortho or para positions it 
was hoped the polarity and subsequent reactivity of the nitrones would be affected one 
way or the other, and this could be studied. The specific results are discussed in the 
platinum oxadiazoline section (5.4). Incorporating a positively charged quaternaiy 
ammonium ion would mtroduce a new binding site to the resulting platinum 
oxadiazoline complex. There is the possibility of binding to the negatively charged 
phosphate ester bridges of DNA. Having hydroxy-, caiboxy- or amino-substituents, 
containing a proton, facilitates the possibility of hydrogen bonding with nitrogen or 
oxygen in the DNA.
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The major confoimding problem making these nitrones was tliat carboxy and hydroxy 
groups especially in the para position, made the nitrones so polar they were difficult 
to isolate from any residual inorganics left after reaction. In the case of pam-carboxy 
nitrone, this was insoluble in anythhig but water, so not only was isolation of the 
product impossible, but hydiolysis of the nitrone was extremely likely. Soxhlet 
extraction for 10 days using DCM only yielded a few milligrams, barely enough for a 
proton NMR spectrum. The absence of a signal at ~10.0 ppm in the spectrum suggests 
reaction of the aldehyde had taken place. In the end it was not possible to proceed 
further with this pailicular nitrone.
Para-hydroxy, /we/a-carboxy and mefa-hydroxy substituted nitrones, could be isolated 
in low yield of 30% by slow recrystallisation from methanol in the freezer. The yields 
improving the longer the crude products were left in the freezer. In the case of the 
para-hyôioxy nitrone, the procedme was improved by usmg ethanol instead of DCM 
as solvent for the synthesis. The higher reflux temperatuie meant that not only was 
more energy imparted to the system, but also the starting aldehyde was completely 
soluble in the reaction mixture. The reaction proceeded fester and went to completion 
resulting in a higher yield, the product stUl being recrystallised from methanol
The synthesis of the or^fro-hydroxy substituted nitrone was trouble free; the starting 
aldehyde and corresponding nitrone being soluble in DCM, which was used to extract 
the product from the crude after vacuum evaporation. This pai ticular nitrone had been 
used within the group to make a platinum(IV) oxadiazoline complex, so it was 
deemed a suitable candidate for cycloaddition with platinum(II) nitrile complexes. 
Hydroxy-substituted nitrones have been reported in the past^ *^ , but the age of the 
publications (ciica 1965) meant there was no detailed characterisation.
To overcome the problem of solubility in the hydroxy-substituted nitrones, it seemed 
we had gone from one extreme to the other, it was decided to fimctionalize the 
hydroxy groups with an alkylation that would result in glycol ether substituents. 
2-bromo-( 1 -methylethyl ether) was used to alkylate p-hydroxybenzaldehyde 
followmg a thermal Williamson ether synthesis using methanol as solvent. Methanol 
was used instead of DMF as it was considered the product would only be extracted 
from DMF using an aqueous work up with some difficulty. Glycol ethers are known
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to be soluble in a wide range of solvents including water. The reaction was slow (10 
days) and the yield poor (40%), but this was greatly improved with the use of 
microwave irradiation. This is described separately in the section on alkylations, 5.2. 
The microwave procedure was extended to meta- and or/^o-hydroxybenzaldehydes 
with similarly good results.
KgCOg
H
OH
C MeOH
Microwave
Scheme 10. Microwave synthesis of formyl phenyl ethers. X= Br or Cl.
Nitrones were produced fiom all three glycol ether substituted benzaldehydes in high 
yield without difficulty using ethanol as solvent.
A nitrone was made from />ara-dimethylaminobenzaldehyde without problem but it 
was considered cycloaddition with platinum nitrile complexes would be confounded 
by competition for the platinum coordhiation site between the amino and nitrile 
nitrogens. In an attempt to overcome this problem it was decided to methylate the 
nitrone using dimethyl sulphate. It was considered that if the powerful methylating 
agent methyl iodide was used it might methylate in other positions, or the iodide may 
interfere with the platinum by way of exchange with chloride. Initially the 
méthylation was attempted using methanol as solvent but this was unsuccessful. The 
result was a mixtuie of products including the aldehyde, possibly an acetal or 
hemiacetal and some starting material. All attempts to methylate the nitrone were 
unsuccessful, and this is described in section 5.2. Finally méthylation of the 
dimethylaminobenzaldehyde was attempted and after many failmes the optimum 
conditions of no solvent other than a fourfold excess of dimethyl sulphate, 70 ”C for 
one hour and a nitrogen atmosphere were discovered. A nitrone was successfully 
made from the product of this reaction.
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+ (CHa)2S0 , ----------------------
70“C 1 Hour
Me
Me I CH.SO.Me L
R= CHO or CN.
Scheme 11. Production of a quaternary amine.
The reactions of the nitrones with platinum complexes are described in section 5.4, 
‘Production of platinum oxadiazoline complexes’, only to mention here that the 
nitrones with electron withdrawing groups did not undergo cycloaddition giving the 
desiied product, whereas the nitrones with electron rich hydroxy groups especially in 
meta and para positions did. However the reaction of these was slower than for the 
unsubstituted nitrone.
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5.2. The 0-aIkyIation of phenols and the méthylation of tertiary 
amines
Apart from the work on platmum directly concerned with the main aims of the 
project, two things aiose from initial work on nitrones and nitriles. Firstly, 
introduction of an hydroxy group on the phenyl ring of nitrones or nitriles greatly 
reduces their solubility in chlorinated solvents. In the case of nitrones, acetone can be 
used as solvent, but with platinum nitriles the hydroxy group renders them only 
paifially soluble in acetone. Their solubility in methanol is better, but this is not the 
solvent of choice for platinum coordinated cycloadditions as it can reduce the 
platinum(II) to platinum (0), being oxidized to formic acid in the process. Good 
solubility is important durmg these reactions in acliieving the correct stoichiometric 
mix. A substituent that would make the precursors more soluble in a wide range of 
organic solvents was required. It was decided that an alkylation on the hydroxy group 
resulting in a glycol ether substituent would be promising as such compounds aie 
known in the coatings mdustiy as coalescent solvents and are compatible with a wide 
range of solvents. Initially a thermal Williamson ether synthesis was used but the 
reaction time was long (96 hours), and the yield low (40%). Clearly what was 
required was an improvement on the Williamson ether synthesis with regards to 
reaction time, yield and work up procedme. Microwave irradiation was employed for 
a series of alkylations on the ortho-^ meta- and joara-hydroxy groups of substituted 
benzaldehydes and benzonitriles, with excellent results.
The second matter worthy of note is that a rapid method of quaternisation of a tertiary 
amine had been developed. This was carried out to eliminate competition fr om the 
nitrogen of the tertiary amine for coordination to platinum rather than the niti ogen of 
the nitrile gioup. Being a more expedient method than the accepted one of using an 
alkyl halide and refluxing DMF, it was decided to spend some time alongside the 
maiu project to try and extend tins work.
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5.2.1 Rapid microwave assisted synthesis of phenyl ethers under 
mildly basic and water free conditions.
The major confounding problem with the cycloadditions attempted in year one was 
the poor solubility of the hydroxy-substituted platinum nitrile complexes. This was a 
two-fold problem, either the platinum nitriles were poorly soluble meaning the nitrone 
was always in excess and only bis products were produced, or secondly, if mixed 
solvent systems incorporating methanol were used, there was a competing reaction 
which reduced the platinum complex to elemental platmum. This had the result of 
either a reduced yield of cycloaddition product, or no cycloaddition at all.
A Williamson ether synthesis had been successfully used to functionalise the hydioxy 
group on one of the nitrones used, and it was decided to extend this approach to the 
hydi'oxy-substituted benzonitrile platinum complexes. Utilising 2-bromo-(l- 
methylethyl ether) as alkylating agent results in a glycol ether substituent, and as 
aheady explained, this should impart greater solubility in a wider range of solvents to 
the compounds.
Due to the long reaction time and poor yield in the previous thermal reaction (8.2.1, 
[14] 40%, 96 hours), microwave irradiation was employed to improve the yield and 
reaction time. The results were encouraging and a significant improvement m the 
Williamson ether synthesis has been developed where pure products in high yield can 
be made in less than an houi* fiom start to finish. The reactions were optimized with 
regard to yield by varying reaction time and temperature, and bromo- and chloro- 
substituted alkylating agents were used for comparison. Initially, microwave 
irradiation was used for only 1 mmute and TLC was used to monitor the progress of 
the reaction. The time was then increased to five mkiutes with successive increments 
of five minutes. When the TLC looked promising the reaction was worked up. This 
procedure was repeated until the optimum conditions were reached. For both the 
formyl and cyano phenols, the j^am-substituted phenol was optimized and the 
optimum conditions applied to the ortho- and meto-substituted phenols. The 
microwave reactor works by setting the reqmied temperatme and microwave 
absorbency settings (high or normal). A lai'ge initial pulse swiftly brings the reaction
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up to the requiied temperature, and further smaller pulses maintain the temperature. 
The reactor monitors temperatuie and pressure in the reaction vessel.
5.2.1.1. Discussion and results.
Microwave irradiation was first used m organic synthesis in 1986^ ’^^ ,^ and since then 
its use has become widespread^^’^ V^ It is generally used where thermal reactions work 
but aie slow, or produce low yields, and microwave irradiation significantly speeds up 
the reaction. This is thought to be due to the so called microwave effect. Polar 
moieties in the substrates and solvents are good absorbers of microwaves and this 
produces hot spots. It is thought this is what increases the rate. With the present 
compounds it could just as likely be due to the high temperatures and pressmes 
associated with the reactions. The use of microwave hradiation in synthesis, lends 
itself to combinatorial chemistry and automated processes employing high thioughput 
schemes^ ®^ '^ '^^ , and is thus atùactive to commercially driven researchers.
Ethers aie typically prepared using the classical Williamson ether synthesis from an 
alkyl halide and an alkoxide or phenoxide salt. To date, most microwave methods 
developed for the preparation of ahphatic ethers involve a large excess of either of the 
strong bases potassium or sodium hydroxide^ ®^ '^ ®^ .
Phenols, being more acidic than aliphatic alcohols, require a much milder base such as 
potassium or sodium carbonate to effect reaction. The use of potassium carbonate has 
been occasionally reported in thermal synthesis, although these reactions have 
required long reaction times (up to 72 h o u r s ) I t  is therefore surprising that 
almost all reaction schemes previously described for alkylation of phenols under 
microwave hradiation employ a lai'ge excess of sodium or potassium hydioxide^*\ 
often in an aqueous medium" This could lead to side reactions such as 
degradation of the alkylating reagent to the corresponding alcohol as the hydroxide 
ion is both basic and considerably nucleophilic. These reactions are therefore very 
often run as a two-step process, initially forming the phenoxide salt by stiiring the 
phenol with base, and subsequent addition of the alkyl halide. This can also lead to 
unwanted side reactions of sensitive fimctional groups present in the substrates such
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as hydrolysis of nitrile groups. As a consequence, only substrates that do not contain 
any functional groups prone to hydrolysis or reaction with bases have been used. 
Other schemes employ solvents with a high boiling point that can be difficult to 
remove such as DMF or glycols"^’"^, and this can cause problems if the reaction 
product is not compatible with an aqueous work-up, due to considerable solubility in 
water. In many cases phase transfer catalysts have been employed to effect reaction"^. 
This can lead to contamination of the product or the need for more sophisticated and 
time consuming work-up procedures. With commercial considerations in mind this 
must increase process costs. In general, the previous methods have taken the thermal 
reaction mixtmes and applied microwaves to them, rather than tailoring the reaction to 
suit microwave hradiation. Very often domestic microwave ovens have been used 
which aie more powerful than bespoke microwave reactors, and they require 
moderators such as sand or silica. The present method is by far the quickest and 
simplest method for the alkylation of phenols to date.
In an attempt to extend the apphcation range of microwave-assisted methods to more 
sensitive substrates and partially water-soluble products bearing glycol ether side 
chains, it has been found that phenols can be alkylated under microwave conditions in 
the presence of a stoichiometric amount of mild base namely potassium carbonate, 
and methanol as solvent, in non-aqueous conditions and without the need of a phase 
transfer catalyst. This is a tine ‘one pot’ synthesis.
,OH
KjCOj r ^  ^  o-
R MeOH
Microwave ^
Scheme 12. Microwave assisted Williamson ether synthesis using substituted 
phenols.
The reaction conditions which are given in Table 7 are favourably mild, have short 
reaction times and high yields. The method is useful for differing aieas of chemistry, 
as the target compounds chosen for this work are frequently used as precursors of 
phaimaceutically relevant compounds^ 19-122 crystalline compounds^^^’^ "^^ or
polymer materials^^^’^ ^^ .
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X = Br X = C1
Entry R — pKa"" T M Time [min] Yield [%] T fC ] Time [min] Yield [%]
14 4-CHO 7.61 1 0 0 15 45 140 30 65
15 3-CHO 8.98 1 0 0 15 78 140 30 74
16 2-CHO 8.37 1 0 0 15 81 140 30 76
17 4-C=N 7.97 1 2 0 30 87 140 30 96
18 3-C=N 8.61 1 2 0 30 89 140 30 73
19 2-C^N 6 . 8 6 1 2 0 30 80 140 30 91
2 0 3.4-OHC5H3CN 160 60 42
Table 7. Reaction conditions and yields
Recently a paper on microwave-assisted méthylation of phenols suggested the use of 
excess potassium carbonate (K2CO3) in refluxing acetone^^ .^ However, at the high 
temperatures required with the alkylating agents used in the present study, acetone 
undergoes a competing aldol reaction with the aromatic aldehydes which are among 
the substrates. Thus, microwave heating of a mixture of 4-hydroxybenzaldehyde and
0.6 equivalents of K2CO3 in acetone at 140 for 30 min produced 24% of £'-4-(4- 
hydroxyphenyl)-3 -buten-2-one. Acetone is therefore not the solvent of choice for the 
present work. This is shown in the reaction scheme below.
\
/ C=0 +  HO -CHO
MW
K2 CO3
O H \\
H sC -C -Ç -Ç -f  
H H
-OH
H2 O n
H
OH
Scheme 13. The competing aldol condensation reaction when acetone is used as 
solvent.
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Methanol, in contrast, can be used without being alkylated. This is consistent with 
previous reports on unsuccessful attempts to alkylate ahphatic alcohols in the 
presence of carbonate as a base*®^ . The use of this weak base in only stoichiometric 
amounts fiirther assur es the mildest possible conditions and the method lends itself to 
schemes using base sensitive substrates.
2 -bromo-(l-methylethyl ether) was used in close to equimolar ratio (1 . 2  equivalents), 
whereas the less reactive 2 -chloro-(l-methylethyl ether) required a thr*eefold excess 
and higher reaction temperatures to achieve comparable results. The chloro-alkylating 
agent also required longer reaction times when used with hydroxybenzaldehydes. 
Despite the chloro-alkylating agent requiring a threefold excess, this would still be 
attractive from the commercial viewpoint as the chloro-compound is considerably 
cheaper than the conesponding bromo-compoimd.
The hydroxybenzonitriles were slightly less reactive than the corresponding 
hydroxybenzaldehydes, and required longer times and higher temperatures with both 
alkylating agents. However, there seems to be no straightforwai'd relationship between 
the reactivity and the pKa values. This is plausible because the reactivity depends on a 
delicate balance between the ease of deprotonation of the phenol and the 
nucleophilicity of the resulting phenoxide. Electron withdrawing substituents in the 2 - 
or 4- position facilitate deprotonation, as reflected in a lower pKa value. On the other 
hand the nucleophilicity of the phenoxide oxygen atom is decreased due to 
delocalisation of its negative charge into the aromatic ring.
The work-up procedme was designed avoiding water from which the products would 
have been extracted with difficulty, and with some loss of yield, and only processes 
that are easily caiTied out by automated systems were applied. After evaporation of 
the solvent fr om the crude reaction mixtme, hexane was used to selectively extract the 
product fr om the inorganic salts. Residual phenolic starting material is not released 
fr om the inorganic solid under these conditions. The hexane can also be recycled and 
reused. In all cases, the product was obtained in high yield and pmity within one hour.
Due to a previous report on the use of a mkture of NaF and K2CO3 as base for the 
alkylation of less sensitive substrates^^^, the synthesis of the target compounds was
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attempted using solvent free conditions and K2CO3 as solid support. However, this led 
to a significant reduction in both yield and purity of the products, compared to the 
analogous reaction in methanol. Substituting methanol with ethanol which is cheaper 
and less toxic led to drastically reduced yields. This is presumably due to the lower 
solubility of the K2CO3 in ethanol (MeOH, 16500 ppm, EtOH, 904 ppm).
Using thermal conditions, 3- and 4-(2-methoxyethoxy)benzaldehyde have been 
previously synthesised from 2 -chloro-( 1 -methylethyl ether) and the corresponding 
hydroxybenzaldehydes, usmg K2 CO3 in refluxing DMF resulting in yields of 60 to
75%. However, no detailed information concerning the reaction conditions, reaction 
times and work-up procedure was disclosed^^^ Reaction of potassium 4- 
formylphenoxide with 2 -bromo-(l-methylethyl ether) in ethanol in a sealed tube 
required a reaction time of 3 hours at 160-170 ®C, resulting in a 50% yield of 
product^^ .^ 2 -(2 -rnethoxyethoxy)benzonitrile was also previously prepared under 
similarly harsh conditions'^^. In the present study it was found that the thermal 
reaction in refluxing methanol as solvent and otherwise equivalent conditions to the 
ones used for the microwave experiments required 96 hours of reaction time and 
yielded 40% of 4-(2-methoxyethoxy)benzaldehyde. In the reaction with 4- 
hydroxybenzonitrile, less than 1% of 4-(2-methoxyethoxy)benzonitrile was obtained 
under these conditions.
Subsequently, the same reaction has been attempted using 3,4-dihydroxybenzonitrile 
as substrate and the optimum conditions for nitriles. Initial results gave a yield of
40% of the desir ed di-glycol ether product (20), the remainder being starting material 
and mixed phenoxides with a glycol ether group in either the meta or para position. 
This would suggest the second alkylation is significantly more difficult to achieve 
than the first one. Column chromatography was required to purify this product, so the 
work-up procedure is not as straight forward as the reaction using mono substituted 
substrates. Attempts to improve tins yield were unsuccessful. The present study is a 
significant improvement on Williamson ether syntheses to date.
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5.2.12. Conclusions.
In conclusion, a simple and rapid method of microwave-assisted alkylation of phenols 
using stoichiometric amounts of K2 CO3 as a mild, cheap and environmentally 
compatible base has been developed. Both reaction and workup proceduie aie easy to 
perform and potentially suited for automated synthesis in high-thi*oughput schemes 
and combinatorial chemistry. The reaction can be run as a true one step reaction, 
without the need for pre-foiination of the phenoxide salt prior to addition of the halo 
compound, and without risk of degradation of the alkylating agent. The mild reaction 
conditions are compatible with functional groups that aie sensitive towaids strong 
bases or hydiolysis. The non-aqueous work-up allows for paitially water-soluble 
products being obtained in high yield, without any loss due to incomplete extraction. 
Overall, only a minimum of reagents is used, and there is no need for a phase transfer 
catalyst that complicates the work-up proceduie. Bearing this is mind; the process is 
also economically and enviromnentally acceptable.
5.2.2. Quaternisation of tertiary amines.
5.2 2.1. The méthylation of tertiary amino substituted aromatic 
aldehydes and nitriles.
A simple method for the quaternisation of tertiary amino-substituted benzaldehyde 
and benzonitrile has been developed tliat used no solvent apart from the methylating 
agent dimethyl sulphate.
The reaction using (4-dimethylaminobenzaldehyde) was attempted as a first step to 
making the quaternaiy ammonium substituted nitrone, as all attempts to methylate the 
dimethylamino nitrogen on the nitrone had failed. Dimethyl sulphate was chosen as 
the methylating agent for two reasons, firstly, the counter ion would not interfere with 
platinum whereas an iodide from methyl iodide would, and secondly, a stronger 
methylating agent such as methyl iodide might methylate the aldehyde oxygen. The 
second reaction (4-dimethylaminobenzonitrile) was carried out to eliminate
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competition from the amino nitrogen for the coordination site on platinum leaving it 
free for the nitrile nitrogen.
The method employs a fourfold excess of the alkylating agent as solvent, mild 
conditions of one hour heating at 70 under a nitrogen atmosphere. Excess of 
dimethyl sulphate is removed with diethyl ether and the product easily purified by 
washing with successive portions of diethyl ether and DCM. The products are 
produced in high yield of 70%. For these substrates this is a sigrrificant improvement 
on the usual method of quaternisation which involves a lengthy reflux using DMF, 
and an aqueous work up fr om which the products may well be difficult to remove^
5.2.2.2. Attempted méthylation of tertiary amino substituted imine 
and nitrone.
It was decided to extend this work and have another attempt at methylating the 
nitrone [11], and also a con-esponding imine. The imine [23] was made from aniline 
and 4-dimethylaminobenzaldehyde^^^ as described in the experimental section, 8.
Results:
The various attempts listed below to methylate the imine and the nitrone were 
unsuccessful.
1. Mild conditions, room temperature with stirring under nitrogen for times 
varying from 30 minutes to 4 horns using excess dimethyl sulphate as solvent.
2. 60 ®C, stirring under nitrogen 30 minutes to 12 hours using excess dimethyl 
sulphate as solvent.
3. 90 °C, stirrmg under nitrogen 30 minutes to 12 horns using excess dimethyl 
sulphate as solvent.
4. 140 °C, stirring under nitrogen for 10-90 minutes.
5. Using a stoichiometric amount of dimethyl sulphate and acetonitrile as solvent 
at room temperature to reflux temperature.
6. Using a stoichiometric amount of dimethyl sulphate and methanol as solvent at 
room temperature to reflux temperature for varying times up to 3 days.
7. All the above without using nitrogen.
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All these conditions were used in an attempt to methylate 4- 
dimethylaminobenzaldehyde, resulting in no reaction for the mild conditions and 
acetal formation for the extreme ones, before the successful solventless synthesis 
under nitrogen was attempted. In the case of 4-dimethylaminobenzonitrile, only the 
successful method was used as this was subsequent work.
Results for méthylation of 4-dimethylaminophenylnitrone.
These fall into thr ee ar eas:
1. Usmg the mildest conditions there was no significant reaction at all judging 
from the proton NMR spectra.
2. At more moderate conditions an oil was produced which based on the proton 
NMR spectrum could be a mixture of starting nitrone, the corresponding 
aldehyde with the nitrone cleaved, possibly some of the desired product, and 
possibly some nitrone methylated on the oxygen of the nitrone.
3. At the more extreme conditions there was also a mixture of products the most 
likely being an acetal.
Results for the méthylation of the imine (23) of aniline and 
4-dimethylaminobenzaldehyde.
Again, at the mild to moderate conditions there was no significant reaction. At the 
more extreme conditions there was a mixture of products (yellow oil), the proton 
NMR spectrum of which could not be interpreted with any accui acy, only to say that 
the major product was not the desired one.
Conclusions
Méthylation of the dimethylamino nitrogen on para-substituted 
dimethylaminobenzene derivatives is difficult to carry out but can be achieved when 
the substituents are formyl or nitrile, however, when they aie an imine or nitrone 
functionality, méthylation is not possible.
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5,3 Platinum nitrile complexes
H2O / RT CHCI3 / 60 °C
K 2PtCl4  + MeCN -> PtCl2 (MeCN ) 2  + RCN ^  PtCl2 (RCN ) 2
Scheme 14. Ligand exchange method of producing bis nitrile platinum (II) complexes. 
A hill descriptonof the complexes produced is given in tables 8 and 21.
5.3.1. The production of bis benzonitrile piatinum(ll) complexes.
Bis(benzonitrile) platinum(II) complexes were fhst described in 1907, when Hohnann 
and Bugge^^ ,^ and Ramberg^^^, synthesized dichlorobis(benzonitrile) platinum(II) 
from potassium tetrachloroplatinate using an aqueous ligand exchange method. In 
1938 Khai'asch and co-workers synthesized the analogous palladium compound with a 
fai’ superior yield by direct ligand attachment starting from palladium dichloride^^. 
They mention that the method employed had been successfully applied previously to 
platinum dichloride but the work was unpublished. Whilst Hartley's review of the 
older literature introduces some doubt as to what method produces which isomer^^’^ ,^ 
more recent publications such as Uchiyama and co-workers^^* accept that all methods 
described to date produce varying mixtures of cis and trans isomers. These have been 
separated by column chiomatography, and the crystal structure of each has been 
published^ \
It is impossible to distinguish cis and trans isomers of dichlorobis(benzonitrile) 
platinum(II) from the proton NMR spectra, if one has pure separated samples. It is 
slightly easier fr om the spectrum of a mixture of isomers as the two sets of signals are 
not perfectly superimposed. In the NMR spectra there aie slight differences 
between the signals of cis and trans isomers. The most obvious is the signal of the CN 
carbon which is at 116.8 and 115.3 ppm for trans and cis isomers respectively^
IR spectroscopy has also been used to identify isomers. The cis isomer should show 
two nitrile stretches at 2285 and 2290 cm'  ^due to coupling whereas the trans isomer 
only exhibits one stretch at 2286 cm‘^  In the present study the findings were not
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so clear cut. The trans isomer shows a nitrile stretch at 2287 cm'  ^ and the cis isomer at 
2285 cm"\ However, a 1 / 1 mixture of the two showed only one stretch at 2286 cm'\ 
Also cited aie the Pt-Cl and Pt-N stietches in the 100-400 cm‘^  region, and the out of 
plane C-H stretches in the 500-1000 cm'^ region^^’^ ^^ . In the cis complex there should 
only be one stretch at 162 cm"\ whereas with the trans complex there should be one at 
158 cm'  ^ and two stretches at 356 cm‘  ^and 394 cm"\ With the instrument used in the 
present study the region below 350 cm'^ cannot be measured, and the region between 
350 and 400 cm'^contains so many absorptions that positive conclusions could not be 
drawn. Again, in the 500-1000 cm'^ region it is suggested that for the cis complex 
many of the stretches should be split, however this was only exhibited by one 
complex made in the present study, which is believed to be a mixtui e of cis and trans 
isomers. For these reasons it is not accepted that IR spectroscopy is a reliable 
technique for distinguishing these isomers. It should be stressed that many of the 
reports, Walton^^  ^ for example, predate the widespread use of multinuclear NMR 
spectroscopy, and pressure would have been on the scientists to assign complexes 
with the techniques available to them.
A method that can definitely distinguish the two isomers is ^^ P^t NMR spectroscopy. 
Rochon and co-workers '^^  ^found that the cis isomer has a signal at -2288 ppm whereas 
the trans isomer has one at -2350 ppm. They explain the lower signal of the trans 
isomer in terms of increased shielding. The trans isomer has less efficient platinum to 
nitrogen back donation, presumably because the tf'ans ligands have to share an orbital, 
either the zx or zy, whereas the cis ligands receive electron density from both these 
orbitals.
To date, the structure of dichlorobis(benzonitrile) platinum(II) has been well 
elucidated. Complexes involving other halide ions such as bromide and iodide have 
been reported but often they have been used as precursors to make something 
else '^ '^’^ '^ ,^ or for IR or Raman spectroscopic studies^^’^ *^’^ ^^ . Detailed characterisation 
has not been reported and the stereochemistry of them is ambiguous. In the present 
study diiodo- and dibromobis(benzonitrile) platinum(II) complexes are characterized 
for the first time. It is believed trans complexes were made exclusively but this is 
more difficult to ascertain when there is no cis complex to compare them with. It is 
known from previous research that trans platinum benzonitrile complexes undergo bis
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cycloaddition in contrast to cis complexes where mono cycloadducts are the sole 
products "^^ .^ This criterion has been used to assign the stereochemistry of platinum 
nitrile complexes where no other spectroscopic teclinique could identify them.
Platinum nitrile complexes of the type in figure 30 were produced, and are described 
more specifically in table 8 shown below.
C om plex no. X R REF.
24 Cl H 52, 91, 92,137,138,139
25 Cl o-OH
26 Cl m-OH
27 Cl p-OR 140 cis complex only
28 Cl m-2 -Me0 C2 H4 0
29 Cl jP-2 -Me0 C2 H4 0
30 Cl 7«,/7-di(2-Me0C2H40)
31 Br H 52,91,138,139,141,142
32 Br m-OH
33 Br /7-OH
34 I H 91,141
35 Cl jf7-N(Me)2 *
36 Cl m,p-di-OH
37 Cl P-NO2
* considered to be coordinated via the amino nitrogen
Table 8. Summary of the platinum(II) nitrile complexes produced.
X,
X
Figm e 30. The structur e of cis and trans platinum(II) nitrile complexes.
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The three methods of production described in section 4.2.2 were used resulting in 
varying mixtures of cis and trans isomers when X = CL This is consistent with the 
literature To make complexes that are mainly trans in confrgirration, specific 
conditions had to be used and these ar e described in section 8. Contrar y to previously 
described methods^\ when X=Br, solely tr'ans isomers were produced in the present 
study. The same was found when X=I, but nothing conclusive about the 
stereochemistry of this complex lias been described previously in the literatur e. In the 
first instance aromatic nitriles bear ing polar substituents such as hydroxy, carhoxy and 
dimethylamino were chosen as ligands. Exchange in chloroform at 60 ®C, typically for 
48 hour s using a 10 molar excess of ligand and starting with dichlorobis(acetonitrile) 
platinum(II) was carried out (method 1).
5.3.1.1 Coordination of hydroxy-substituted benzonitrile.
The first three platinum complexes made using method 1 were the para-^ meta- and 
ort/zo-hydi*oxy substituted nitrile compounds. Coordination became increasingly 
difficult moving from para to meta to ortho. Meto-substituents have no electronic 
effect on the nitrile group unlike para- and ort/zo-substituents, which eiqilains the 
difficulty in coordinating the meto-liydroxybenzonitrile compared to its isomers. 
There are also increasing steric effects of the hydroxy group going fi’om meta to 
ortho. The ort/zo-substituted product is unstable in solid and solution (deuterated 
acetone), the fiee ligand being liberated. This was noticeable in the complex turiring 
from bright yellow to darker orange, and an odour characteristic of the fi*ee ligand.
The initial kinetic product is generally the cis isomer which is more polar* and has less 
symmetry than the trans isomer, so is less likely to crystallise out. The 
thermodynamic trans product is more symmetrical and less polar and though it is 
produced second, may well be the first to precipitate out. It was found that 
occasionally ligand exchange using para-hydroxybenzonitrile produced the trans 
isomer in large enough amounts to imdergo bis cycloaddition, the cis isomer 
characteristically can only undergo mono cycloaddition. However, in the majority of 
cases, the product of this method of hgand exchange was predominantly the cis 
isomer.
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X-ray crystallography would indisputably be able to assign cis and trans isomerism, 
however the trans isomers once precipitated were not soluble enough to grow decent 
crystals. Also in the case of mixtures of cis and trans isomers many ciystals would 
have to be scanned to estimate the composition. Poor solubility is also a problem for 
i^^Pt NMR spectroscopy, and experiment times ran to days rather than horns. And of 
course two isomers are required for comparison. In contrast to para- 
hydroxybenzonitrile, »?eto-hydioxybenzonitrile produced mainly a trans platinum 
complex. It was able to undergo both mono and bis cycloaddition. This lends weight 
to the theory that the difficulty in coordination of this ligand is one of steric rather 
than electronic influence.
Figme 31. cis and trans isomers of PtCl2 (/w-OH-C6 H4 -CN) 2
Whilst figure 31 does not immediately demonstrate any excessive steric hindrance in 
the cis isomer, it does show, in conjunction with figures 26 (b) and (c), that the 
substitution of the second ligand would be made easier by approach fiom the side 
which results in a trans complex.
Exchange was also attempted using 3,4-dihydroxybenzonitrile but this proved more 
difficult than would have been expected compared to the two mono hydroxy- 
substituted ligands. Ten days at 90 “C using 4 /1  toluene / chloroform as solvent gave 
a poor yield. IR spectroscopy suggested that the bulk of the product was possibly a 
species with one acetonitrile ligand and one di-hydroxybenzonitrile ligand, the broad 
absorption at 2341 cm"^  being roughly intermediate of the two. ^^ P^t NMR 
spectroscopy gave the major signal at -2303 ppm compared to -2339 ppm for the 
pflra-hydroxy nitrile complex, and -2369 ppm for the corresponding meta complex. 
Analysis of the analogous glycol ether substituted complexes showed the disubstituted
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complex to have an almost identical signal to the para-substituted complex, at -2315 
and -2313 ppm respectively. The discrepancy further suggests that the product 
obtained fiom 3,4-dihydroxybenzonitrile was not the intended complex. It was not 
particularly soluble in chloroform or acetone, so recrystallisation and crystallography 
were not possible, and the complex showed no evidence of cycloaddition. Possibly the 
insolubility of the product of the first substitution meant it immediately precipitated 
and the second substitution was rendered impossible.
5.3.1.2. Coordination to glycol ether substituted benzonitriles.
Platinum nitrile complexes^^’*^ , and their platinum oxadiazoline counterparts^^ are 
notoriously insoluble in all but chlorinated organic solvents. It was hoped that the 
introduction of an hydr oxy group would impart solubility to the platinum oxadiazoline 
end products in more polar solvents. Unfortunately, this rendered the para-hydroxy 
nitrile complex only partially soluble in acetone and methanol, and in dimethyl 
sulphoxide, it rapidly exchanged. Methanol is best avoided in platinum chemistry as it 
is oxidised by platinum(II) which in turn is reduced. This poor solubility would 
inevitably lead to problems with the cycloaddition reactions with regard to 
stoichiometry, so it was decided to fimctionalise the hydroxy group in a similar' way to 
the firnctionalisation of hydroxybenzaldehydes in section 5.1 and 5.2. i.e. with a 
glycol ether substituent. This is still a polar group but unlike hydroxy is aprotic. It was 
hoped this would make the products soluble in a wider range of solvents. This was 
cari'ied out on the three hydroxybenzorritriles using microwave irradiation as 
described irr the previous section and illustrated in the scheme below. The 3,4- 
dürydr oxybenzorritrile ligand was treated in the same way.
K2 CO3
MeOH
Microwave
Scheme 15. Microwave synthesis of cyano-substituted phenyl ethers. X= Br orCl.
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Ligand exchange using dichlorobis(acetonitrile) platinum(II) and all four glycol ether 
derived ligands was attempted. This proved to be much more difficult than the 
hydroxy-compounds and took 10 days at 90 °C, and 2 weeks for the di-substituted 
compound. Products were isolated and characterised for aU of these except the ortho- 
substituted complex which was either unstable or did not coordinate in the first place. 
There is undoubtedly steric hindrance of the glycol ether group with either or both the 
platinum centre and the other ligand. It was considered that with such large side- 
chains only the trans complexes would be possible and this was borne out in the 
cycloaddition reactions, where in the case of the para-substituted platinum complex 
both mono and bis products were produced.
5.3.1.3. Coordination of carboxy-substituted benzonitrile.
Attempts to coordinate para-carboxybenzonitrile to platinum using method 1 were 
thwarted by the insolubility of the fiee ligand in chloroform. DMF was used instead 
but it was impossible to isolate a product using either solvent extraction or aqueous 
work up. Ligand exchange using water and potassium tetracldoroplatinate was canied 
out without work up in order to determine the ^^ P^t NMR signal. However the signal, 
at -2034.2 ppm, was not where it was expected and it is thought that the most likely 
outcome was that the nitrile had been hydrolysed to an amide, or that only one ligand 
had exchanged resulting in a [PtClgligand]" charged species. This will be expanded on 
later in the chapter. Exchange was also attempted using THF and 
dichlorobis(acetoniti‘ile) platinum(II), but the results were erratic and non- 
reproducible. The product isolated, although having a consistent proton NMR 
specti-um, did not undergo cycloaddition. The only reliable conclusion to be drawn 
from it was that THF is not a suitable solvent for exchanges in platinum chemistry.
5.3.1.4. Coordination of/?am-dimethylaminobenzonitrile.
Coordmation of para-dimethylaminobenzonitrile was attempted but IR absorption 
spectroscopy showed that the amino nitrogen is likely to have coordinated to platinum 
rather than the nitrile nitrogen. Tliis was indicated by the nitrile stretch being at 
ai ound 2235 cm"^  which is typical of the uncoordinated nitrile, rather than at 2280-
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2290 cm"^  which is where a coordinated aromatic nitrile appears. Comparison of the 
*^ P^t NMR spectrum with known amines^ "^ ® supports the assumption. Rochon found 
that primary and secondary amines coordinated to platinum have signals at -2230 ppm 
and -2180 ppm respectively. Extrapolating for the tertiary amine gives a signal of 
approximately -2130 ppm, which is in rough agreement with 2124.7 ppm which is the 
signal found for the present complex. The tertiary amine was methylated as described 
in section 5.2. Coordination of the quaternary ammonium salt 4-(Me)3N^- 
C6H4 CN.MeS0 4 ' was attempted but it was not possible to separate the product, if any, 
from the stalling materials for reasons of solubility. It was inconclusive fr om proton 
NMR spectroscopy if exchange had taken place, but in the IR spectrum a small 
absorption was visible at 2295 cm'  ^ which is in the right region for a platinum 
coordinated nitrile. The positive charge on the quaternary ammonium nitrogen is 
strongly electron withdrawing, and would draw in towards the nitrogen the lone pair 
on the para-nitrile substituent. This would make coordination to platinum more 
difficult.
5.3.2 Coordination employing direct ligand attachment starting with 
platinum dichloride^^’^ ^(method 2).
P tC l2+ 2R C N  ^  PtCl2(RCN)2
Scheme 16. Ligand attachment method of producing bis nitrile platinum (II) 
complexes at temperatiues varying from 85-160  °C depending on the ligand.
A frill descriptonof the complexes produced is given in tables 8 and 21.
5.3 2.1. Coordination with benzonitrile varying the halide ion.
Platinum chloride, bromide and iodide were employed using benzonitrile at 110 °C 
and Kharasch’s method^^’^  ^(method 2). The literatme regarding the configuration of 
the products is contradictory. According to Hartley^^, who refers only to the bromo- 
and chloro-compounds, the complexes formed are cis in configuration. However 
Uchiyama and co-workers claim a mixtme of isomers depending on temperature 
To date, the situation regarding the chloro complexes is clear. All methods produce
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varying mixtures of cis and trans isomers. The present study foimd that in the case of 
the latter two halides only trans products were produced contraiy to previous findings, 
and it is hoped this will be confirmed by X-ray crystallography. Whilst cw-iodo 
platinum complexes are common, it is easy to accept that at the high temperatuies 
used in the present project, the thermodynamic trans product will be made in 
preference to the kinetic cis product.
In the case of the cliloride it was clear from TLC that there were two products 
presumed cis and trans, and these were separable using column chromatography, the 
trans product running fii'st. It was also found that with the chloride, mcreasing the 
time of reaction increased the proportion of trans isomer produced. This is 
demonstrated in figuie 32 below.
% Yield
90
trans -dichlorobisbenzonitrile platinum(ll) thermal 
route starting from PtClz
50 100
Time (mins) at 110%
150
Figme 32. The yield of /raw5'-PtCl2(PhCN)2 produced by thermal route with 
relation to time at 110 ”C based on six experiments.
Reactions were worked up at various times (six experiments) ranging from ten 
minutes to two hours, and the isomers sepaiated by column chiomatography. All 
reactions were carried out at 110 °C. The yields were calculated from the theoretical 
maximum yield from a known amount of starting material. A line of best fit was 
applied so figme 32 is designed to show the trend for the optimisation of the 
production of the trans isomer. It is not intended as a plot to calculate a rate constant, 
so results have not been averaged and error bars indicate estimated weighing error and
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residual solvent of + / - 1% and -1% respectively. Whilst at first glance, the figure 
appeal's to show an attiactive mathematical relationsliip between yield and time, 
unfortunately this is not the whole story. Platinum dichloride is a polymeric 
compound with a repeating square planai' PtCfi unit. Different batches may vaiy in the 
length of the polymer chain and the trans isomer may take longer to form and the 
yields be lower. Generally the yield of trans isomer mcreased with time up to about 
90 minutes. The cis isomer however was isolated in some cases but in others the 
second product off the column was unstable in solution and tinned from a diity yellow 
to gi'een to black in a few hours. Recrystallisation for X-ray analysis was therefore not 
possible. Little could be learned about the structure from proton NMR and IR 
spectroscopy, or MS-FAB spectrometiy, save that there is possibly evidence of nitrile 
functionality at 2300 cm'  ^ in the IR spectrum. The *^ P^t NMR spectrum was more 
illuminating; the main signal is at -2343 ppm which is roughly in agreement with 
Rochon's finding at -2350 ppm for the ti'ans isomer. There is also a smaller signal at - 
2288 ppm which corresponds to Rochon's cis complex^ '^ ®. This would suggest that in 
the main, the unknown complex possesses similai* stereochemistry to 
diclilorobis(benzonitrile) platinum(II). It was thought this was most likely a polymeric 
platinum nitrile complex. Uchiyama et alP^ found that the proportion of trans to cis 
isomer is increased with increasing temperature. The present study found this to be 
true but only for short reaction times of a few minutes. With increasing time, at 160 
”C, a second product of unknown structure but similai' to the one just mentioned is 
produced. Figme 33 below shows a possible dimeric structme of the unknown 
complex.
C l \  /N C R
RON Cl
Figme 33. Possible structme of a dimeric platinum nitrile complex.
Dimeric platinum and palladium complexes aie not uncommon '^^’^ .^ Because of the 
imwanted product formed at higher temperatm es, it is believed that the method of the 
present study at 110 is a more reliable method for making the trans complex than 
that of Uchiyama. Although it takes longer, better yields are achieved.
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Platinum bromide gave the same high yield under similar conditions but IR and 
proton NMR spectroscopy, TLC, and reactivity pointed strongly to only one product, 
the trans isomer being formed. In the case of platinum iodide it was difficult to see 
any reaction taking place because of the strong deep red coloui' of the starting 
material. However precipitation with petroleum ether, filtration and extraction of the 
residue with DCM did yield an orange / red sohd. Spectroscopy confirmed the 
product, which was not paiticularly stable and reverted back to a deep red colour with 
evolution of an intense almond smell characteristic of benzonitrile. Cycloadditions 
were carried out immediately with the iodide complex and confirmed its trans 
configuration. The failure to isolate cis benzonitrile complexes with bromide and 
iodide ligands is consistent with the increasing size of the halide moving down the 
group, introducing the possibility of steric hindrance. There may also be a small 
contribution due to the increasing trans effect from chloride to iodide^ '^ In the cis 
complexes the benzonitrile would be increasingly labilised going from chloride to 
iodide weakening the platinum-nitrogen a  bond. This would make the complexes 
inherently unstable in the case of bromide and iodide. This must lead to the more 
stable thermodynamic trans complexes being produced. The cis-
dibromobis(benzonitrile) platinum(II) complex has been previously claimed and
characterised using I.R. spectroscopy by Walton^^ .^ However, subsequent attempts by 
Walton to repeat the synthesis resulted in a trans complex, much to his
fi'ustration '^*' ’^^ '^ .^ Eysel and co-workers claimed the cis-iodo complex which has 
also been reported without characterisation as a precursor to other platinum 
complexes '^^^ The fact that in Dhaia's synthesis of cisplatin (scheme 3) the cz.s-iodo 
complex is exclusively produced by reaction of ammonia with potassium 
tetraiodoplatinate, which is why the starting reagent is chosen, may appear*
contradictory when comparing the analogous benzonitrile complexes. However it is 
the strong trans effect of the iodo ligands that have orbitals energetically similar* to 
platinum that allow back bonding from platinum to iodine and stabilise 
diamminediiodo platinum(II). The ammonia ligands have a strong trans influence, 
which means the platinum-nitrogen bond is strong and the molecule is further 
stabilised. In the benzonitrile complex the platinum-nitrogen bond is not strong so 
having iodo ligands in trans position would destabilise it.
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One of the aims of the project was to produce more polar complexes, and 
consequently ones more soluble in polar solvents. Changing the halide from cliloride 
to bromide certainly achieved tliis in the nitrile complexes, and it was hoped this 
would be reflected in the corresponding oxadiazoline complexes, /rawi'- 
dichlorobis(benzonitrile) platinum(II) is only sparingly soluble in acetone, whereas 
P'a«6'-dibromobis(benzonitrile) platinum(II) is very soluble in acetone. From a 
medical point of view, as bromine is found in the body m trace quantities, 260 mg in a 
56 kg body, it was not considered that platinum bromide complexes would be 
inappropriate. It would mevitably exchange with chloride which is present in the 
bloodstream m much lar ger concentrations, and be readily excreted by the kidneys.
5.3.2.2. Coordination with hydroxybenzonitriles using a hot melt 
system (method 2).
Pora-hydroxybenzonitrile and mefa-hydroxybenzonitrile were coordinated to 
platmurn dichloride and dibromide. The melting points of the fr ee ligands are 115 ®C 
and 85 respectively, and in the latter case the ligand rapidly vaporises due to its 
high vaporu' pressme, and condenses further up the reaction vessel. Care has to taken 
to keep the temperatme just high enough to keep the ligand molten. Addition of a 
small amount of toluene is also helpful in this respect and it also dissolves some of the 
platinum dichloride. However, there is a lower energy input than in the benzonitrile or 
j9am-hydroxybenzonitrile reactions.
In the case of me^o-hydroxybenzonitrile a mainly trans product is formed from 
platinum dichloride, and solely trans from platinum dibromide. This adds to the 
evidence from method one exchanges, that formation of the product is controlled by 
steric effects. Using j?ara-hydroxybenzonitrile and platinum bromide results in a trans 
isomer, similar* to the corresponding benzonitrile reaction. However when it is 
coordinated to platinum dichloride a mixture of products results and this varies with 
different batches of the platinum dichloride, and reaction conditions.
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In some cases fom* ai*omatic systems are visible in the proton NMR spectrum. Apait 
from the cis and trans isomer, the other signals aie thought, again, to be polymeric, 
possibly dimeric, platinum compounds. A diremic complex is more likely as the form 
of the proton NMR spectum is too simple to be polymeric.
Whilst mass spectrometry data should be treated with caution, because reactions can 
occui' during the process, there is some evidence to support the presence of dimeric 
species. The structure of one possible complex shown in figure 34, has formula 
Pt2Cl4N202Ci4Hio, and formula weight 770.21 g. In the MS-FAB spectrum there is a 
peak for M-OH at 753, and M-OH-HCl at 717. There is also a small peak for [PtCl(p- 
OH-C6H4 -CN)2]"*'Cr at 623, and a large one at 588 for the positive ion [PtCl(p-OH- 
C6H4 “CN)2] .^ These are shown in figure 35.
o
N
Cl
Figure 34. Proposed structur e of the dimeric platinum species suspected to be one of 
the products of the Kharasch method^^ of the reaction of platinum dichloride and 
pam-hydroxybenzonitrile.
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Figme 35. The MS-FAB spectrum of the products of the Khaiasch method of the
reaction of platinum dichloride and /7ara-hydroxybenzonitrile.
The unknown species are a confounding problem with regard to cycloaddition as 
unlike the dichlorobis(benzonitrile) platinum(II) complex, the platinum hydroxy- 
substituted nitrile cannot be purified by column cinematography. The solubility is 
poor in chlorinated solvents or mixtmes, and if  dissolved in an excess of acetone or 
mixtm es incorporating acetone, the mixtme of products runs off the column together. 
If methanol is used the compounds tmn green on the column. The poor solubility also 
rules out reciystallisation. Preparative TLC can be used to sepaiate small amounts of 
the complex and this was performed in order to carry out IR analysis. However it was 
unclear' whether the mixtme had separated or decomposed on the plate. The first spot 
to run was bee ligand with an absorbance at 2225 cm '\ The second was a mixtme of 
bee and coordinated ligand with absorptions at 2225 and 2284 cm"\ There is no 
information in the literatme to con&m this par ticular complex but it is consistent with 
known similar* complexes. The third spot had a weak absorbance at 2285 cm"\ As the 
last two absorptions are so close it is not possible to tell if these are the same complex 
or cis and trans isomers. What is for certain is that it was not an efbcient way of 
separating the isomers. With the meta-lnyàxoy substituted complex the impmity was to 
a lesser extent, but there was a visible difference in the IR absorption spectrum, with 
signals at 2307 and 2300 cm \  In the ^^ p^t spectrum a broad signal with two peaks 
was seen at -2368 and -2372 ppm. The problems incmred dming the cycloaddition
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reactions are discussed in section 5.4, and the characterisation of one of the impurities 
in section 8.9.3.
This problem was paitially overcome by heating the mixed products in toluene / 
acetone, 4 / 1 ,  and a ten molar excess of bee ligand, for 30 hours. This reduced the 
number of aromatic systems visible to two, with one in large excess, hopebilly the 
trans isomer. However this was found not to be the case and it was thought that the 
impurity was a poly nuclear platinum nitrile complex, similar to the result found for 
the reaction of benzonitrile with platinum dichloride. It was not possible to overcome 
this problem using this method, but an almost puie complex was eventually made by a 
modification of method 1, stalling bom dichlorobis(acetonitrile) platinum(II) and a 
mixtui e of toluene / chloroform in 4 / 1 ratio as solvent. This was stirred for 45 hour s 
at 85 °C. The use of toluene at this temperatur e removes acetonitrile bom the system 
and shibs the equilibrium to the right, i.e. towards the desired product. The high 
temperature also favoui's production of a trans complex. Star ting bom a mononuclear" 
platinum complex also eliminates the polymeric impurity problem.
5.3.3 Aqueous ligand exchange using potassium tetrachloroplatinate 
(method 3).
H2 O /R T
PtCl2(M eC N ) 2  +  2R C N  PtCl2(RCN ) 2  +  M eC N
Scheme 17. Aqueous ligand exchange method of producing bis nitrile platinum (II) 
complexes. A bill descriptonof the complexes produced is given in tables 8 and 21.
A variation of the Hoffinan and Bugge method^which is the same method used by 
Walton^^  ^and Eysel et al. was employed in the present study. The exact method is 
described in the experimental section, only to mention that for bromide complexes, 
potassium bromide was dissolved in water in a ten fold excess compar ed to potassium 
tetrachloroplatinate, as well as a ten fold excess of the bee ligand. This facilitates 
exchange of bromide for chloride as well as bee ligand for halide on the platinum 
centre.
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For chloride complexes, ortho-, meta- and p«ra-hydroxybenzonitrile were used and 
products although discolourised pale green, crystallised out. This discolouration may 
well be due to the liberation of elemental platinum. The tetrachloroplatinate anion is 
unstable in halide media, according to the following equation^^;
2[ptcg2- —  -  Pt(0) +  [Ptcy2- +  2CI
However for the chloride complexes halide media was not employed. The low yield 
compared to the previous two methods may be due to the reaction not going to 
completion, i.e. the first product formed [PtCl3 (PhCN)]^Cr may be rmstable in 
aqueous solution. Another possibility is that under the reaction conditions the hydroxy 
groups are prone to oxidation and elemental platinum is produced by reduction of 
platinum(II). In the case of bromo complexes {meta- and pora-hydroxybenzonitrile, 
and benzonitrile) there was no crystallisation although the solutions turned varying 
shades of yellow. The products were isolated by evaporation and solvent extraction. 
There was no spectroscopic evidence to support coordination of meta- 
hydroxybenzonitrile (in the case of bromo). The bromo complexes of benzonitrile and 
para-hydroxybenzonitrile were identical according to analysis with the trans 
complexes made by the previous hot melt method. The yields for bromo complexes, 
like the chloro complexes, were greatly reduced compared to the previous two 
methods of production, but there was enough for a thorough spectroscopic analysis. 
No iodo platinum complexes were isolated by this method.
Considering the dibromobis(benzonitrile) platinum(II) made by method three, a trans 
complex was produced, rather than a cis complex as previously reported by Walton^ 
Inbared spectroscopy had been used by Walton as the sole method of characterisation. 
He refers to absorptions in the 500 -  1000 cm"^  region, which correspond to the out of 
plane C-H stretches of the phenyl ring, stating that a cis complex would inliibit bee 
rotation of the aiomatic ring, resulting in two sets of stretches for the C-H bonds. In 
the present study this was not evident even for c/5'-diclilorobis(benzonitrile) 
platinum(II) where the isomers had been separated by chromatography. Although the 
CN stretch differs by two wave numbers, 2285 and 2287 respectively, for cis and 
trans isomers, in the mixtuie of the two isomers only one CN stretch is evident. The 
pattern described by Walton was observed on one occasion using meta- 
hydi'oxybenzonitrile as ligand. As it has abeady been established that this produces a
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mixture of cis and trans isomers even under mild conditions, it is suggested that the 
IR pattern is a result of conformational differences of the aiomatic rings resulting 
bom steric hindrance of the hydroxy groups in the cis isomer. It was concluded 
therefore that IR spectroscopy alone is not a good technique for definitely assignhig 
cis and trans isomers.
5.3.4 The effect of a strongly electron withdrawing substituent on 
coordination.
Because of the lack of positive results using a cai'boxy-substituted benzonitrile, it was 
decided to tiy a nitro-substituted benzonitrile. It was thought the solubility of this 
would lend itself to the process. To investigate this effect platinum dichloride, 
potassium tetiachloroplatinate and /?ara-nitrobenzonitrile were used employing 
methods 2 and 3, which should produce in the main, tr^ ans and cis isomers 
respectively. In both cases coordination was difficult taking ten days to produce 
complexes with about 10% yield. The /^ara-substituent withdraws electron density 
bom the ring and must deactivate the CN bond by drawing the lone pair of nitrogen in 
towards the nucleus. The lone pan electrons which are sp hybrids and point away 
bom the nitrogen and so are not able to be delocalised, as shown in figure 36.
O s  + O_E—
Figure 36. Electron withdrawing effect of a niti'o-substituent on a nitrile group.
Using the aqueous method there was more than one product which could be due to 
exchange of hydi oxide for chloride, or hydr olysis of the nitrile group. It may also be 
due to exchange of only one chloride with a nitrile ligand resulting in a negatively 
charged platinum species. The *^ P^t NMR signal is consistent with similar previously 
reported findings '^^ .^ Due to the difficulties encountered it was decided not to proceed 
with the cycloadditions, but to obtain ^^ P^t NMR spectra of the platinum nitriles and 
this is discussed below in section 5.3.6. It was concluded that nitrile ligands with 
strongly electr on withdr awing substituents are not suitable candidates for coordination 
to platinum.
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5.3.5. Conversion of cis to trans isomers of platinum nitriles.
The Kukushkin method^^ of heating the cis or a mixture of cis and trans isomers in 
the solid state at 100 for 10 days was used. The nitrile complexes used were 
dichlorobis(benzonitrile) platinum(II), and its ortho-, meta- and para-hydioxy 
substituted analogues. In addition the ^nm-hydroxy substituted complex was heated 
under reflux for 10 days in toluene. The products which were a green-grey colour 
were extracted with a suitable solvent, acetone for the hydioxy-substituted complexes 
and DCM for the benzonitrile complex. Proton NMR and IR spectroscopy were 
carried out to illuminate any changes and cycloaddition was attempted. The findings 
did not support Kukushkin’s conclusions^^ that the cis isomer is easily converted to 
the trans isomer by this method, though he offers little evidence to support his 
assumption. The IR spectroscopy data taken alone initially supports the claim of cis to 
trans conversion. There is a change in position of the CN absorption, most maiked for 
the orfbo-hydroxybenzonitrile complex, from 2280 to 2288 c in \ However the free 
ligand was evolved and could be seen condensed on the sides of the reaction vessel. 
This was also evident but to a lesser extent with the mgfa-hydioxyhenzonitrile 
complex. In the meta- and j?am-hydroxy nitrile complexes absorptions at 2232 cm'  ^
and 2234 cm"^  respectively were visible signifying the presence of free ligand. All 
thiee crude products were only sparingly soluble in appropriate solvents and the 
yields after extraction were low, below 20%. The proton NMR spectra showed the 
presence of an aromatic system in all cases but this only shows what is in solution and 
tells nothing about coordination to platinum. Cycloaddition was either unsuccessful or 
in such a small amount that work-up was not viable.
It was concluded that the Kukushkin method is not suitable for the conversion of cis 
to trans isomers for the nitrile complexes of this study, and that the most likely result 
is that some of the ligand is evolved, the remainder being a polymeric complex of 
platinum mixed with some stai'ting platinum nitrile. Using both the mildest and most 
extreme reaction conditions, solely ^raw '^-dibromo bis nitrile platinum complexes are 
produced. The selected IR data for this method and the other thi*ee described methods 
are summarised in table 9 below.
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Com plex M ethod IR, % proportions 
W ave number (cm'^)
[PtCl2(w-HO-C6H4-CN)2] 1 2306 (50) 2295 (50)
[PtCl2(p-HO-C6H4-CN)2] 1 2286
[PtCl2(m-HO-C6H4-CN)2] 2 2295 (50) 2307 (50)
[PtCl2(p-HO-C6H4-CN)2] 2 2287
[PtCl2(m-HO-C6H4-CN)2] 3 2292
[PtCl2(p-HO-C6H4-CN)2] 3 2286
[PtCl2(o-HO-C6H4-CN)2] 3 2280
[PtCl2(o-HO-C6H4-CN)2] cis>trans 2288 (90)
[PtCl2(m-HO-C6H4-CN)2] cis>trans 2295 (90) 2234 (10)
[RCl2(p-HO-C6H4-CN)2] cis>trans 2287(99) 2234(1)
[PtCl2 (MeCN)2 ] cis and trans 1 2360(55) 2334(45)
[PtCl2 (PhCN)2 ] cis and trans 1 2286
[PtCl2 (PhCN)2] cis and trans 2 2286
m-[PtCl2(PhCN)2] 2 2285 [lit. 2285 sharp, 2290 
shoulder"^, 2284 [lit. 2284^ ]^
^raws-[PtCl2(PhCN)2] 2 2287 [ht. 2286^']
trans- [PtBr2 (PhCN)2] 2 2288
/ra«5-[PtBr2(PhCN)2] 3 2288
cw-[PtBr2(PhCN)2] Walton Lit. 2285'"^
trans- [Ptl2 (PhCN)2 ] 2 2288 [lit. 2285(m)^']
Table 9. Selected IR absorptions of platinum nitrile complexes (the numbers in round 
brackets represent the relative size of the absorptions subjectively estimated).
81
5.3.6. Study of NMR spectral data of platinum nitrile
complexes.
NMR spectroscopy data were collected for the platinum nitrile complexes as part 
of the characterisation. However some interesting trends emerged which warrant 
closer examination.
5.3.6.1 The effect of halide ligand on the ^^ F^t NMR spectroscopic 
signal.
From mixed chloro bromo complexes of platinum(II) and platinum(IV) a linear" 
correlation is the result of plotting ^^ ^Pt NMR signal against composition, as shown in 
figur e 37. This suggests that the main mode of bonding of these ligands is one of a, 
with little contribution from n bonding. The data in table 10 ar e the published findings 
of Kerrison and Sadler '^*  ^ who recorded the ^^ P^t NMR signals of the complex ions 
PtCfi^' and PtClô "^, and ions with successive replacements of chlorine by bromine.
ending up with PtBr4^'and PtBrg .^
Pt(rV) complex -ô(ppm) Pt(II) complex -0(ppm)
1 PtCl6 -^ 0 Ptcu^ ' 1631
2 PtCbBr^' 286.8 PtClsBr^- 1858
3 trans-VtCUBr2^~ 585.1 trans-nC\2^X2^‘ 2101
4 yhc-PtClgBrs^" 892.7 PtClBrs^- 2380
5 trans-VtCli^XA^' 1215.9 PtBr"4^ ' 2676
6 PtClBrs'"' 1547.6
7 PtBre^- 1894
Table 10. *^ P^t signals for Pt (II) and Pt (IV) chloro / bromo complex ions. (ref. 
NaiPtClg)
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Mixed halide complex ions of Pt(ll) and Pt(IV)
3 0 0 0  - ,
2 5 0 0
2000
R(1V) com plex  io n s  
R (ll) com plex  io n s1 5 0 0
1000
5 0 0
Complex ion (see data table)
Figure 37. Plots of NMR signal against ion for mixed bromo / chloro Pt (II) and 
Pt (IV) complex ions based on the data in table 10.
Whilst the plots are not perfect straight lines, any significant n back bonding would 
result in an appreciable deviation from the straight line. This becomes obvious on 
scmtiny of ^^ P^t NMR signals of complexes that contain known tt acceptor ligands 
such as phosphines and ai'sines. Using the results of Goggin and co-workers on 
platinum phosphine and arsine complexes, figme 38(a) and (b) have been generated 
which are plots of ^^ P^t NMR signal against complex vaiying the halide ligands (a), 
and the relative numbers of phosphine and chloride ligands (b). Contrasting figmes 
38(a and b) with figures 37, shows a strong deviation fiom stiaight line in the case of 
figme 38(a and b).
1000
8 0 0
6 0 0
4 0 0
200
trimethylphosphine
trimethylarsine-200
- 4 0 0
- 6 0 0
- 8 0 0
-1000
-1200
P t X 2 L 2
Figure 38(a). Plot of ^^ P^t NMR signals of platinum phosphine and arsine complexes, 
/rans-PtX2L2 , varying halide. X is 1=C1,2=Br, 3=1.
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Figure 38(b). Plot of NMR signals of platinum chloride phosphine complexes, 
vaiying the relative numbers of each ligand, 1= [PtClsPMcs]", 2= ïrûW5'-PtCl2(PMe3)2, 
3= [PtCl(PMe3)3]\
S.3.6.2. The effect of ring substitution on the ^^ P^t NMR signal of 
platinum nitrile complexes.
Table 11 below contains selected ^^ ^Pt NMR signals of the platinum nitrile complexes 
made in the present study.
Complex Solvent Ô (ppm) trans Ô (ppm) cis
[Ptl2(PhCN)2] CDCh -3935 NA
[PtBr2(PhCN)2] CDCh -2860 NA
[PtBr2(p-HO-C6H4-CN)2] de-acetone -2833 NA
[PtBr2(?«-HO-C6H4-CN>2] de-acetone -2873 NA
[PtCl2(PhCN)2] CDCh
CDCh
de-acetone
-2345
(lit.-2350‘^ °) 
-2375 (acetone)
-2285
(lit. -2288*'*“)
[PtCl2(p-HO-C6H4-CN)2] de-acetone -2335 -2245
[PtCl2(m-HO-C6H4-CN)2] de-acetone -2362 -2272
[PtCl2(o-HO-C6H4-CN>2] de-acetone -2333
[PtCl2(p-Me0C2H40-C6H4-CN)2] CDCh -2313
[PtCl2(W"Me0C2H40-C6H4-CN)2] CDCI3 -2346
[PtCl2(p-N02-C6H4-CN)2l* de-acetone
CDCI3
-2355, 
-2305 n.b.
-2270
Table 11. The Pt NMR signals of selected platinum nitrile complexes 
* Product not isolated so the structure is uncertain.
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n.b. uncertain as to whether the difference between these signals is a solvent effect or if  
the complex is a mixed ligand complex, possibly [PtCl2(M eCN)(p-N 0 2 -C 6H4-CN)].
It is easy to see that for bromo complexes, the para-hydroxy substituent has a greater 
effect on the signal, compared to the unsubstituted nitrile complex, than the meta- 
substituent. This is because ortho- and para-substituents have a direct electronic 
polarizmg effect^*’ on the nitrile group which is not the case with the meta- 
substituent. The signals of the /«efa-substituted nitrile complexes are closer to that of 
the benzonitrile complex as a result. This trend is not so obvious in the case of the 
cliloro complexes. This may be due to the solvent used for the NMR experiments, 
acetone for the hydroxy-substituted complexes and chloroform for the benzonitrile 
complex meaning like is not being compared with like. To circumvent this problem 
the *^ P^t NMR spectrum was carried out on dichlorobis(benzonitrile) platmum(ll) 
using deuterated acetone. This took some time due to the poor solubility of the 
complex m this solvent but the result was enlightening. There is a significant shift 
from -2245 ppm to -2275 ppm. Comparison of the signals of the hydi'oxy-substituted 
complexes now fit the pattern weU. The signal of the para-hydi*oxy complex is very 
close to that of the ortho complex which is to be expected, as both have a similar 
electronic effect on the platmum nitrogen bond, and the signal of the weto-substituted 
complex is closer to the bis benzonitrile platinum complex.
In the case of the strongly electron withdrawing para-miro substituent, the greatest 
effect on the NMR signal is exliibited. It is difficult to rationalize this as it would be 
expected to have an opposite effect to a complex with an electron donating effect. 
However factors such as the choice of solvent and the way the complex is solvated 
can affect the position of the signal.
O
N/ /O
= N = P t
Figure 39. The electronic effect of a strongly electron withdrawing ring substituent on the 
platinum centre.
85
Examination of the resonance structuie of the nitro-substitiited complex shows 
electron density being withdrawn from the platinum, see figure 39. This slight 
deshielding would explain the sliift downfield. Applying the same criteria to the 
hydroxy- substituted complex should therefore result in a shift upfield as the platmum 
nucleus has greater electron density surrounding it. One explanation is that 
mtermolecular hydi ogen bonding of the hydi oxy proton to the acetone solvent and to 
chlorine and hydioxy oxygen, has a deshielding effect on platinum resulting in a 
slight shift downfield.
X-ray crystallography data is rare for platinum nitrile complexes of this type, but 
considering the Pt-N bond lengths of cz5-[PtCl2(p-OH-C6H4CN)2]*'^  ^ and 
c/5-[PtCl2(C6H5CN)2]^^ the hydroxy-substituted complex has a slightly shorter bond 
length, 197.6 pm compaied to 201.0 pm. This suggests a stronger bond for the former 
complex consistent with the electron donating effect of the hydroxy-substituent. 
However this extra electron density is small compared to the sliieldmg the platinum 
nucleus aheady experiences ftom its own electrons and therefore there is no apparent 
shielding exhibited by the ^^ P^t NMR signal of the hydroxy-substituted complex 
compaied to the bis benzonitrile complex. In fact the opposite is observed with a 
small downfield shift.
5 3.6.3. The monitoring of aqueous ligand exchange using NMR 
spectroscopy.
In order to throw some light on the mechanism of aqueous exchange an NMR 
experiment was conducted using deuterium oxide, potassium tetrachloroplatinate and 
mefa-hydroxybenzonitrile at room temperatuie. ^^ P^t NMR spectra were acquired 
regularly for fourteen days. After two days the coloui* had changed from red to orange 
and a significant signal was detected at -2022 ppm. This is consistent with Rochon’s 
findings^ "^ ® for [PtCbnitrile]'. The signal took longer to acquire as the days passed and 
a yellow crystalline deposit built up in the NMR tube. The crystals were filtered and 
the solution extracted with excess DCM. ^^ P^t NMR analysis was carried out on each 
part. The solid was foimd to be mainly a trans complex with some cis complex. The 
DCM extract was mainly cis complex, with only a small signal conesponding to the
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trans isomer, and the aqueous phase contained the complex with the signal at - 2 0 2 2  
ppm. MS-FAB' showed the aqueous layer to contain 420.5 [PtClg(3-OH-C6H4 CN)]' ,  
and the MS-FAB+ showed 459.65 [ PtCl3 (3 -OH-C6H4 CN )]'. This confirms that
one chloride is exchanged first and the species is present for many days. It is known 
that the rate of exchange of ligands on platinum(II) complexes is slow '^ ’^^ .^ A similar 
result is also found for the aqueous reaction using / 7«ra-nitrobenzonitrile. In this case 
the predominant species present is [PtCl3 (4 -N0 2 -C6H4 CN)]". This reflects the strong 
electron withdrawing effect of the nitro group which renders the nitrogen a poorer a  
donor. The ionic mono nitrile complex is also stabilised in aqueous solution.
The same experiment was cairied out usmg /?ara-hydroxybenzonitrile yielding similar 
results. The first signal to appear was at -1991 ppm, again consistent with Rochon’s 
findings "^^ ,^ with subsequent signals appearing corresponding to mamly cis  ^ and a 
small amount of trans isomers. The main difference with this reaction was the speed 
of it. ^^ P^t NMR spectroscopy showed the major species present after fom' days were 
bis /?z2ra-hydroxybenzonitrile complexes, with only a small signal for the mono 
benzonitrile complex. In the case of the mefa-hydi‘oxybenzonitrile experiment, there 
was still a significant signal for the mono complex after seven days. This is consistent 
with the para-substituted benzonitrile bemg more electron rich than the meta- 
substituted benzonitrile, facilitating a  donation of the para-substituted nitrile. The 
mild conditions of the reactions mean the cis isomer is expected for the bis complex. 
In the case of meto-hydroxybenzonitrile there is the possibility of steric hindiance, 
and the slower rate suggests an associative mechanism. This is consistent with 
published data^ .^
Summing up, for complexes that are structuially faiidy simple, the chemistry of 
platinum(ll) nitrile complexes is fai* fiom simplistic. It appears that the similarity of 
chloride and nitrile ligand with regard to trans effect, means mixtuies of cis and trans 
isomers are produced with differing reaction conditions. In the case of bromide and 
iodide complexes the increasing trans effect should result in cis complexes under mild 
conditions, but trans complexes were produced under all conditions. The increasing 
size of the ions may play a part in this. Whilst more time could have been devoted to
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tlîis subject it was not the main aim of the project, so it was decided to move on with 
the complexes produced. The products are summaiised in table 12 below.
P R O D U C T P R O D .
N o .
S T A R T .
M A T .
M E T H O D R E S U L T
PtCl2(PhCN)2 24 K2PtCl4 1 mainly cis product
PtCl2 2 mainly trans product
PtCl2(o-OH-C6H4-CN)2 25 K2PtCl4 1 unstable product
PtCl2(w-OH-C6H4-CN)2 26 K2PtCl4 1 mainly trans product
PtCl2 2 mainly trans product
KjPtCL, 3 mainly trans, low yield
PtCl2(p-OH-C6H4-CN)2 27 K2PtCl4 1 high yield mainly cis
Ptcb 2 high yield mainly trans
K2PtCl4 3 low yield cis product
PtCl2(p-Me3N^-C6H4-CN)2 n / a K2PtCl4 1 no product isolated
PtCl2(m-Me0C2H40-H-C6H4-CN)2 28 K2PtCl4 1 product unstable
PtCl2(p-Me0C2H40-H-C6H4-CN)2 29 K2PtCl4 1 mainly trans product
Ptcb 2 mainly trans product
PtCl2(o-MeOC2H4 0 -H-C6H4-CN)2 n / a K2PtCl4 1 no product
PtCi2(3,4-di-(Me0C2H40)-H-C6H4-CN)2 30 KzPtCh 1 trans product
PtBr2(PhCN)2 31 PtBr2 2 high yield trans product
K2PtCl4 3 low yield trans product
PtBr2(/M-0H-CgH4-CN)2 32 K2PtCl4 3 no product
PtBf2 2 high yield trans product
PtBr2(p-OH-C6H4-CN)2 33 K2PtCl4 3 low yield trans product
PtBf2 2 high yield trans product
Ptl2(PhCN)2 34 Pt%2 2
3
low yield unstable trans
product
no product
PtCl2(p-Me2N-CgH4-CN)2 35 KaPtCb I low yield, coordination 
via Mc2N
PtCl2(tn,p-di-OH-C6H4-CN)2 36 KzPtCh 1 Poor yield
K2PtCl4 3 no pure product isolated
PtCl2(p-N02-CgH4-CN)2 37 KzPtCb 1 low yield, used for
PtCl2 2 characterisation only
Table 12. A summary of the platinum nitriles produced and methods used.
5.4. Cycloadditions reactions.
5.4.1. Mono oxadiazoline platinuni(n) complexes.
Mono cycloaddition products, rather than bis complexes, were initially chosen as 
targets for biologically active compounds as it was considered that these would be 
more reactive with regard to substitution reactions than their bis counterparts, and 
therefore more likely to bind to DNA.
The Pt-NC- part of the complex is linear so the platinum is not axially hindered by it 
unless there are bulky substituents on the ring of benzonitrile. In contrast, bis 
oxadiazoline platinum(II) complexes have considerable axial hindrance as can be seen 
in the simulated structure below (figure 40). Unfortunately, to date there are no X-ray 
structures of trans -platinum mono cycloadducts for comparison.
Figure 40. Space filling representation (Molekel) of [PtCl2 (oxa)2 ] showing axial steric 
hindrance.
For these reasons it was considered that bis oxadiazoline platinum complexes would 
be too chemically inert to be of much use as anti-cancer drugs, but mono complexes
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would be more promising. The results of the substitution reactions with mono and bis 
complexes are discussed in section 5.5.
5.4.11. Mono oxadiazoline platinum(II) complexes with hydroxy- 
substituents.
X
O Me /I H  WX ' - / \ ( V -YCgH, H OCl
When X= mera-OH, Y= H, (38),
When Y= meta- or para-OH, X=H, (39,40).
Scheme 18. The mono cycloaddition reaction of a nitrone with a platinum nitrile 
complex.
Thiee mono oxadiazoline platinum(II) complexes with hydroxy-substituents were 
prepaied, the proceduie for which is described in the experimental section (8.5). It 
was not possible to produce a mono complex where X -  pnra-hydroxy according to 
the scheme. This was for reasons of poor solubility. To successfully produce a mono 
complex with only a minimum of the bis complex, it is important to either have the 
platmum nitrile totally dissolved and always in excess to the nitrone in solution, or 
both starting materials completely dissolved and in 1:1 stoichiometry. Unfortunately 
/ra«5-[PtCl2(p-OH-C6H4CN)2] is only spaiingly soluble in chlorinated solvents, and 
only pai'tially soluble in acetone or alcohols. On the other hand the nitrone is soluble 
in most common organic solvents. Tliis means that the nitrone is always in excess, 
and monitoring the reaction by proton NMR spectroscopy revealed signals 
conesponding to the bis cycloaddition product soon after appearance of the mono 
signals. For these reasons only a bis cycloaddition product was produced.
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5.4.I.I.I. Mono oxadiazoline platiniim(ll) complex made from /rfl«x-[PtCl2(w- 
0H~C6H4CN)2] and iV-methyl-C-phenyl nitrone (38).
The platinum /«eto-hydroxybenzonitrile complex is much more soluble in acetone 
than its pnra-hydioxy isomer, and it was possible to get the coixect 1:1 stoichiometric 
mix in solution. Mild conditions of 25 ®C meant a mono complex was formed fii'st. 
Applying heat, as little as 40 °C resulted in a mixtui e of mono and bis products. By 
monitoring the reaction with proton NMR spectroscopy, the reaction can be stopped, 
and the mono product isolated by column chiomatography at the fii'st appeaiance of 
bis signals. The kinetics of similar reactions has been reported and this will be 
touched on in section 5.4.4.1.
5 4.1.1.2. Mono oxadiazoline platlnum(II) complexes made from hydroxy- 
substituted nitro nes.
Products were success&lly made using meta- and pnfra-OH-C6H4 -CH=NMeO. Again, 
these nitrones are only sparingly soluble in chloroform, so the mixture is stirred and 
the nitrone gradually dissolves and reacts with the platinum benzonitrile complex. If 
moderate conditions of 30 are applied a mono complex is the result. As the 
platinum nitrile is in a large excess at the start and for most of the reaction, it therefore 
mimics first order kinetics. As the reaction nears completion the mechanism becomes 
less pseudo fir*st order in character and more second order. The ort/zo-hydroxy nitrone 
was also attempted but although it was completely soluble in chloroform there was no 
significant reaction. Even with the application of heat, 60 for several days, there 
was only about 28% conversion and the products were mixed. As solubility is not a 
problem, this must be due to the electronic effect of the orf/zo-hydroxy group. This 
has an electron donating effect on the carbon of the HC^-N fimctionality of the 
intermediate. This stabilises the intermediate (fig. 22) by rendering the less polar 
and consequently less reactive. Quantum chemical calculations®"  ^predict the first bond 
to form in the two step cycloaddition is between the O' of the nitrone and the nitrile 
carbon, so the electronic effect of the or^/zo-hydioxy group may not be a significant 
factor in the fast step. There is also the possibility of steric effects of the ortho- 
substituent. The para-hydroxy group has a similai* electronic effect and the reaction at
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room temperature is likewise extremely slow. The progress of these reactions is 
depicted in the figuie below.
The c om paris ion  o f th e  p e rcen tag e  fo rm ation  o f m ono  oxadiazoline  platinum(ll) 
co m p lex es  u s ing  o rtho , m eta  an d  pa ra  hydroxy su b s titu ted  phenyl n itro n es  an d  tra n s -  % Conversion d ich lo rod ibenzonitriie  platinum (li)
....  ........... ..............................
❖ Mono-para % conversion at 303K
Mono-meta % conversion at 303K 
Mono-ortho % conversion at 333K
* o Mono-ortho % conversion at 303K
*
*
Time (Hours)
Figure 41. The rate of formation of mono oxadiazoline platinum complexes made 
from hydroxy-substituted nitrones.
The form of the curves mirrors the findings of Desai et for the reaction of 
unsubstituted nitrones with /r««5-diclilorobis(benzoniti'ile) platinum(II). The present 
reactions are slower in reaching maximum conversion, as the temperatine was lower 
at 30 rather than 40 ®C. The lower temperature was chosen in the present study to 
avoid formation of the bis product. As previously mentioned, solubility is also an 
issue with the present reactions.
The maximal yields of the products were slightly improved by about 10% by reducing 
the temperature to 25 °C and lengthening the reaction time to thiee days. At this lower 
temperature the competing bis cycloaddition does not occur. This is aided by some of 
the mono cycloaddition product being precipitated with the passage of time.
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5 4.1.2. Mono oxadiazoline platinum(ll) complexes with glycol ether 
substituents.
Two complexes were made according to scheme 18; when X= j!?-CH3 0 (CH2)2 0 -, Y= 
H, (41), when Y=j9 -CH3 0 (CH2)2 0 -, X= H, (42). The motivation behind the synthesis 
of these complexes was the difficulty encountered due to the poor solubility of 
nitrones and platinum nitrile complexes with hydioxy-substituents. This problem was 
overcome by this modification as previously described.
5.4.I.2.I. The reaction of ^m«s-IPtCl2(4-(2-Me0 C2H4 0 )-C6H4CN)2l with 
PhCH=NMeO (41).
It was not possible to make a mono oxadiazoline platinum complex using a para- 
hydroxy substituted platmum nitrile complex, but with a para-g\yco\ ether substituent 
this was successful. The cycloaddition is slower than with hydioxy- or non-substituted 
platmum benzonitrile and has to be heated for seven days at 30 °C. Close monitoring 
of the reaction using proton NMR spectroscopy is imperative and the reaction stopped 
at the first appearance of bis oxadiazoline platinum signals at 8.80 ppm. The 
characteristic signal corresponding to the ortho protons of the PtC=N“C6H4 part of the 
complex are at 9.00 ppm. The corresponding reaction using a meto-substituted 
platinum nitrile was attempted, and although initially promising signals appealed in 
the proton NMR spectrum, as time progressed these signals got smaller coinciding 
with the appearance of many products, the main one being an aldehyde which could 
be fiom decomposition of the nitrone or of the oxadiazoline ring. After cycloaddition 
the resulting Pt-N=C-C6H4  bond is no longer lineai*, and the aiyl ring is shifted 
towai'ds the platmum. If the fii'st cycloaddition is slow, the second cycloaddition may 
occui" before the first one reaches completion. The bis cycloadduct may be unstable 
due to the two glycol ether groups coming into close proximity, depending on the 
conformation of the molecule. Decomposition of the bis cycloadduct would account 
for the appeaiance of signals corresponding to multiple products in the proton NMR 
spectrum, and the slow disappearance of the mono cycloadduct signals. Attempts to 
halt the reaction at the mono stage and work-up were thwailed by the reaction mixtuie 
being unstable and turning green on silica during chiomatography. It was not possible 
to isolate a pure product.
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5.4.I.2.2. The reaction of /m«s-[PtCl2(PhCN)2] with 4-{2-Me0 C2H4 0 )-C6H4- 
CH=NMeO (42).
In contrast to the previous reaction, this cycloaddition occimed rapidly at 25 ®C, 
yielding 40% of the mono cycloadduct in two hours, and 70% in seven hours. It then 
slowed down and after four days all the nitrone was consumed with no evidence of the 
bis cycloadduct in the proton NMR spectrum. This is in conti ast to the corresponding 
hydroxy nitrone reaction where bis product formed before all the nitrone was 
consumed. As the glycol ether and hydroxy-substituents are electronically similar, this 
is difficult to explain. A purely speculative explanation may be the ability of the 
hydroxy group of the mono complex being able to hydrogen bond with the nitrone 
thus bringing it into the vicinity of the nitrile ligand and facilitating bis cycloaddition. 
The analogous meto-substituted glycol ether nitrone reaction was carried out and 
although the proton NMR spectrum was very promising the product turned green with 
some black deposit on the silica dui ing chiomatography and only a poor yield of the 
product was recovered which quickly decomposed in solution (CDCI3) in the NMR 
tube.
5.41.3. Mono cycloadditions where both the platinum nitrile 
complex and the nitrone have polar substituents.
Vai'ious reactions were attempted where the substituents were both either hydroxy- or 
glycol ether, or where the substituents were mixed. Although the proton NMR 
spectrum suggested successfiil cycloaddition in all cases, unfortunately the products 
did not crystallise out and it proved impossible to achieve any sepaiation by 
chromatography or solvent extraction. It was regrettably decided not to pursue fiirther 
this aiea of research at the present time. The proton NMR spectrum of one of these 
experiments is shown in figure 42.
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Figure 42. Bis cycloaddition of /ra«5 -[PtCl2(4 -CH3 0 C2 H4 0 -C6H4 CN)2] with 
4-0H-C6H4-C(H)=N(0)Me (crude).
5.4.1.4. Mono cycloaddition using cis-[PtCl2(PhCN)2] and 4-(2- 
Me0 C2H4 0 )-C6H4-CH=NMe0 .
c/5-[PtCl2(PhCN)2] is far less soluble in chloroform than its trans isomer. It was 
difficult to achieve a 1 / 1 stoichiometry in solution. As a result, although signals 
indicative of a mono cycloadduct were initially seen in the proton NMR spectrum, 
with time, the signals disappeared, and the result was a mass or a mess of aromatic 
signals. It is known that cis bis oxadiazoline platinum complexes are unstable and 
rapidly decompose, and it is thought that the mono product was more soluble in 
chloroform than the starting nitrile and it underwent bis cycloaddition with the excess 
nitrone and then decomposed.
5.4.1.5. The characterisation of mono oxadiazoline platinum(Il) 
complexes.
Various ID and 2D NMR spectroscopic techniques as well FT-IR spectroscopy and 
mass spectrometry were used to characterise the complexes. This is illustrated by the 
full characterisation of the mono oxadiazoline platinum complex product 42 trans- 
[PtCl2(PhCN){N=C(Ph)-0 -N(Me)-CFI(p-Me0 -C2 H4 0 -C6 H4 )}], in the experimental 
section (section 8.6.2)
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Figure 43. The structure of product 42 /ra«.s-[PtCl2(PhCN){N=C(Ph)-0-N(Me)- 
C H (p -M e 0 -C 2 H 4 0 C 6 H 4 )} l(4 2 ).
As can be seen from figure 43 above, there are three aromatic ring systems present. 
The glycol ether substituted ring will result in a pair of doublets in the proton NMR 
spectrum, each equivalent to two protons, and a singlet equivalent to three protons. 
The two remaining phenyl rings will each produce a doublet equivalent to two 
protons, a triplet equivalent to two protons, and a triplet equivalent to one proton. 
Proton (fig. 44) and COSY NMR spectra (fig. 45) were used to assign the aromatic 
rings. The NMe will produce a singlet at circa 3.00 ppm, and the CHN of the 
oxadiazoline ring will produce a singlet at 5.90 ppm.
UL 1
Figure 44. The proton NMR spectrum of product 42 [PtCl2(PhCN)(N=C(Ph)-0- 
N(Me)-CH(p-Me0-C2H40-C6H4)}].
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Figure 45. The COSY 2D NMR spectrum of product 42, trans- 
[PtCl2(PhCN){N=C(Ph)-0-N(Me)-CH(p-Me0-C2H4 0 -C6H4)}].
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Figure 46. The HMQC 2D NMR spectrum of product 42, trans- 
[PtCl2(PhCN){N=C(Ph)-0-N(Me)-CH(p-Me0-C2H4 0 -C6H4)}].
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HMQC NMR (fig. 46) was used in conjunction with the NMR spectrum to assign 
the carbon signals. Mass spectrometry (fig. 47) was used to assign the molecular peak 
and fragmentation pattern.
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Figure 47. The MS-FAB spectrum of product 42 /ra/25-[PtCl2(PhCN){N=C(Ph)-0- 
N(Me)-CH(p-Me0-C2H40-C6H4)}].
5.4.2. Bis oxadiazoline platinum(Il) complexes.
Bis cycloaddition introduces a second chiral centre to the platinum complexes, which 
can exist in either of two diastereoisomeric forms; RS and SR which are meso 
compounds, and RR and SS which are enantiomers. In the present study a mixture of 
diastereoisomers has normally been produced, varying from 50 / 50 to 75 / 25, and the 
diastereoisomers have slightly different proton NMR spectra. In some instances one 
of the diastereoisomers crystallised out from the mix and an X-ray structure obtained 
(figure 50). This shows it to be the RS isomer which being a meso compound has a 
high degree of symmetry, specifically a centre of inversion.
The second cycloaddition is considerably slower than the mono cycloaddition by a 
factor of four*"*^  The forward reaction is favoured by an excess of nitrone and this will 
be expanded on in section 5.4.4.1. Bis oxadiazoline platinum complexes were made as 
shown in figure 48 below.
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When X = H, Y =para-OR (45), 
meta-OR (46), 
j9ûrra-(2-Me0C2H40) (49).
When Y = H, X = para-OR (47), 
meta-OR (48), 
para-(2-Me0C2H40) (50).
Figure 48. Bis oxadiazoline platinum complexes produced. (Exact reaction conditions 
aie given in the experimental section 8).
5.4.2.1. Bis oxadiazoline platinum(II) complexes with hydroxy 
groups.
Four complexes were made successfully with hydi'oxy-substituents without much to 
report other than the solubility of the /7ara-hydi‘oxy substituted complex was poor m 
all organic solvents. In the case of complex 45 the product had to be dissolved in a 
mixture of deuterated acetone, deuterium oxide and sodium carbonate in order to 
acquire a and ^^ P^t NMR spectrum. The solubility of the meto-hydroxy complexes 
was better in acetone and mixtur es of DCM / ethyl acetate, and chromatography was 
possible for purification. Compound 48 is worthy of special note as one 
diastereoisomer crystallised out during manufacture, and it was difficult to dissolve, 
but the other one was so soluble in most mixtures of organic solvent, that it was 
impossible to recrystallise.
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5 4.2.2. Bis oxadiazoline platinum complexes with glycol ether 
groups.
Two complexes of this type were made according to figure 46. From the viewpoint of 
solubility the complexes were a success, being soluble m most common organic 
solvents. This property also enabled the purification of these complexes by 
chromatogr aphy. The solubility of the complexes in aqueous systems is discussed in 
section 5.7. The second cycloaddition reaction took considerably longer than for the 
corresponding hydr oxy complexes. This may be due to the glycol ether groups of the 
mono complexes inhibiting the approach of the second molecule of nitrone in some 
way. In general the bis cycloaddition is slower than the analogous mono reaction, 
but these were particularly slow.
5.4.3. Cycloaddition reactions varying the halide.
Both mono and bis cyclo addition products were made where the halide was bromide 
or iodide, firom the corresponding platinum bis benzonitrile complexes and jV-methyl- 
C-phenyl nitrone. A bis complex (53) was attempted using PtBr2 (p-OH“C6H4 CN) 2  but 
it is thought this was contaminated by a polymeric, possibly dimeric impurity, similar* 
to the case aheady described for the analogous platinum chloro complex. In both 
cases the nitriles were made by the Kharasch method. To date a pure sample of tliis 
complex has not been isolated. There is httle to report concerning the mono 
cycloadditions, the NMR and IR spectroscopy characterisation differed little fiom the 
chloro complex.
The bis cycloadditions proved to be much more interesting. In the case of the bromo 
complex, very broad proton NMR signals were observed. This could be explained by 
the bromide ions being larger in volume than the chloride ions and firee rotation of the 
oxadiazoline ligands being inhibited. In the bis chloro complex, broad signals are 
observed for the CHN and NMe protons of the oxadiazoline ring. These ai e due to 
ring flipping about the tetrahedral NMe of the ring. The spectrum of the bis 
oxadiazoline bromo complex has much broader signals including the aromatic region, 
which are sharp in the analogous chloro complex. The bromo complex proton NMR
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spectrum is shown in figure 49 below, and can be contrasted with figure 56, which is 
a chloro bis oxadiazoline complex.
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Figure 49. The proton NMR spectrum of PtBr2(oxa) 2  (52) at 298 K.
X-ray diffraction analysis was performed on the crystals produced in the reaction, 
and these were found to be the R,S isomer. The structure (figure 50) shows the phenyl 
ring of PhC=N of each ligand to be on opposing sides of the PtBr2N2 plane. This gives 
a high degree of symmetry to the complex and the crystals once formed are extremely 
difficult to re-dissolve in chloroform, presumably due to high lattice energy. Proton 
NMR spectroscopy was carried out overnight using one single crystal. This showed 
the crystal to be one isomer. It is also clear from the structure, simulated in figure 51, 
that free rotation of the phenyl rings would be difficult and this explains the broad 
aromatic signals. The oxadiazoline ring CH-N signal is also very broad and this is 
due to very restricted rotation of the Pt-N bond which means the oxadiazoline ligands 
are able to rock from side to side rather than completely rotate. The N-Me on the 
oxadiazoline although having fi*ee rotation itself is also affected by the lack of fi*ee 
rotation of the oxadiazoline ring. Another important feature is the tetrahedral 
geometry of the nitrogen (NMe) taking into consideration lone pair. This is able to 
invert faster than the time interval between the pulse and acquisition, an intrinsic part 
of the NMR experiment, so what is seen is an averaged signal which is consequently 
broad.
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Figure 50 compares a simulation modelled from the X-ray crystal structure of the 
complex in figure 51 below, with the analogous chloro complex. This shows that the 
phenyl groups of the bromo complex are much closer together than its chloro 
analogue, suggesting there is hindrance to free rotation in the bromo complex.
Bromo-compound: the phenyl groups appear to be very close together.
Chloro-compound: there is a larger gap between the phenyl groups allowing more freedom of 
rotation.
Figure 50. Comparison of the simulated models (Molekel) of PtBr2 (oxa) 2  with 
PtCl2(oxa)2.
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Figure 51. Platon representation of (/?,5)-rra«5-PtBr2(oxadiazoline)2 based on X-ray
data.
The corresponding iodide complex was expected to have even broader NMR signals 
due to the much larger iodide ions restricting free rotation of the oxadiazoline rings. 
The observed spectrum could not have been more surprising. Not only were the 
signals sharp but there were at least four observable for the NMe and CHN protons of 
the oxadiazoline ring. The proton NMR spectrum also suggests there are two 
diastereoisomers, and each of these has two conformations. This was concluded by 
observation of the signals between 8.60 and 8.80 ppm which are shown in figure 52 
below. The signal at 6.05 ppm and doublet at 8.95 ppm belong to the mono cyclo 
adduct. It is hypothesized that this is due to total restriction of rotation of the rings and 
what is being observed are distinct conformations. On standing in solution for 24 
hours most of these signals disappear leaving just two sets of signals (figure 53). 
Either there is a conformational change possibly by ligand exchange or some of the 
isomers are unstable and decompose. There was some precipitate observed suggesting 
either decomposition, or precipitation of the less soluble isomers but there were no 
extra signals in the proton NMR spectrum which would be expected from 
decomposition, i.e. signals corresponding to nitrone or mono oxadiazoline complex. 
To date it has not been possible to obtain an X-ray diffraction structure of the bis iodo 
complex.
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Figure 52. Proton NMR spectrum of Ptl2 (oxa) 2  (55) before purification showing four 
isomers, and inset the 8.6-8.8 ppm region which is the Pt-N=CPh ortho protons.
78 69 3 PPM
Figure 53. Proton NMR spectrum of Ptl2 (oxa) 2  (55) after 24 hours and column 
chromatography (which only removed the unreacted nitrone).
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5.4.4.1 NMR experiments with bis oxadiazoline platinum complexes 
to illuminate the mechanism of the cycloaddition reaction.
Experiments were carried out using both iodo and bromo bis oxadiazoline platinum 
complexes in order to see if a conformational change could be achieved through 
heating as shown below.
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Scheme 19. An attempted conformational change in bis oxadiazoline platinum 
complexes with bromo or iodo ligands achieved through heating.
A single crystal (one diastereoisomer) of each was dissolved in chloroform in NMR 
tubes and placed in a sand bath for 48 hours at 60 °C. No conformational change was 
observed but surprisingly signals corresponding to the mono oxadiazoline platinum 
complex appeared in both cases. It would be expected that if the reverse reaction 
happened then so should the forward reaction, but on further heating this did not 
occur. Conversion back to the bis complex was only observed when an excess of 
nitrone was added, and the mono complex signals disappeared with time. This would 
strongly suggest that for the mono reaction equimolar quantities of reagents can be 
used and the forward reaction is favoured following a second order type mechanism. 
For the second cycloaddition i.e. bis cycloaddition, the reverse reaction is favoured 
and an excess of nitrone has to be used to force the forward reaction. This would help 
explain why the bis reactions using hydroxy-substituted nitrones, which were poorly 
soluble in chloroform, were so slow. Also, for bis reactions it is important to choose a 
solvent in which the nitrone is soluble. Is it plausible that the second cycloaddition is 
reversible whereas the first is not? Observation of the crystal structure and model of 
PtBr2 (oxa) 2  (figs 50 and 51) show significant steric hindrance to free rotation of the 
phenyl rings. This may make the complex thermally unstable in solution when heated 
for lengthy periods as in this experiment. Formation of the mono cycloadduct
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immediately alleviates this hindrance. In the mono complex the benzonitrile aromatic 
ring points away from the platinum centre due to the lineai* nature of the Pt-N=C-C 
bonds. Also considering the hybridisation states of the nitrogens bonded to the 
platinum, the nitrile has sp, and the oxadiazoline has sp^ hybridisation. The latter has 
greater p  chaiacter than the nitrile and the stronger bond that results will labilise the 
Pt-N bond of the nitrile. This means the platinum will have less of a polarising effect 
on the C=N than on the equivalent bond in bis benzonitrile complexes, and is 
consequently less susceptible to cycloaddition. The mono cycloadduct is fuitlier 
stabilised as a result. Another factor to consider is the electronegativities of bromine 
(2.96) and iodine (2.66) which are lower than that of chlorine (3.16) on the Pauling 
scale. This means in complexes of the former two halides platinum is a weaker Lewis 
acid and the benzonitrile of the mono cycloadduct will not be so activated towaid the 
second cycloaddition as in the chloro complex. This means for bromo and iodo 
complexes, the forward reaction has to be forced with an excess of nitrone, and if the 
bis cycloadduct is heated in solution the reverse reaction happens reverting to the 
more stable mono complex.
5.4.4 2. An NMR experiment at elevated temperatures to effect a 
conformational change using PtB: 2(oxa)2 .
A proton NMR experiment was cairied out using a single crystal dissolved in 
deuterated toluene as solvent to ti*y and effect a conformational change. The spectrum 
obtained for the single crystal showed it was only one isomer. The temperatuie in the 
spectrometer was raised by increments of 10 up to 100 “C. Although the broad 
signals sharpened, no conformational change was observed, and the broad signals 
retuined on cooling. The spectra aie included m appendix 1.
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5.4.4 3. A comparison of the *^Pt NMR spectral data for platinum 
complexes varying both the halide and the lone pair donating 
nitrogen ligand.
In section 5.3 a linear relationship was shown for the '^^Pt NMR spectral data of 
mixed halide platinum(II) and platinum(IV) complex ions, which signified that the 
bonding of the halide is mainly one of a  bonding. This result is further developed 
below in figure 54, not only varying the halide but also the other two ligands.
Effects of varying halides and ligands on the
195 Pt NMR shifts (^e)
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Figure 54. The comparison of *^ P^t NMR spectral data, varying ligands.
Varying the non-halide ligand from bis-benzonitrile to benzonitrile / oxadiazoline, to 
bis-oxadiazoline shows a linear relationship for all three halides. This shows that a  
bonding predominates in these complexes, with negligible n overlap or back bonding. 
In this respect the bonding is similar to that of the halide ligands, and is consistent 
with accepted theory on platinum square planar complexes with nitrogen donor 
ligands. This states that the main bonding is one of a  end on overlap between the 
electrons of the platinum dsp^ hybrid orbitals and in this case nitrogen lone pairs^ .^ n 
overlap between d^, d^ and cP is limited in the case of the benzonitrile ligands due to 
the linear nature of the P t-N ^ - bonds. The triple bond n system is in the square plane 
of the complex and not orientated towards it, as shown in figure 55 below.
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Figure 55. The different orientations of n systems in platinum nitrile and acetylene 
complexes.
Bonding to n systems by platinum is favoured when the n system is perpendicular to 
the square plane such as is the case with the acetylene ligand^  ^ or as in Zeise’s salt see 
figure 2 0 , although it should be noted that acetylene can also bond end on after 
deprotonation. In the case of the oxadiazoline ligand, the Pt-N=C bond angle is 130.8° 
so it is difficult to envisage any significant overlap of the double bond n system 
and the platinum n orbitals, though probably more than in the case of the nitrile.
5.4.5. The characterisation of bis oxadiazoline platinum complexes
Various ID and 2D NMR spectroscopic techniques as well as IR absorption 
spectroscopy and mass spectrometry were used to characterise the complexes. This is 
demonstrated below by the full characterisation of [PtCh {N=C(Ph)-0-N(Me)-CH(p- 
HO-C6 H4 )}2 ](4 7), the structure of which is shown below in figure 55 (enlarged for 
clarity).
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Figure 56 (a). The structure of [PtCl2 {N=C(Ph)-0 -N(Me)-CH(p-H0 - C6 FL,)}2 ](4 7 ).
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Figure 56 (b). The proton NMR spectrum of [PtCl2{N=C(Ph)-0-N(Me)-CH(/7-H0- 
C6H4)}2l(47) in d6-DMSO.
SS ©
Figure 57. The 2D COSY NMR spectrum of [PtCl2{N=C(Ph)-0-N(Me)-CH(p-H0- 
C6H4)}2](47).
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Figure 58. The 2D HMQC NMR spectrum of [PtCl2{N=C(Ph)-0-N(Me)-CH(p-H0- 
C6H4)}2l(47).
As can be seen from figure 56, there are two aromatic ring systems; a pair of doublets 
each with an integration of two protons is expected from the /7-OH-C6 H4 , and the 
phenyl rings will have a doublet with an integration of two for the ortho protons, a 
triplet with integration of two for the meta protons and a triplet with integration of one 
for the para proton. These can be clearly seen in the 1D proton and 2D COSY spectra 
(figs 56 and 57). The signals can then easily be read off from the 2D carbon / 
proton correlation, HMQC (fig 58), and the ^^ C spectra.
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Figure 59. The MS-FAB spectrum of [PtCl2(N=C(Ph)-0-N(Me)-CH(p-H0- 
C6H4)}2](47).
The following fragmentation pattern is observed in figure 59 which is the MS-FAB 
spectrum of complex 47, MS-FAB\ m/z: 775.1 [M ]\ 701.9 [M - 2HC1], 737.1 [M -  
HCl], 797.2 [M + Na]. The spectroscopic information together with elemental 
analysis (in section 8) leads one to the conclusion that a pure sample of product 47 has 
been prepared. Although an X-ray structure was not obtained of this particular 
complex, one was obtained of a similar complex*^, and the proton NMR spectra of the 
two are similar enough to conclude the correct complex has been made. The full 
characterization of product 47 is in section 8.7.3.
5.4.6. Attempted unsuccessful cycloaddition reactions between tr a n s -  
dichlorobis(benzonitrile) platinum(Il) and nitrones bearing electron 
withdrawing substituents.
Having electron deficient species in para and ortho positions of the phenyl ring of the 
nitrone, should render the nitrone more polar and consequently more reactive. 
Surprisingly the results of the reactions were not cycloaddition.
I l l
O Me
N - R - N =
Me
/%=N ClA "Me"^
Figure 60. The reaction scheme for attempted cycloadditions of nitrones with an 
electron withdrawing ring substituent, which were unsuccessful.
The following nitrones were chosen where R= W-CO2 H (8), o-SOsTSfa  ^ (10), p- 
(CH3)2N (included for its structural relationship), p-(Me)3N^ (12) and /?-(Me)2HN^ 
(protonated derivative of 11). The latter being prepared by reaction of /?-(CH3)2N- 
C6H4 -C(H)=NOMe (product 11) with one molar* equivalent of glacial acetic acid, and 
used without purification. Wlien R = 7M-CO2H, the reaction followed the normal 
cycloaddition route but with reduced yield of 10%.
5.4.6.I. Reaction with m e ta - c a r h o x y  substituted nitrone (8).
This nitrone was chosen as the substituent, being in the meta position, would have no 
electronic effect on the dipole, but it would hopefully make the product of 
cycloaddition more soluble in polar solvents. Tliis nitrone was expected to be similar* 
in reactivity to an unsubstituted nitrone. Surprisingly only a small amount of 
cycloaddition product, less than 10%, was evident in the proton NMR spectrum after- 
reaction at 60 °C for* 10 days. It is believed the reason for* this is the choice of solvent 
used for* the reaction. The nitrone is insoluble in chloroform so acetone was used. This 
is more polar and not only stabilises the dipolar* nitrone, but also the proposed 
intermediate shown in figure 61 below.
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Figure 61.The expected intermediate of the cycloaddition r eaction between a nitrone 
and a platinum nitrile complex.
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Also visible in the proton spectrum was a signal equivalent to an aldehyde proton 
suggesting either hydrolysis of the nitrone or the intermediate. The starting nitrile 
complex and nitrone were also seen. Various mixtur es of chloroform and acetone, and 
chloroform and methanol were also attempted, with no significant improvement in 
yield. It was concluded the reaction did not go to completion due to solvent 
stabilisation of the starting nitrone and intermediate and also because of a competing 
hydrolysis reaction.
5.4.6.2. The reaction of the remaining nitrones with tr a n s -  
dichlorobis(benzonitrile) platinum(11).
The reactions of the other four nitrones are dealt with together as they gave a similar* 
result. For reasons of solubility acetone was once again chosen as solvent. The 
reactions were carTied out using 2 /1  nitrone / platinum nitrile stoichiometry at room 
temperature for up to 140 hours, or 48 hours at 60 °C for two days. Both sets of 
conditions gave similar* results. All four reactions result in a mixture of at least two 
products, one of which is suspected to be an aldehyde due to the appear ance of a 
characteristic shar p singlet at ar ound 10.00 ppm in the proton NMR spectra. There ar e 
two possibilities for an aldehyde being produced, fir stly hydrolysis of the nitrone, 
which is unlikely as it would not explain the other product, and second hydrolysis at 
the C(H)-N bond of the intermediate. This might lead speculatively to structures (a) 
and (c) shown below in figure 62.
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113
hl^Me Hyvie 
0 —N N—O
> l
Ph Y 7 Ph H H
(c)
2+ HO^Me Oy/le
O -N N—O \ /
.P IPh  ^  ^ PhH 1H
(d)
2+
Figure 62 a-d. Possible structures of the reaction of dichlorobis(benzonitrile) 
platinum(II) with nitrones 10, 11, 12 and the protonated derivative of 11.
The compounds (b) and (d) are highly unlikely to be made this way but correspond to 
signals in the mass spectrum. It should be stressed these latter two structures are 
highly speculative. The structures (c) and (d) are ring structur es isomeric of (a) and
(b) respectively. Platinum is known to form ring structures with nitrogens coordinated 
in CIS positions^^.
The proton NMR spectra of the four reactions are very similar*, only differing because 
of the different substituents on the aldehydes produced. There is also a doublet at 
about 8.90 ppm (ortho protons of Pt-N=C-Ph) and a singlet at 2.80 ppm (NMe), with 
the conect integr ation which is normally characteristic of a cycloaddition, however 
there is no broad singlet apparent at 5.90 ppm conesponding to the C(Ph)HN of the 
heterocycle, so an oxadiazoline can be ruled out. It is because of this similarity, 
especially the doublet at 8.80 ppm, that it is believed the reactions proceed to the 
intermediate stage of cycloaddition but not to the second stage of ring closure. The 
ortho protons of Pt-N=C-Ph would be in a similar environment in both cases. This is 
shown in figure 63 below and can be compared with figure 56, wliich is the proton 
spectrum of a bis oxadiazoline platinum complex.
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Figure 63. The proton NMR spectrum of the products of reaction of trans- 
PtCl2 (PhCN) 2  with the protonated derivative of nitrone 11.
The ^^ P^t NMR signals of the reactions using nitr ones 10 and 12 are identical at - 
2261 ppm using chloroform as solvent. So there is definitely a platinum species 
present that is different to the starting nitrile which has a signal at -2348 ppm. The 
former is the main platinum species present apart from a small residual signal at -2348 
ppm. In the case of the protonated quaternary ammonium nitr one (derivative of 11) 
the signal is at -2248 ppm but the solvent used was D2 O, and the difference is small 
enough to be explained by solvent effects. In ^^^PtNMR spectroscopy, half height line 
widths are used as a form of characterisation. Sometimes it is possible to tell 
something about the coordination environment from the line width, for example, 
whether the platinum is coordinated to two chlorines and two nitrogens, or to four 
nitrogens. In tliis particular* case there is overlap, with known line widths ranging from 
700 -  1700 Hz. The ^^ P^t NMR spectra and a table of known line widths are included 
in appendix 2.
In the mass spectrum, a case could be made for structures (a) and (c) wdth a peak at 
566.9 which fits PtCl2N4 O2 Ci6H2 0 , [M-2HC1] at 494.0 witli a very large relative 
abundance, and [M+Na] at 589.9. The isotopic patterns of these peaks are similar to 
the peaks at 775.1 and 701.9 which are tlie molecular* ion peak and the [M-2HC1] of
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the bis oxadiazoline platinum complex product 47 in figiue 59. Both compounds 
contain the fragment PtCl2N4 0 2  which is the major contribution to the isotopic 
splitting pattern. Both figures are reproduced in appendix 2 side by side for claiity. 
There is also a peak at 619.9 which could be [PtCl2N4 O4 Ci6 H2 0+Na] representative of 
structmes (b) and (d). This is shown in figure 64 below. It would be extremely 
difficult to explain mechanistically how (b) and (d) could be produced from the 
stalling compounds, however production of (a) and (c) is very plausible by hydi olysis 
of the intermediate. Reactions can also take place duiing mass spectrometry which 
could explain spurious peaks.
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Figme 64. Mass spectrum of the reaction between ^raw5'-[PtCl2(PhCN)2] and the 
protonated derivative of 11.
As the proposed product could not be isolated in puie form or recrystallised, and there 
is no evidence of purity the proposed stiuctures aie described as both tentative and 
speculative. However, the available evidence favouis structures (a) and (c) over (b) 
and (d).
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5.4.7 Variable temperature Proton NMR spectroscopy experiments 
using platinum oxadiazoline complexes and uncoordinated 
oxadiazoline.
Examination of the proton spectra of platinum oxadiazoline complexes, show some of 
the signals, particularly the singlet equivalent to CHN of the oxadiazoline ring at 5.90 
ppm, to be broad. This suggests a conformational change of the said ring. This can 
only occur at the N-methyl of the ring, which has a lone pair of electrons and 
tetrahedral geometry. Inversion of the lone pair occurs as shown in figure 65 below.
Figm e 65. The two conformations of the oxadiazoline ring.
Considering the CNO part of the ring and the geometry surrounding the nitrogen, if 
this is thought of as the flap of an envelope then the left hand structure has the flap 
folding into the plane of the paper and the nitrogen obscures its lone pair of electrons. 
In the right hand structme the flap is pointing out of the plane of the paper and the 
lone pair (shown to the right for clai ity) would be in front of the nitrogen, coming out 
of the plane of the paper. The broad signals are caused by rapid flipping Jftom one 
confoiination to the other so what is seen in the proton NMR spectmm is an average 
of the signals. It was decided to investigate whether by increasing the temperatm e or 
by lowering it, the conformation could be fixed in one position or the other. The 
following platinum complexes and oxadiazoline were used;
1. PtCl4 (PhCN)(oxa).
2. PtCl2 (PhCN)(oxa).
3. PtCl2(oxa)2.
4. 2-methyl-3-tolyl-5-phenyl-A'^-1,2,4-oxadiazoline (shown in figme 66 below).
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Figure 66. The structme of 2-methyl-3-tolyl-5-phenyl-A'^-l,2,4-oxadiazoline.
The uncoordinated oxadiazoline was made by the Hermkens method^* by a final year 
imdergraduate within the group (Timothy Garland). The bis oxadiazoline platinum(II) 
complex contained the ligand shown in figure 66.
5.4.71. NMR experiment using PtCl4(PhCN)(oxa).
The proton NMR spectrum of this platinum(IV) mono oxadiazoline complex at room 
temperature contains only sharp signals, in contrast to its platinum(II) counterpaif. 
Raising or lowering the temperature in the range 213-333 K had no effect on the 
spectrum. It is considered this is due to the ligand being locked into a particular 
configuration by the presence of the axial chloro ligands. When the NMe attempts to 
flip it would push the phenyl group of CHPh in towards the chlorine, and this is 
resisted and the ring is prevented fiom flipping. In this way the conformation of the 
molecule as a whole is locked in place.
S.4.7.2. Variable temperature NMR experiments using free 
oxadiazoline and PtCl2(PhCN)(oxa).
These two experiments are dealt with together because both behave similarly, and the 
spectra of the mono oxadiazoline platinum complex ar e displayed to show the result. 
The stacked plots shown in figure 67(a) clearly demonstrate the drift of the signals as 
the temperatme increases. This drift is dependent on how far apart the two signals of 
the exchanging conformations are fiom each other. The coalescence point can be 
estimated at 283 K or thereabouts. At this temperatme the flipping is at the same rate
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as the difference between the two signals in Hertz, and the NMR signal is at its 
broadest. At low temperature the speed of the flip slows down. Two distinct products 
should be visible, the main one at approximately 3.14 ppm and a minor product which 
is not obvious from the figure upheld of the main signal. The coalescence point shows 
the average of these signals. The flip is instantaneous so the molecule is in one 
conformation or the other. The broad signal is an artefact of the NMR experiment. 
The molecule is in a dehnite conformation but the operating speed of the spectrometer 
is not sensitive enough to pick it out. A good analogy is of a blurred photograph of a 
racing car. At any instant the car is solely in one position, but the camera shutter 
speed is too slow to pick it out
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Figure 67(a). The proton NMR spectra stacked plot of the NMe protons of mono 
oxadiazo line platinum(II) from 213 K-313 K.
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Figure 67(b) The proton NMR spectra stacked plot of the CHN proton of mono 
oxadiazoline platinum(II) from 213 K-313 K.
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Figure 67(c) The proton NMR spectra stacked plot of the C(Ph)=N ortho phenyl 
protons of mono oxadiazoline platinum(II) .
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Inspection of figure 67(b) confii*ms the proposed coalescence point at approximately 
283 K. This figure shows the stacked plot for the CHN proton which occms at ~ 6.00 
ppm. In this case the minor product is downfield of the main conformation. Also 
noticeable is that the range of the drift is not as large as for the NMe protons. This 
may be due to the flip having less of a spatial effect on the CHN proton compar ed to 
that of the NMe group. This is best envisaged by observation of figure 65 and 
imagining the CNO part of the ring flipping up and down. Figure 63(c) does not 
illustrate any broadening of the doublet at approximately 9.00 ppm, therefore these 
protons are not involved in the exchange at this temperature. The C(Ph)=N ortho 
protons are on the opposite side of the ring to where the flip occms, so the drift 
observed is thought to be due to local anisotropic efiects rather than the flipping 
action. It is more likely a result of the spatial position of the protons in relation to the 
5dii lone pair electrons on the platmum centre.
5.4.7.3. Variable temperature NMR experiments using bis 
oxadiazoline platinum(Il) complexes.
Bis oxadiazoline platinum complexes differ ftom their mono counterparts in the 
following ways, they not only exist as two diastereoisomers but can adopt different 
conformations as well. The oxadiazoline substituent phenyl rings can be on the same 
side of the PtX2N2 plane or on opposing sides. This is evident in the crystal structure 
shown in figure 48. These rings lie above and below the platinum centre and come 
fairly close together. This may inhibit complete free rotation of the phenyl rings, and 
also of the heterocycles about the Pt-N bonds. Examination of the stacked plot (figure 
68) of this experiment showed that all the proton signals sharpen or broaden 
depending on the temperature, but there is very little drift observed. Tliis may be due 
to a ring flip on one ligand of the complex resulting in the simultaneous opposite flip 
on the other ligand. This cancels out the overall effect of the flip. This is shown in 
figure 68 below.
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Figure 68. The proton NMR spectra stacked plot with varying temperature for a bis 
oxadiazoline platinum(II) complex.
The coalescence point can be estimated at approximately 273 K. Curiously, 
considering the ortho phenyl protons of N=CPh at 8.80-9.00 ppm, which are four* 
bonds away from the flipping nitrogen and represent the two diastereoisomers; as the 
temperature falls the diastereoisomer with the broad signal at coalescence becomes 
sharp. Also obvious is the appear ance of a smaller signal between the two signals of 
the diastereoisomers. There is an exchange occmring but tliis is possibly a 
conformation change rather than a ring flip. The smaller signal could be the minor 
conformation product of the diastereoisomer closer to 9.00 ppm. There is vhtually no 
drift of the other diastereoisomer. This feature is also seen in the 5.70 -  6.00 ppm 
range. If rotation about the Pt-N is frozen by steric effects, the conformational 
difference could be due to orientation of the oxadiazoline ligands, such as;
N—Pt-N or N— Pt— N
At present it is not possible to state with any certainty what is occurring with the bis 
oxadiazoline platinum complex.
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5.5. Substitution reactions of platinum complexes.
Prior to biological testing, it was considered usefril to learn something about the 
reactivity of mono and bis oxadiazoline platinum complexes with regard to 
substitution. Potential platinum anticancer agents commonly fail in vivo due to 
substitution of the ligands by compounds containing sulphur moieties, such as 
metallothioneins, found in the bloodstream or the cytoplasm of cells^^’^®. This means 
the active diug never reaches its site of action. The functionalities mvolved in this 
substitution are thiols and thioesters. DMSO was chosen for the present reactions, not 
that it mimics the in vivo substitutions, but rather because it is the choice of solvent 
for biological testing and for making stock solutions in pharmaceutical chemistry. 
This means that any potential anti-tumour drugs would have to be stable in DMSO, 
This is expanded on in section 5.7, Biological testing. Platinum nitrile complexes and 
both bis and mono oxadiazoline platinum complexes were used for these 
substitutions. In order to test the possibility of the complexes binding to DNA, 
pyi'idines, amines, and imidazole were chosen. The nitrogen of pyridine in pai ticular 
is similai* to the N7 of guanine (figure 69) which is imown to bind to cisplatin^^.
Figure 69. The structure of guanine (protons not shown).
5.5.1. Substitution using DMSO.
5.5.11. Substitution using platinum nitrile complexes.
[PtCl2 (p-OH-C6H4 CN)2 ] and [PtCl2 (p-MeO-C2H4 0 -C6H4 CN)2] were chosen for 
investigation as it was considered the two substituents on the ring were similai' 
electronically so the major difference would be a steric influence from the glycol ether
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group. Reactions were carried out in the NMR tube using deuterated DMSO in large 
excess as solvent according to the scheme;
Cl DMSO DMSO __
R— = N —P t -N = — R  ► Cl— Pt-DMSO +  2 R = N
Cl 2 H t s I RT Cl
Scheme 20. Substitution reactions of bis nitrile platinum complexes with DMSO.
The proton spectra were run initially (approximately after ten minutes), at two horns, 
and at 23 hours. The spectra were acquhed at 298 K and the tubes stored at room 
temperatme and 50% relative humidity. The results for the two experiments were 
similai', after ten minutes there had been approximately 20% substitution and 100% at 
two horns. This shows that the glycol ether substituent in the para position does not 
axially hinder substitution at the platinum centre. The intermediate product 
PtCl2(nitrile)(DMS0) is not seen in the proton NMR spectra, only the starting 
platmum nitrile complex and the uncoordinated nitrile. This suggests that the second 
substitution occurs rapidly after the fir st one and the concentration of the intermediate 
complex never builds up to high enough concentration to be visible m the spectra. 
This is consistent with DMSO having a strong trans effect resulting in the nitrile 
ligand being labilised. The PtCl2 (DMSO) 2  complex is generally poorly soluble and 
precipitates as a white solid, so no fmther substitutions take place. Whilst the 
experiment in no way mimics the relative concentrations of drug and sulphur 
containing substances in vivo, the rapid exchange demonstrates that platinum nitrile 
complexes would not be suitable candidates for medical testing.
5.5.12. Substitution with DMSO using bis oxadiazoline piatinum(ll) 
complexes.
Due to the poor solubility of hydroxy-substituted bis oxadiazoline platinum 
complexes in chloroform and acetone, deuterated DMSO was used to perform NMR 
experiments as a matter of course. Bis oxadiazoline platinum complexes were foimd 
to be stable in DMSO for many weeks without any significant exchange. Reaction
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only occurs when heat is applied (60 ®C) for several days. It was considered that bis 
oxadiazoline platinum complexes might be too inert with regard to substitution to be 
of much use for biological testing.
5.5.I.3. Substitution using a mixture of mono and bis oxadiazoline 
platinum complexes.
PtCl2 (PhCN)(oxa) + DMSO ^  PtCl2 (oxa)(DMSO) + PhCN ^  PtCl2 (DMSO) 2  + oxa 
PtCl2 (oxa) 2  + DMSO PtCl2 (oxa)(DMSO) + oxa PtCl2 (DMSO) 2  + oxa
Scheme 21. The sequence of substitutions m mono and bis oxadiazoline platinum(II) 
complexes by DMSO.
A mixture of mono and bis complexes in a 2 / 1 ratio was used in order to compare in 
situ the substitution of ligands by DMSO.
The unsubstituted platinum complexes shown in figure 70 below were used and the 
following three experiments carried out;
1. A large excess of DMSO (150/1 molar excess).
2. A smaller excess of DMSO (10/1  molar* excess)
3. A stoichiometric amount of DMSO.
C,/
I N—Me
HCI\ y
Me—N
(a) (b)
Figure 70. (a) Mono oxadiazoline platinum complex, (b) Bis oxadiazoline platinum 
complex (these were made according to the Desai and Wagner rnethod^ '^ ®).
Experiment 1.
30 mg of the mixture of mono and bis complexes was placed in an NMR tube with 0.5 
ml of deuterated DMSO and proton NMR spectroscopy monitored over the following
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24 hours. The signals corresponding to the mono complex gradually disappear, 70% 
in the first three hours. The product was a mixture of cis and trans PtCl2 (DMSO)(oxa) 
complexes. Unfortunately the bis oxadiazoline platinum complex does not dissolve so 
it was not possible to tell if it exchanged or not. Proton NMR signals equivalent to 
free oxadiazoline^* were visible but this could be produced by substitution of the 
oxadiazoline ligand of the mono complex.
It is considered from observation of the proton NMR spectra, that over the first 24 
hours the benzonitrile ligand of the mono complex is substituted by DMSO and the 
oxadiazoline ligand over the following five days. The presence of the large 
oxadiazoline ligand significantly slows down the rate of substitution of the 
benzonitrile ligand compared to platinum bis benzonitrile complexes. It was 
considered that the increased reactivity of mono oxadiazoline platinum complexes, 
with regard to substitution, compared to their bis counterparts would make them 
potential anti-tumour agents and good candidates for biological testing.
Substitution reaction of a mono oxadiazoline platinum 
complex using a large excess of DMSO
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Figure 71. Substitution of the benzonitrile ligand in PtCl2(PhCN)(oxa) using a large 
excess of DMSO at 25 ®C, over the first 24 hours of reaction.
Figure 71 above shows the trend in the rate of exchange of DMSO for benzonitrile in 
PtCl2 (PhCN)(oxa). The percentage substitution is calculated from the signal integrals 
in the proton NMR spectra. The line is one of best fit. There are five points up to
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approximately 3 hours and then one at twenty-two hours. This accounts for the rather 
sharp tailing off observed in the figure. The reaction should follow pseudo-first order 
kinetics as the DMSO remains in large excess throughout. To test this a plot of 
log{[PtCl2 (DMSO)(oxa)]infinity “  [PtCl2 (DMSO)(oxa)]time} against time should be 
drawn (The first term is called logA in figure 72). The percentage of substitution used 
in figure 71 is directly proportional to concentration so this quantity was used, and the 
concentration (percentage) at infinity assumed to be 100%. The result is shown in 
figure 72 below. Whilst these graphs were generated from one experiment without 
repeats to reduce error, the line is a good fit and straight. This would suggest that over 
the initial stages of the substitution, pseudo first order kinetics is followed. This is in 
general agreement in cases where the solvent coordinates to square planar platinum 
complexes, displacing a ligand^ .^
Exptl. Mono oxadiazoline platinum complex, substitution 
using DMSO as solvent
1.6 = 0.9759
1.4
3.52.50.5
Time (hours)
Figure 72. Expt. 1, plot of log A against time for the exponential part of figure 71.
Experiment 2.
In an attempt to prepare and isolate the platinum (DMSO)(oxa) complex, a second 
reaction was carried out using a much smaller excess of DMSO (10 molar). This was 
placed with 30 mg (0.05 mmol) of pure mono oxadiazoline platinum(II) complex in 
an NMR tube with one drop of deuterated chloroform to solvate it, and left for four 
days at room temperature. After this time proton NMR spectroscopy and TLC showed 
a mixture of products. Column chromatography was carried out using initially DCM 
to remove the benzonitrile and unreacted mono oxadiazoline platinum complex. Then 
DCM / ethyl acetate in a 3 / 1 ratio was used to elute the products. These were found 
to be a mixture of cis and trans PtCl2 (DMSO)(oxa) complexes, as found in
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experiment one. This was the first time a trans complex of this type was seen. The cis 
complex has been reported*^ starting with a mixed platinum (DMSO)(PhCN) complex 
but the synthesis is not without problems and a improvement would be beneficial.
Experiment 3.
The experiment was repeated using a stoichiometric amount of DMSO and deuterated 
chloroform as solvent in the NMR tube. At ambient conditions there was no exchange 
within 24 hours. The temperature was raised to 60 °C and the progress of the reaction 
monitored over the following six days (fig. 53). The exchange was slow, only 50% 
conversion after three days. Solely c/5-PtCl2(DMSO)(oxa) was formed, and some 
PtCl2 (DMSO) 2  complex. This is consistent with existing theory that with DMSO 
platinum complexes, the trans isomer forms first, but is readily isomerised to the more 
stable cis isomer, or that both isomers are formed and the trans isomer goes on to 
form the bis DMSO platinum complex as a result of its strong trans effect. Under the 
conditions of this experiment not only is the cis isomer produced preferentially but the 
bis substitution is also forced.
Substitution reaction of mono oxadiazoline 
platinum complex with DMSO using equimolar 
amounts at 60 °C % substitution
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Figure 73. Substitution of benzonitrile ligand in PtCl2 (PhCN)(oxa) by DMSO using 
equimolar quantities at 60 ®C.
128
The progress of the reaction shows the same trend as expt 1, when DMSO is used as 
solvent (figure 71) but much slower. As equimolar quantities were employed, it might 
be suspected that the reaction follows a second order type mechanism. To test for 
second order kinetics a plot of the reciprocal of the concentration of starting platinum 
complex against time was generated. To satisfy the requirement for second order, the 
plot should be a straight line. However this was found not to be the case. The data 
were also treated in the same way as experiment 1, and a plot of logA against time 
produced what appeared to be a straight line for the bulk of the reaction, except for a 
kink in the first few hours. This can be seen in figure 74 (a).
ExptS. Mono oxadiazoline platinum, DMSO 
substituion reaction in chlorofbmfi at 333k
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Figure 74 (a). DMSO exchange experiment 3, plot of logA against time.
It is possible that the reaction is complicated by the bis reaction taking place as well 
as the mono substitution, and therefore the data are no longer wholly valid. The plots, 
figures 74 (b) and (c), are contained in appendix 4 for interest.
A trend in the rate of substitution of platinum nitrile and oxadiazoline complexes with 
DMSO has been established; PtCl2 (PhCN) 2  > PtCl2 (oxa)(PhCN) > PtCl2(oxa)2 . As the 
rate of substitution decreases as the substituents become increasingly bulky, an 
associative mechanism for the substitution would be expected. If there was a 
dissociative mechanism at work, increasing steric hindrance of the ligands would not 
affect the rate of substitution. This is in agreement with published work 
However this is not in agreement with previous reports that in the substitution of 
square planar platinum complexes, configuration is retained^^. Experiment 1 resulted 
in both cis and trans isomers.
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5.5.2. Substitution reactions nsing pyridines.
PtCl2 (PhCN)(oxa) + pyi' -> PtCl2 (pyiO(oxa) + PhCN -> PtCl2 (pyr)2 + oxa 
PtCl2 (oxa) 2  + pyr -> PtCl2 (oxa)(pyr) + oxa PtCl2 (pyr)2 + oxa
Scheme 22. The sequence of substitutions in mono and bis oxadiazoline platinum(II) 
complexes by pyridine.
5.5.2.I. The reaction of pyridine with a mixture of PtCl2(oxa) 2  and 
PtCl2(PhCN)(oxa).
A similar approach to the DMSO substitution was initially adopted to investigate the 
susceptibility of bis and mono oxadiazoline platinum complexes toward substitution. 
A 50 / 50 mix of mono and bis oxadiazoline platinum(II) complexes was used and a 
thirty molar excess of pyridine without solvent. This was left at room temperatm e for 
fom' days. On addition of chloroform there was a white precipitate. This had a proton 
NMR spectrum consistent with a platinum bis pyiidine complex. There was no 
evidence of mono oxadiazoline platinmn complex, but the bis oxadiazoline platinum 
complex was clearly visible in the NMR spectrum and isolated by chromatography. 
The experiment was repeated using deuterated chloroform as solvent in the NMR tube 
and the proton NMR spectra acquiied periodically. A mixtme of products was 
obtained, again there was a white precipitate of platinum bis pyridine but the other 
two main products were not so easily identified. Close examination of the integration 
of the spectrum led speculatively to the following conclusion; the products were a 
mixtm e of the hydrolysis product of the mono oxadiazoline platinum complex and the 
hydrochloride salt of pyiidine. These are shown in figme 75 (a) and (b) below.
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Figme 75(a) The structme of the hydrolysis product of PtCl2 (PhCN)(oxa), 
PtCl2 (NH=C(OH)-Ph)(oxa).
HAA
Figme 75 (b). The hydrochloride salt of pyiidine.
This is feasible as water, which always finds a way into deuterated chloroform, can 
produce hydrochloric acid, which would both facilitate the hydrolysis of the nitrile 
ligand, and produce the hydrochloride of pyridine. It should be stressed however, that 
these structmes are not the only possibilities and remain speculative. The proton NMR 
spectrum is included in appendix 4. The experiment was repeated with the following 
modifications, pme mono oxadiazoline platinum complex was employed, the 
chloroform used was fiom an ampoule (0.05 ml) and only a stoichiometric amount of 
pyridine was used. It was considered the benzonitrile of the mono oxadiazoline 
platinum complex would be selectively substituted under these conditions. The NMR 
tube was left for fom* days at room temperatme. After this time the reaction was 
checked by proton NMR spectroscopy which looked to be consistent with the desired 
product. Over the following two days the product crystallised out in the tube and X- 
ray diffraction analysis carried out. This confiimed the product as a mixed ligand 
Pt(oxa)(pyr) complex. While this structme is not a Pt(oxa)(FhCN) complex, 
nevertheless, this is the first X-ray structme obtained for a mono oxadiazoline 
platinum complex.
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Figure 76. Representation of the X-ray structure (Platon) of trans-p\si\n\xm dichloride 
(oxa)(pyr) complex.
As can be seen from figure 76, it is a trans complex which is in contrast to DMSO 
substitution which prefers the cis configuration when coordinated to platinum. The 
coordination of pyridine tends to agree with previous reports that in substitution 
reactions of square planar platinum(II) complexes, configuration is retained This is 
generally explained by an associative mechanism with a five coordinate bipyramidal 
intermediate. The two trans-ch\onde ligands assume the axial positions and the new 
ligand coordinates in the triagonal plane. On exit of the leaving group, the trans 
configuration is retained. This is shown in figure 77 below. What is obvious from the 
present work is that generalisations about the substitution reactions of platinum cannot 
be made, and the configuration of the products is dependent on the relationship 
between the ligands and platinum.
ClIA—Pt—LICl
ClIB—Pt-A +  L
-B
BCl ^ Cl
Figure 77. An associative, bipyramidal mechanism for platinum substitution reactions.
132
5.5.2.2. Reaction of PtCl2(oxa)(PhCN) with 2,6-diacetylpyridine.
Equimolai’ quantities of platinum complex and the di-substituted pyridine were placed 
in an NMR tube with 0.5ml of deuterated chloroform and left at room temperatme. 
The proton NMR spectrum was monitored periodically but no reaction was evident 
after several days. This is not wholly unexpected as the acetyl groups are strongly 
electron withdiawmg and délocalisé the nitrogen lone pah in towards the ring. This 
effectively deactivates the nitrogen. There is also the possibility of steric hindrance by 
the or//zo-substituents. The reaction was heated for 24 hours at 60 °C, with no reaction 
observed.
5.5.2.3. Reaction of PtCl2(oxa)(PhCN) with DMAP.
The same procedme as for 2,6-diacetylpyridine was adopted. The dimethylamino- 
substituent introduces competition for coordination to platinum via the ring nitrogen. 
However, being strongly electron donating it activates the ring nitrogen in para 
position making it more strongly cr donating. Also the tertiary amino nitrogen is 
considerably more basic than the pyr idine nitrogen with pKa values of 11 and 6 
respectively. This is due to the different hybridisation states of the nitrogens. The 
amino nitrogen is sp^ hybridised whereas the pyridine nitrogen is s ^ .  This means that 
the pyridhie nitrogen lone pair electrons are more closely boimd to the nucleus than 
the amino nitrogen lone pah as the sp^ hybrids have 33% 5 character and sp^ have 
only 25% s character. It was expected that a mixtme of products would be the 
outcome and this was the case. The ^^ P^t NMR spectrum showed the main product at 
-2173 ppm and at least four other minor products with signals ranging from -2006 to - 
2217 ppm. Chr omatography only separated one pme product, which was not the main 
one, and this was more polar than the other products. On the TLC plate the isolated 
product stuck to the baseline and the eluent had to be made more polar* to get it off the 
column. At this stage it was considered to be coordinated via the pyridine rmg 
nitrogen, its ^^ P^t NMR signal was at -2035.6 ppm, slightly upheld of that for* the 
PtCl2 (pyr)(oxa) complex at -2023 ppm, which was coordinated via the pyridine ring 
nitrogen. This is in contrast to Rochon’s findings for cw-diamine platinum 
complexes*"^ ,^ — 2230 ppm for primary amines and —  2180 ppm for secondary
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amines. Considering the signal found for the platinum dimethylaminobenzonitrile 
complex (tertiary amine) at -2124.7 ppm, which is believed to be coordinated via the 
amino nitrogen, this is consistent with Rochon’s findings. The assignment is 
supported by the proton NMR spectrum where the dimethylamino protons display 
only one signal, indicating their possible equivalence. Coordination to the amino 
nitrogen should result in two signals as the chiral CHN(Ph) carbon renders the methyl 
groups non-equivalent.
Nucleus Pyridine complex Free pyr idine AÔ
‘H 0- 8.70 ppm 8.59 ppm +0.15 ppm
m~ 7.71 ppm 7.62 ppm +0.09 ppm
P- 7.22 ppm 7.23 ppm -0.01 ppm
o- 153.8 ppm 149.9 ppm +3.90 ppm
m- 138.1 ppm 135.9 ppm +2.2 ppm
P- 125.3 ppm 123.7 ppm +1.6 ppm
DMAP complex Free DMAP
‘H 0- 7.13 ppm 8.21 ppm -1.08 ppm
m- 6.06 ppm 6.46 ppm -0.04 ppm
NMB2 2.95 ppm 2.96 ppm -0.01 ppm
''C Cq 157.6 ppm 154.1 ppm +3.50 ppm
0- 151.6 ppm 149.7 ppm +1.90 ppm
m- 108.3 ppm 106.5 ppm +1.8 ppm
NMC2 39.1 ppm 38.8 ppm +0.3 ppm
Table 13. Contrast of the proton and ^^ C NMR signals of free and coordinated 
pyr idine and DMAP.
Closer scrutiny of the proton and ^^ C NMR spectra of this experiment and the 
previous pyridine erqreriment show a difference (see table 13). Coordination to 
platmum via the pyridine nitrogen should increase the electron deficiency of the 
ar omatic rmg compar ed to the free hgand, resulting in a downfield shift of the NMR 
signals for both proton and carbon. This is the case in the unsubstituted pyridine 
experiment, but in the DMAP experiment the opposite is true for the proton NMR 
spectrirm.
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It is possible that the pyridine ring is experiencing some magnetic effect such as ring 
current effects, by being in close proximity to one of the aromatic rings of the 
oxadiazoline ligand. This suggests the possibility of a cis complex, however a 
molecular model shows that there would be excessive steric hindrance. This is the 
case for cis coordination via the amino nitrogen as well and this is shovm in figure 78. 
In the event of trans coordination to the ring nitrogen, the pyridme and phenyl rings 
do not come into close contact at all, as can be seen in figui*e 76. Also fi*ee rotation 
about the C-N bond would make the methyl groups equivalent, consistent with the 
proton NMR.
Ph
C i- p t - N
Ph
Me Me
Figm'e 78. Possible cz\s-PtCl2 (DMAP)(oxa) complexes showing hindiance to free 
rotation.
It is inconclusive whether the isolated complex is the cis or trans isomer but excessive 
steric liindrance would make the cis complex unlikely. In the spectrum of the 
analogous cis-DMSO complex, the methyl groups have distinctly different signals and 
the confrguiation of this complex has been previously confiimed as cis by X-ray 
crystallography^^. It is therefore imlikely that coordination is via the ammo nitrogen. 
However, direct compai'isons between a sulphur donor and a nitrogen donor ligand 
should be treated with caution. Another feasible explanation for the difference in the 
proton NMR signals is that if the platinum is electron withdi'awing regaiding the ring, 
then the amme nitrogen is electron donatmg by resonance and this accounts for a 
slight upfield shift of the NMR signals of the ortho and meta protons. Takmg into 
account the ^^ P^t NMR signal and the other evidence, the complex is most likely 
trans-coordmsLted via the pyridine nitrogen.
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5.S.2.4. Reaction of PtCl2(oxa)(PhCN) with amines.
PtCl2(PhCN)(oxa) + L ^  PtCl2(oxa)(L) + PhCN ^  PtCl2(L)2 + oxa
Scheme 23. The sequence of substitutions in mono oxadiazoline platinum(II) 
complexes by amines.
5.5.2 4.1. Reaction with 3-aminophenol.
This ligand was chosen as it was considered the amine would easily displace the 
nitrile ligand, and the hydroxy group would both introduce a polar group and a 
hydrogen bonding motif This would make the resulting complex more soluble in 
polar solvents and introduce a possible new binding site to DNA. Also, DNA and 
proteins in the cells and bloodstream contain amine groups, and these can substitute 
onto a potential drug and deactivate it. A successful exchange indicates if the starting 
complex will be easily deactivated m the bloodstream, or if it will bind to DNA. So if 
the exchange is rapid, within two horns, there is very little chance of the complex 
reaching the target DNA.
Observation of the proton NMR spectra acquired at regular* intervals showed no 
substitution reaction had taken place, even when heat was applied (60 °C for 30 
minutes). Rather the amine decomposed.
S.5.2.4.2. Reaction with l-amino-2-propanol.
The reaction of PtCl2 (PhCN)(oxa) with this amine was rapid, with some reaction 
observed after only ten minutes at room temperature. This amine is of a similar 
basicity to concentrated ammonia solution (o.g. 0.880), but is considerably 
nucleophilic. Both benzonitrile and oxadiazoline ligands were replaced, the signals of 
the ftee oxadiazoline clearly visible in the proton spectrum. There was evidence of 
many products. As this amine is also extremely hygroscopic and is sold commercially 
containing 5% water this is suspected to be due to base hydiolysis of the ligands. 
However the most likely position for hydrolysis is the C(H)-N bond of the
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heterocycle. This would result in an aldehyde and this is not apparent in the proton 
NMR spectrum.
5.5.2.5. Reaction of PtCl2 (oxa)(PhCN) with 2-amino-l- 
methylim idazole.
The use of the 2-amino-1 -methylimidazole ligand introduces two nitrogen sites for 
coordination to platinum, an amino nitrogen and an heterocyclic nitrogen, the lone 
pail* of the N1 ring nitrogen being pai*t of the aromatic system. The reaction was 
carried out at room temperatuie and over the fust 24 houis there was approximately 
30% exchange. Four products were observed in the proton NMR spectrum. As no free 
oxadiazoline was evident in the spectra (see experimental section, substitution 
reactions), the products are presumed to be cis and trans isomers of a mixed 
Pt(imid)(oxa) complex, with the imidazoline coorninated by the N3 ring nitrogen, and 
cis and trans isomers coordinated via the amino nitrogen. Increasing the temperature 
to 50 °C made no difference to the progr ession of the reaction, which appeared to 
have reached completion at 30% conversion. Due to the low conversion and large 
number* of products, no attempt was made to isolate the products. A copy of the 
proton spectrum for* this reaction is included in the experimental section 
(substitutions).
5.S.2.6. Reaction of PtCl2(oxa)(PhCN) with trit>hetiylphosphine.
PtCl2 (oxa)(PhCN ) +  P(Ph ) 3  ^  PhCN +  PtCl2(oxa)(P(Ph)3)
Scheme 24. The attempted substitution of benzonitrile by triphenylphosphine in a 
mono oxadiazoline platinum(II) complex.
The reaction of triphenylphosphine with this complex is rapid and proton NMR 
analysis was carried out hnrnediately after* the addition of a stoichiometric amount of 
the phospliine. Substitution occurs within fifteen minutes but exchanges carry on for* 
several days. There is no one end product though undoubtedly the main end product is
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a platinum triphenylphosphine complex with no oxadiazoline or benzonitrile ligand. It 
was expected, based on the evidence of the previous substitutions, that 
triphenylphosphine would exchange with the benzonitrile ligand. Whilst it was 
believed the expected product was apparent in the proton NMR spectrum, it was not 
possible to identify this complex (shown below in figure 79) in the mass spectrum. A 
tentative hypothesis is that triphenylphosphine replaces a chloride ligand resulting in a 
charged species (the proposed complex in figure 79). Stereoisomers of these are 
possible and there would be steric hindrance between the triphenylphosphine and the 
oxadiazoline ligands possibly leading to instability.
PhC NI
01-------P t — [P P h 3 ]
Cl
o x a — P t -------[P P h 3 ]
Cl
Figure 79. The proposed and expected initial products of the reaction of 
triphenylphosphine with PtCl2 (oxa)(PhCN).
The molecular weight of the proposed complex is 834.22 and a strong signal with the 
correct isotopic pattern was observed at 833.9 m/z (figure 80).
m«07090&t)«i RT 0.08 AV; 1 NL: 3.80E5 
T: ♦ c FAB Full m * 1149.60-950 50J
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Figure 80. MS-FAB signal at 833.9 of proposed complex, [PtCl(oxa)(PhCN)(tpp)]^
This is further supported by the absence of signals corresponding to free benzonitrile 
in the NMR spectra obtained at various times after the initial reaction. The CN and
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quaternary C(l) signals at 118.8 and 112.4 ppm are distinctive and not overlapped by 
other signals, which unfortunately is the case for the C(2,6), C(3,5) and C(4) signals. 
More curiously the mono oxadiazoline platinum complex appears to be regenerated in 
part as the reaction proceeds. There is also evidence in the proton spectrum for some 
bis oxadiazoline platinum complex. It is difficult to explain why the benzonitrile or 
oxadiazoline ligands should undergo re-coordination after being freed. Sometimes in 
the NMR spectra it appears that a compound is increasing in concentration if another 
one is slowly precipitating. However this was not obvious,
*^ P^t and NMR spectroscopy was performed on the initial product in an attempt to 
characterise it before further exchanges took place (With the time required to carry 
out these processes further exchanges cannot be ruled out). The two sets of results 
were consistent. A doublet was apparent in the ^^ P^t spectrum centred at -3598 ppm 
with a * j'^^Pt-^'P coupling constant of 3450 Hz. In the *^P spectrum a singlet was seen 
at 3.83 ppm corresponding to uncoupled phosphorus, and a doublet (— 4.5 / 12.3) 
centred at 3.83 ppm which also had a ‘j^'P-'^^Pt coupling constant of 3450 Hz 
representing phosphorous coupled to ^^ P^t. This is shown in figure 81 below.
10 0 •6 PPM25 15 52030
Figure 81. The *^P NMR spectrum of the reaction of triphenylphosphine with 
PtCl2 (oxa)(PhCN) after two hours.
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The coupling constant is consistent with published data for a phosphine ligand trans 
to a chlorine ligand, i.e. a cis complex^^’^ "^ .^ The relative integration was 1 / 4 / 1 ,  and 
this is close to the ratio of magnetic platinum to non-magnetic platinum. There is also 
evidence in figure 81 of a tmm-PtClzCPPhs)! complex. Considering the doublet just 
visible above the baseline at 13.70 / 26.70 ppm which is centred at 20 ppm, and has a 
ij3ip_i95pt coupling constant of 2632 Hz, this is consistent with published data for 
complexes of the type t?*a«.s-PtCl2 (PR3)2 '^^ .^ A doublet corresponding to this complex 
was not so easy to spot in the ^^ ^Pt NMR spectra. There is also a doublet (~ 5.0 / 23.2) 
centred at 14.3 ppm which would also appear* to be a cis complex, judging by the 
coupling constant but could not be seen in the ^^ ^Pt NMR spectra. The ratio of the two 
coupling constants 3450 / 2632 is 1.31 which is close to the published ratio of 
1 4 j^ 52,149 and trans isomers of the same formula. In the present study the
structure of the complexes is not known with certainty. The *^P NMR signal of the 
suspected trans complex is downfreld of those of the suspected cis complexes and this 
is also consistent with the literatm'e^^’^ '^ ,^ and explained by the more efficient back 
bonding fi*om platinum to phosphorus in the cis complexes.
Spectra were acquired after 24 hours and at least five species were apparent, mostly 
downfield of the first to appear*. These can only be presumed to be subsequent 
substitutions by a triphenylphosphine ligand. These signals are consistent with 
published data. Clark and MartW^^ used a substituent summative approach to predict 
the NMR signal of platinum bis phosphine complexes of the type PtCl2 (PR3)2 . 
Adapting their* approach to a mixed PtCl2 (oxa)(P(Ph)3) complex gives a close 
conelation to the experimental results. Taking -2120 ppm for PtCl2 (oxa) 2  and -4450 
ppm for the PtCl2 (PPh3 ) 2  gives an average of -3285 ppm for PtCl2 (oxa)(P(Ph)3). 
Signals were found at -2919 ppm and -3390 ppm. The deviation of the former signal 
ftom the average is consistent with the findings of Clark and Martin for* bulky 
phosphines. They explain the large deviation in terms of deshielding of the platinum 
centre due to steric effects of the bulky ligands. Crystallography shows the Pt-P bond 
to be longer in complexes containing bulky phosphine ligands^^’ The latter* signal 
could correspond to [PtCl(oxa)(PhCN)(P(Ph3)]^ although it is impossible to say 
categorically, which complexes the signals correspond to. Whilst plenty of time could 
have been spent investigating these exchanges, further results were not considered in 
strict keeping with the aims of the project so the work was discontinued. It can be
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concluded that in the case of substitution by triphenylphosphine, an initial rapid and 
selective reaction takes place, but then further substitutions take place and it is unclear 
what the initial product is.
Summing up, the various exchanges carried out with different ligands that beai* 
similarity to components of the bloodstream and DNA, have given an indication how 
the complexes of the present study may behave in vivo. Bis oxadiazoline platinum 
complexes are resistant to substitution by sulphur containing compounds but they also 
do not exchange readily with pyridine. This may mean they are not suitable as 
candidates for anti-tumour agents. On the other hand their mono counterparts are 
more susceptible to substitution by pyridme, imidazoline, aliphatic amine and DMSO. 
It remains to be seen how they perform during in vitro testing.
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5.6. Oxidative addition reactions of Platinum(II) oxadiazoline 
complexes. (All the following halogénations were canied out in an NMR tube 
and monitored by proton NMR spectroscopy).
trans-ViX.'^^l} +  Y2 trans t^rans t^rans-VÏK'^Y'zi-}!} 
where X = Cl or Br and Y = Cl or Br, LI = PhCN or oxa, L2 = oxa
Scheme 25. The oxadation with halogens of mono and bis oxadiazoline platmum(II) 
complexes.
Oxidative addition reactions were attempted using the mono oxadiazoline platinum(II) 
complex rmrt5-[PtCl2(PhCN){N=C(Ph)-0-N(Me)-CH(Ph)}] and the elemental 
halogens, chlorine, bromine and iodine. Bis oxadiazoline platinum(IV) complexes 
have been previously reported*^’^ ,^ but were made fi'om platinum(IV) benzonitrile 
complexes. It was decided to attempt the production of these ma the chlorination of 
platinum(II) complexes to see if the method was an improvement. The drawback with 
the previous method is that platinum(IV) benzonitrile complexes rapidly hydiolyse 
and can only be stored in a moisture free environment.
Additions were also attempted using hydrogen peroxide, benzoyl peroxide and tert- 
butyl-peroxide, intending to introduce polar* hydroxy- and benzoyl-gi'oups to the 
complexes and hopefully impart better solubility in polar solvents to the complexes. 
The mechanism of the addition of chlorine is one of induced dipole and electrophilic 
addition. This is shown in figure 82 below.
Cl PhCN PhCN
oxa oxa
Cl
oxa
Figure 82, The mechanism of tlie oxidative addition of chlorine to PtCl2(oxa)(PhCN).
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5.6.1. Chlorination of bis oxadiazoline platinum(II) complexes.
The complexes;
1. [PtCl2 {N=C(p-MeO-C2H4 0 -C6H4 )-0 -N(Me)-CH(Ph)}2] (49)
2. [PtCl2{N=C(Ph)-0-N(Me)-CH(p-HO-C6H4)}2] (47)
3. [PtCl2{N=C(/«-H0-C6H4)-0-N(Me)-CH(Ph)}2] (46)
were used for the oxidation reactions. Chlorine was bubbled through a solution of 
each complex in the NMR tube. This meant the progress of the reaction could be 
monitored by proton NMR spectroscopy. There was also a colour* change from pale 
cold yellow to an intense warm yellow. The reactions were slow and chlorine had to 
be bubbled through them for* two minutes to achieve a maximum conversion of 50%. 
Presumably the lack of reactivity is due to the bulky oxadiazoline ligands which 
hinder the chlorine and platinum centre coming into contact. The products were 
unstable and it was not possible to acquire full characterisations. There is also the 
possibility of chlorine reacting with the C=N double bond of the heterocycles and 
chlorination of electron rich ar omatic rings.
The indicative signs of a successful oxidation in the proton NMR spectrum are a sliift 
from ~ 5.9 ppm to 6.7 ppm corresponding to the C(Ph)H of the heterocycle, and from 
~ 8.8 ppm to 8.2 ppm equivalent to the ortho protons of C6H4 C=N of the heterocycle. 
Of the three complexes used the most successful was product 49 which has para- 
glycol ether substituents on the N=C-C6H4 -. This is a conjugated system and any 
electron donating effect of these groups can be delocalised into the heterocycle and to 
the platinum. So the phenyl rings may remain stable and resistant to chlorination. The 
delocalisation is shown in figure 83 below. This complex achieved 50% conversion 
and was stable long enough to attain ‘^ ^Pt and NMR spectra. A characteristic 
downfield shift from -2124.0 to -98.2 ppm consistent with oxidation from Pt (11) to Pt 
(IV) was seen in the ^^ P^t NMR spectrum.
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Figure 83 . E lectro n ic  e ffe c t  o f  g ly co le th er  substitu en ts on the co m p lex .
The proton NMR spectrum of the reaction of product 47 was a mass of aromatic and 
aliphatic signals with little evidence of the desired product. There was an appreciable 
amount of starting material left but it was not possible to identify the products. This 
complex has para-hydroxy groups on the other aromatic ring system, i.e. C(H)C6H4 
ring. The electron donating effect of these groups is not delocalised to the heterocycle, 
and activates the ring in ortho and para positions with reference to the position of the 
hydroxy group (see figure 84). It is possible these positions could be activated toward 
chlorination.
C N
Ô-
0 :H
Figure 84. Effect of the hydroxy group on the aromatic ring system.
In the case of product 46 there was approximately 30% reaction but it was not the 
only product. The products were unstable and decomposed on standing. The meta- 
hydroxy group has no electronic effect on the ring but can be oxidised itself to a 
quinone.
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5.6.2. Oxidation of mono oxadiazoline platinum complexes.
Due to the lack of success with bis oxadiazoline platinum(II) complexes it was 
decided to use mono oxadiazoline platinum(II) complexes. The platinum centre is 
much less hindered as can be seen in the x-ray structure of the platinum pyridine / 
oxadiazoline complex, figure 76, and should be consequently more susceptible to 
oxidation by chlorine.
5.6.2.1. Reaction of chlorine with mono oxadiazoline platinum 
complexes.
The complexes;
1. [PtCbCPhCN){N=C(PhCN)-0-N(Me)-CH(Ph)}]
2. [PtCl2(p-Me0 C2H4 0 -C6H4CN){N=C0 -Me0 C2H4 0 -C6H4)-0 -N(Me)- 
CH(Ph)}]
were used for this purpose. In contrast to the analogous reaction for bis complexes, 
and as expected, the reaction was rapid, the colour change evident in seconds. Proton 
NMR spectroscopy confirmed nearly 100% reaction. The products were precipitated 
with petroleum ether and isolated by filtration. Full characterisation was obtained for 
both. The reactions going to completion is expected as access to the platinum is 
easier, facilitated by the linear natur e of the Pt-NCR bond of the nitrile ligand which 
makes the ligand stick straight out from the platinum, and in the squar e plane. This is 
not the case in the bis oxadiazoline complexes where the phenyl groups tend to wrap 
arormd the platinum centre above or below, liindering electrophilc attack by the 
halogen.
5.6.2.2. The reaction of bromine with PtCl2(PhCN)(oxa).
In the hope of obtahiing a mixed chloro / bromo platinum complex, PtCl2 (PhCN)(oxa) 
was reacted with a stoichiometric amount of bromine according to the equation
[PtCl2(PhCN){N=C(PhCN)-0-N(Me)-CH(Ph)}] + Bra ^  [PtBr2Cl2(PhCN){N=C(PhCN)-0-N(Me)-CH(Ph)}] .
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The reaction was monitored by proton NMR spectroscopy and was significantly 
slower than the analogous chlorination, taking minutes rather than seconds. One major 
product was visible in the proton NMR specti-um, however with the passage of time 
more products appeared. In the initial spectrum there was a negligible amount of 
[PtCl2 (oxa)2l complex. The integration of the ortho phenyl protons at 8.60-8.80 ppm 
was considerably less than that of the -CH 2 - group of diethyl ether (3.45 ppm), which 
was an impurity that was used as an internal reference. After two hours there was 
considerably more [PtCl2(oxa)2] than diethyl ether. This can be seen by comparing the 
aforementioned integrals in figures 85 (a) and (b) below. This can only be explained 
by an oxadiazoline ligand being displaced, presumably by a halogen, resulting in 
uncoordinated oxadiazoline. This would then replace a benzonitrile ligand in the 
residual [PtCl2 (oxa)(PhCN)] complex.
k 'mL
3 PPM
Figure 85(a). The proton NMR spectrum of the initial product of bromination of 
PtCl2 (PhCN)(oxa) after 10 minutes.
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Figure 85(b). The proton NMR spectrum of the products of bromination of 
PtCl2 (PhCN)(oxa) after 140 minutes.
Figure 85 (b) also shows several signals between 6.60 and 7.00 ppm coiTesponding to 
the Ph-CH-N proton of the complex. It is believed these are due to ligand exchanges 
between chloride and bromide resulting in various combinations of ligands (this can 
be seen much clearer in figure 86 below, which represents the chlorination of 
PtBr2 (PhCN)(oxa)). There is possibly a small amount of Pt(IV)(oxa) 2  which would 
also explain the signals at 8.20 ppm, corresponding to the ortho phenyl protons. In a 
mono oxadiazoline platinum(II) complex these protons appear* at 9.00 ppm, and in a 
bis complex they appear upfield between 8.60 and 8.80 ppm, and normally appear as a 
doublet and a broad singlet. These represent two diastereoisomers. It is therefore 
reasonable that the signals upfield (8.15 and 8.20 ppm) of the signal conesponding to 
the mono oxadiazoline platinum(IV) complex (8.38 ppm) are the bis oxadiazoline 
platinum(IV) complex. Another possibility is that they are the uncoordinated 
oxadiazoline, however they are not in strict agreement wifii Herinken’s reported 
values at 8.04 ppm, deuterated chlorofonn being used in both cases^ .^
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Mono Pt(IV)
Bis Pt(ll)
Mono
Pt(ll)
Bis Pt(IV)
Figure 86. The 8.0-9.0 ppm range of the proton NMR spectrum of the products of 
bromination of PtCl2 (PhCN)(oxa) after 140 minutes.
The apparent triplet at 8.15 ppm may possibly be a pair of overlapped doublets. If the 
ligands are locked in place by the presence of the axial halides, the two ortho phenyl 
protons of Pt-N=C-Ph may lose their equivalence but be similar enough to be 
overlapped.
As the reaction progressed there was an orange / red precipitate. This was filtered and 
dried and was found to have an elemental composition consistent with 
[PtBr4 (PhCN)(oxa)]. hi the MS-FAB spectrum there is a signal at [M-2HBr] at 694.8. 
Assuming [PtBr*4 (PhCN)(oxa)] to be insoluble, when it precipitates it effectively 
removes bromine from the system of exchanges. This means there should be a greater 
abundance of the chloride rich complexes in the final proton spectr um. This is borne 
out in the enlargement of the 6.5-7.0 ppm region of the stated spectrum, shown in 
figure 87 overleaf.
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PtBrzClzL'L^
PtBrClsLT^
PtBr4UL^ PtBraCi VL
PfCl4L\2
7.0 6.9 6,8 6.7 6.6 6.5 PPM
Figur e 87. The 6.5-7.0 pprn range of the proton NMR spectrum of the bromination of 
PtCl2 (PhCN)(oxa) after 140 minutes.
5.6 2.3. The reaction of iodine with PtCl2 (PhCN)(oxa).
It was expected that this reaction would be slow, but there was no observed oxidation 
reaction at all, even after the application of heat for several days. This is very likely 
due to the large size of iodine compared to chlorine making coordination of iodine 
much more difficult, and the fact that iodine is considerably less reactive compared to 
chlorine.
S.6.2.4. The reaction of iodine chloride with PtCl2 (PhCN)(oxa).
Not being deterred by the failure with iodine it was decided to attempt the reaction 
using iodine chloride. This is a covalent compoimd but has considerable ionic 
character and the electron poor iodine should be more susceptible to nucleophilic 
attack than molecular* iodine. Also the steric hindrance would be reduced by only 
incorporating one iodine ligand. Again, there was no apparent oxidation. After 24 
hours there was evidence of degradation in the proton NMR spectrum and some 
residue in the tube.
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5.6.3. The oxidation of PtBr2 (PhCN)(oxa) with halogens.
5.6.3.I. The reaction of PtBr2 (PhCN)(oxa) with chlorine.
It would be expected that the products of tliis reaction would be the same as for the 
reaction between bromine and PtCl2 (PhCN)(oxa). However in the twenty minutes that 
elapsed between addition of chlorine and the running of the initial proton NMR 
spectrum, five compounds had formed. It is thought that the initial product was not 
stable and various ligand exchanges took place. Considering the Pt(IV)-N-CH(Ph) 
proton, after twenty minutes, there were five signals visible centring at 6.70 ppm and 
these coiTespond to the different combinations of bromide and cliloride in the 
platinum complexes, i.e. PtBr4 L^L^(not seen), PtBrgClL^L^, PtBr2 Cl2 L^L ,^ 
PtBrClgL^L^ and PtCUL^L^ . The signals aie shown in figure 88 below. Chloride rich 
species predominate and it is thought this is due to, firstly, the insolubility of bromo 
platinum(IV) complexes, and secondly the difficulty delivering a stoicliiometric 
amount of chlorine gas. Despite flushing the solution with nitrogen, it was considered 
more important to acquire an initial proton NMR spectiaim than to thoroughly de-gas 
the solution.
PtBrClaCL^
PtCU I V
PPM6.66.76.87.0
Figure 88. The 6.0-7.0 ppm range of the initial (after approximately 20 minutes) 
proton NMR spectrum of the reaction of chlorine with [PtBr2 (PhCN)(oxa)].
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After one hour there was some orange / red precipitate and the solution was yellow. 
Proton NMR spectroscopy showed [PtCl4 (PhCN)(oxa)] to be the predominant product 
in solution. In contrast to the bromination of [PtCl2 (PhCN)(oxa)], there was no bis 
oxadiazoline platmum(II) complex visible in the proton NMR spectrum acquired at 
the end of the reaction (70 minutes), and this had been evident in the initial starting 
material and the initial proton NMR spectrum. Again, this is considered to be due to 
oxidation by excess chlorine. It is believed the signals surrounding 6.60 ppm in figuie 
88 aie [PtX4 (oxa)2] species. Platinum NMR spectroscopy was also carried out but was 
not successful for the following reasons; firstly, plenty of time and concentrated 
solutions aie required to acquire ^^ P^t NMR spectia, so the process does not lend itself 
to the analysis of rapid ligand exchanges. Secondly, as the reaction proceeded a red 
precipitate collected on the sides of the NMR tube which causes inhomogeneity of the 
sample in the spectrometer. Lastly, with many species present at any one time, there 
was not sufficient concentration of any one complex present to be visible in the 
spectra.
5.6.3.2. The reaction of PtBr2(PhCN)(oxa) with bromine.
Following the addition of a stoichiometric amount of bromine solution there was an 
almost immediate reaction with a red precipitate. However proton NMR spectroscopy 
revealed that the reaction was only 50% complete, even after allowing a few minutes 
for further reaction to take place. A fuither stoichiometric amount was added resulting 
in more precipitate, but the NMR spectrum showed that the oxidation was 80% 
complete. Similar to the bromination of PtCl2 (PhCN)(oxa) in section 5.6.2.2, there 
was also a doublet apparent at 8.20 ppm. This grew as the reaction progressed, and as 
the red solid precipitated, the proton NMR spectrum simplified. After tliree hours, 
there were two major products left in solution in a ratio of 2:1. The minor product is 
bis oxadiazoline platinum(II) complex, and this is characterised by its broad signals. 
The major is thought to be a decomposition product of the oxadiazoline and is given 
the tentative structure shown m figure 89 below.
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Figure 89. Proposed structuie for the oxadiazoline decomposition product following 
bromination of [PtBr2 (PhCN)(oxa)].
8  = PtBrz(oxa)2
= Ph-CH=NMe
\_ jK J 1
Figure 90. The proton NMR spectrum of the reaction of bromine wiüi 
[PtBr2 (PhCN)(oxa)] after 3 horns, tentatively thought to be the structure in figure 89.
Examination of figure 90 shows that the integration is roughly correct for the stated 
ratio of the proposed mixture. The broad signals are a good match for those found 
experimentally for the cycloaddition product PtBi*2 (oxa) 2  (see figure 49). As there was 
negligible dibromo bis oxadiazoline platinum(II) complex present at the start, this 
must be produced in the same way as in the bromination of PtCl2 (PhCN)(oxa) 
experiment. The red residue is most likely a mixture of the deshed product 
[PtBr4 (PhCN)(oxa)] and a [PtBi'e] '^ species. Elemental analysis is inconclusive but 
consistent with a mixture of the two in a 4:1 ratio. It was possible to completely assign
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the proton NMR spectrum of the mixed halide signals between 6.5 and 7.00 ppm, 
including the signal corresponding to the Ph-CH-N of [PtBr4(PhCN)(oxa)] at 7.00 
ppm. In the ear lier mixed halogen experiments this was an assumption.
5.6.3.3. Summary of NMR spectral data of mixed halogen mono 
oxadiazoline Platinum(IV) complexes.
^^^Platinum NMR spectroscopy was also canied out on all the mixed halogen 
complexes and the data summarised in table 14 and figure 91 below;
No. in graph Complex '^^Pt Ô (ppm)
1 [PtBr4 (PhCN)(oxa)] -1649.1
2 [PtBr3Cl(PhCN)(oxa)l -1325.2
3 [PtBr2 Cl2 (PhCN)(oxa)] -976.5
4 [PtBrCl3 (PhCN)(oxa)] -647.8
5 [PtCl4 (PhCN)(oxa)] -340.7
Table 14, ^^ P^t NMR signals for mixed halide mono oxadiazoline platinum(IV) 
complexes.
R a n g e  N M R  s h i f t s  o f  m i x e d  h a l i d e  m o n o  o x a d i a z o l i n e  p l a t i n u m  c o m p l e x e s
-400 0-600-800-1400 -1200 -1000-1600-1800
ppm Platinum Complex (see table)
Figure 91. ^^ P^t NMR signals for mixed halide mono oxadiazoline platinum(IV) 
complexes.
153
Examination of the table and graph show a summative trend as bromine is replaced by 
chlorine going from PtBr4 - to PtCfr-. The straight line demonstrates that the main 
bonding type is that of a  rather than ti, and reinforces the evidence found for platinum 
complexes with mixed halides in section 5.3.6. The graph also shows increased 
shielding of the platinum nucleus moving from PtCfr- to PtBi'4 -, and this is 
presumably due to the larger size of the bromine with its associated electron cloud.
5.6.4 The reaction of PtÏ2 (PhCN)(oxa) with chlorine.
Due to the lack of success with the reaction of iodine with PtCl2 (PhCN)(oxa), it was 
considered the analogous reaction using the diiodo platinum mono oxadiazoline 
complex and the much more reactive halogen, chlorine, would be more successful. 
Proton NMR spectroscopy showed an almost immediate reaction, which suggested a 
platinum(IV) species, but the product decomposed. The chlorine then attacked the 
ligands and many aromatic and aliphatic signals were apparent in the NMR spectrum 
within minutes. There was a black precipitate increasing with time which could be 
platinum iodide or elemental platinum. There was not a sufficient concentration of 
any one platinum species to obtain a decent ^^ P^t NMR spectrum.
5.6.5. The reaction of PtCl2(PhCN)(oxa) with peroxides.
/Tfl!«.s-PtCl2 (PhCN)(oxa)+ ROOR /rara,/ra«5?,^ra/75-PtCl2(OR)2(PhCN)(oxa) 
where R = H, benzoyl, tertAmtyl.
Scheme 26. Attempted oxidation of mono oxadiazoline dicliloro platinum(II) complex 
with peroxides.
The previously reported method of Tilset and co-workers^^^ was employed where a 
stoichiometric amount of peroxide is used with acetone as solvent. The reactions were 
stined at ambient temperature and the products should precipitate out. Using all three 
peroxides previously mentioned there was no reaction at room temperatme. The 
reactions were refluxed for 24 hours but there was also no reaction. Tilset and co­
workers use platinum(II) complexes with methyl ligands and neutral ligands such as
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bipyridine, the halides are counter ions. With our compounds the chlorides are in the 
coordination sphere and are fundamentally different to Tilset’s compounds. It is 
difficult to offer an explanation why Tilset’s reactions work and ours do not. His 
reactions were rapid, ten minutes at room temperature or two hours at -10 ®C. Possibly 
with OUI' complexes, the reaction is slow and the peroxides react with the solvent, 
acetone, first.
155
5.7. The aqueous solubility and biological activity of platinum 
oxadiazoline complexes.
The following complexes (figvires 92 and 93, and table 15) were chosen to be tested 
biologically for anti-tumour effect. The criteria used to select them were; the ease of 
manufacture, the yield and pui ity, and the reproducibility of the synthesis. The mono 
oxadiazoline platinum complexes aie generally easier to make and purify than their 
bis counterparts. Both mono and bis complexes with similar* substituents were chosen 
to compar e the difference in activity of the two types of complex. If  time and money 
had allowed, we would have gone on to test substituents in different positions such as 
an hydroxy group in para or meta position.
N—Me
“N Cl "
Me—N
Figure 92. Bis oxadiazoline platinum complexes tested for biological anti- 
tumour* activity.
Test name Complex no. X Y
JS5 45 H OH
JS7 49 H MeO-C2 H4 0 -
JS4 47 OH H
Table 15. Bis oxadiazoline platinum complexes tested biologically for anti-tumour* 
effect.
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Figure 93. Mono oxadiazoline platinum complex tested biologically for anti-tumour* 
activity, JS6 , complex 41.
5.7.1 The Solubility of mono and bis oxadiazoline platinum complexes.
The major obstacle encoimtered with previous platinum oxadiazoline complexes was 
that they were not only insoluble in water, but also in DMSO / aqueous mixtures. This 
meant that in vitro testing was not possible as the choice of solvent of biologists is 
DMSO. This is because it is non-volatile and consistent amoimts of the compounds 
being tested can be delivered to the cells. Unless potential drugs can be dissolved in 
DMSO they will never be tested as the methodology used by biologists are 
entrenched. In the present project, a milestone was passed when the complexes with 
polar substituents proved to be soluble in DMSO and DMSO / aqueous mixtirres. To 
be of any use as an intravenous drug, the complexes have to be soluble in water*. 
Platinum complexes are notoriously insoluble in aqueous systems. Cisplatin is only 
soluble 1 - 2  mg / ml in water at room temperature, and this rises to 8 - 1 0  mg / ml at 
60 This is considered to be the minimum requirement for cisplatin to be of use 
as a drug.
In the first instance UV absorption spectroscopy was used in an attempt to determine 
the solubility of bis oxadiazoline platinum complexes. However* this proved to be 
impossible as the bis complexes made are varying mixtures of diastereoisomers, and
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the solubility of each isomer is different. They are both poorly soluble but one is more 
insoluble than the other. Making a standar d solution of the mixtur e was therefore not 
possible. It was decided to determine the solubilities by weight difference. Biologists 
prefer to use solubilities measured in phosphate buffered saline that has the serum 
concentration of 9 mg / ml. However the concentration proved to be so low, that the 
amount of the phosphate buffer and sodium chloride greatly exceeded the amount of 
complex in solution. The inaccuracy meant that the results were not realistic. Lastly, 
solubilities were carried out in distilled water at 25 °C. Saturated solutions were made 
utilising a sonic bath at 40 and then transferring to a sand bath at 25 °C with 
stirring for two days. The sample vials were allowed to settle at 25 and four* 1ml 
aliquots withdrawn by syringe and allowed to evaporate slowly over four days, in 
open topped pre-weighed vessels, in the sand bath at 25 °C. The results are shown in 
table 16 below. The mono oxadiazoline platinum complexes were treated in the same 
way. Proton NMR spectroscopy carried out on the residues of JS4 and JS7 after this 
revealed a small amormt of decomposition of JS4, less than 10%, and no 
decomposition of JS7. This is important as many medicinal preparations are in 
aqueous solution and if there is significant decomposition in water, then the doses can 
only be prepared a few hours before use and carmot be stored m aqueous solution. As 
a rule of thumb half lives in aqueous solution should be greater than 24 horn s.
Proton NMR spectroscopy was not carried out on the complexes dissolved in water so 
it is impossible to say if they dissolved or if ligands exchanged with water.
Test name Substituent Aqueous solubility at 25®C mg / ml
JS3 p-hydr oxy (nitrone) mono 4 .2 -4 .3
JS4 ^-hydroxy (nitrone) bis 0 .2 - 0 . 8
JS5 /7-hydroxy (nitrile) bis 0 .6 - 1 . 1
JS6 /7-glycol ether (nitrile) mono 0 .2 - 0 . 6
JS7 /7-glycol ether (nitrile) bis 0 .2 - 0 . 6
Table 16. The solubility range of the platinum complexes undergoing biological 
testing, in water at 25
158
The two obvious trends that emerge from table 16 are that mono complexes are more 
soluble than then bis counterparts, and hydroxy-substituted complexes are more 
soluble than glycol ether substituted ones. When the solubility values are very low, 
caution should be taken as even small inaccrrracies when weighing can lead to 
significant enor in the apparent solubility. Also, in the case of JS4, there was some 
decomposition of the complex observed in the proton NMR spectrum acquhed afl;er 
the solubility test. If the decomposition products are water soluble then this will 
necessar ily give a false result. Whilst the solubilities of the bis complexes are lower 
than the desirable level, there are formulation tricks such as encapsulation that can 
improve the delivery of the dr ug. More important is the dose related to solubility. The 
dose should be soluble in 20 ml of water. Estimation of the dose, which requires 
animal testing, is not within the scope of the present project. In short poor solubility is 
not an insur mountable barrier to drug development.
5.7.2 Stock solutions used in biological testing.
It is common practice for biologists to make stock solutions in DMSO. This is 
because it is non-volatile and does not evaporate every time the lid is removed. This 
facilitates very accrrr ate dilutions with water, and exactly the right amount of complex 
is applied to the cells. As cisplatin takes approximately two days to solvate in DMSO 
using a sonicator, this does raise the question whether cisplatin is dissolving or 
exchanging. Proton NMR spectroscopy was carried out using cisplatin and DMSO, 
and a peak was apparent at 3.5 ppm within five minutes, and it continued to grow for 
many days. This is shown in figure 94 below.
s o  45  4Q 35  30  3 5  PPM
Figure 94 (a) The initial proton NMR spectrum of cisplatin in D2 O with a twenty 
molar* excess of DMSO.
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Figme 94 (b) The proton NMR spectium of cisplatin in D2 O with a twenty molar 
excess of DMSO after twelve days.
This cannot be the ammine groups in this position, and can only be DMSO 
exchanging. The question is what ligand is being exchanged? A quick literature search 
revealed the answer. Sundquist et aL carried out a similar* experiment monitoring the 
exchange between DMSO and both cisplatin and transplatin, using ^^ P^t NMR 
spectroscopy^^^. Exchange was apparent within the hour*. They isolated a product in 
the transplatin experiment, and X-ray diffraction analysis showed a chloride ligand 
replaced by a DMSO ligand. The result was the cationic complex, trans- 
[PtCl(DMSO)(NH3)2 ]^ . Using proton NMR spectroscopy this exchange is apparent 
in minutes, and the technique is much faster to perform as the tuning and matching 
associated with ^^ P^t NMR is unnecessary with proton NMR.
This raises further important questions concerning cisplatin, more specifically, is the 
biological testing carried out from 1964-76 wholly valid, and does the introduction of 
a DMSO ligand affect the activity. To answer the first question, as cisplatin has been 
approved for thirty years and has been used as an effective drug in the treatment of 
particularly testicular cancer, the biological testing that went before is largely 
irrelevant. Cisplatin was approved despite being extremely cytotoxic. To answer the 
second question, work has been carried out on the rates of exchange of DMSO 
substituted platinum complexes and DNA nucleotides. It has been found that 
solvation of transplatin in DMSO for as little as five minutes not only increases the 
rate of substitution with DNA, tlueefold over short reaction times (< 1 hour) and 
twofold over longer times ( 6  hours), but also effects the type of adducts produced. 
The major product, 92% after 42 hours when DMSO is excluded, was found to be the 
guanine-guanine bis adduct. In sharp contrast, when [PtCl(DMSO)(NH3)]'*‘Cf was
160
used, many adducts were produced, only 17% after 47 hours being the guanine- 
guanine bis adduct. As this adduct is considered to be important in the anti-tumour 
effect of platinum complexes, solvation of these complexes in DMSO can give a 
falsely negative picture of biological testing and has to be called into question^^ .^
The aforementioned complexes of the present study were all solvated in DMSO, and 
were compatible with aqueous mixtures. This was a significant improvement on 
previously reported platinum oxadiazoline c o m p l e x e s ^ T h e  bis complexes used 
are resistant to substitution by DMSO, as has already been stated; however the mono 
complexes can be substituted in a matter of days at room temperatrue, when DMSO is 
used as a solvent. As the stock solutions used for biological testing are kept in the 
fi'idge, and the DMSO will be in the solid state, it is unknown whether exchange takes 
place under these conditions. When diluted with water the rate of substitution would 
also be reduced, and at 4 °C in the fi'idge, may not occur at all.
5.7.3.1 The biological testing of platinum oxadiazoline complexes.
The biological testing was carried out by Dr. Helen Coley of the Postgraduate 
Medical School, The University of Surrey. The cell lines reported aie PEOl which is 
a human ovaiian cancer cell line and PEOlCai'boR which is a carboplatin resistant 
cell line cultuied by Dr. Coley which is cross resistant to cisplatin. Its resistance is 
approximately five-fold. The assay used is a colorimetric assay called MTT [3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. This is reduced by living;: 
cells to a pink formazan compound. A spectrophotometer then measures the intensity 
of the coloui' and the dose required for a 50% kill can be calculated. This type of assay 
has been used for about twenty yéais, and was a significant improvement on the 
previously used Clonogenic assay which involved cell counting
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Figure 95. A cell culturing plate showing a variation in colour dependent on the
extent of cell death.
5.7.3.2 The results of biological testing, the MTT assay.
Cytotoxicity testing was determined by the MTT assay. Cells were seeded into 96 
well plates (figure 95), left overnight and then treated with a range of increasing drug 
concentrations. The assay was terminated after 72 h (or 96 h according to the 
doubling time of the cell line in question) of drug treatment by addition of 20 pi of 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (obtained from 
Sigma, 5 mg / ml PBS (phosphate buffered saline)). After 4 h the media was aspirated 
and formazan crystals formed were re-suspended in 200 pi of DMSO. Absorbance 
was read at 540 nM using a Multiskan RC spectrophotometer (Labsystems, UK) and 
Genesis Software (Life Sciences UK). IC5 0 values were determined as the drug 
concentration of drug necessary to cause a 50% reduction in cell viability compared to 
untreated controls. The results to date are summarised in table 17 overleaf.
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JS6 JS5
O X K
Me—N I
JS4
OH
JS7
CELL LINE cisplatin carboplatin JS4 JS5 JS6 JS7
PEOl 
Ovarian cancer
1.34(0.82) 32.6(11.6) 16.6(3.4) 8.7 (3.0) 16.3 (3.3) 39.6 (19.3)
FEOlCisR
(cisplatin
resistant)
5.1 (1.4) 138 15.6(1.9) 6.9 (0.92) 11.2(5.3) nd
PEOlcarboR
(carboplatin
resistant)
6.3 (2.6) 130.7 (43.5) 25.5 (13.4) 8.9 (4.9) 5.2 (1.8) 43.6 (15.4)
SK-OV3 
Ovarian cancer
13.1 (2.1) 92.8(6.1) 32.3 (3.7) 10.4 (3.2) 35.8 (5.0) > 1 0 0
SW948 
Colon cancer
44.8(13.3) nd 29.4 (4.30 9.6 (1.9) 22.3 (8.9) nd
N-TERA 
Testicular cancer 0.78 (0.27) nd 7.3 (0.7) 1.95(0.9) 6 . 1  (0 .6 ) > 1 0 0
nd = not done. The values shown are IC50 values in laMoi. The values are the means for >3 repeat 
assays, with the standard deviation shown in brackets.
Table 17. Summary of the IC5 0  values of platinum oxadiazoline complexes (structures 
shown above) with those for cisplatin and carboplatin for comparison.
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The most important point to note is that all the tested compounds, except JS7, have 
IC5 0  values lower than that of carboplatin in the cell lines where all were tested. The 
best performance was by JS5 which was at least three times more effective than 
carboplatin in PEOl, and more than ten times more effective in the carboplatin 
resistant cell line. Another important feature is the ratio IC50 PEOlCarboR / IC50  
PEOl. For JS5 this is ~ 1 compared to 4.33 for carboplatin. This means JS5 is as 
active in the carboplatin resistant cell line as it is in PEOl. Also noteworthy is that the 
activity of JS5 is comparable to that of cisplatin in all the cell lines. Particularly 
promising is that JS5 is active in a var iety of cell lines including colon cancer where 
its activity surpasses that of cisplatin. As cisplatin is extremely toxic it is not generally 
used as the benchmark by wliich other potential drugs are measured. Today 
carboplatin fills that role, and in the cell lines tested, JS4, JS5 and JS6  surpassed the 
activity of car boplatin. Of particular interest is the low IC50 value for JS6  used in the 
carboplatin resistant cell line (PEOlCarboR) compared to that for the carboplatin 
sensitive cell line (PEOl), 5.2 and 16.3. The fact that JS6  is more cytotoxic m the 
resistant cell line than the sensitive cell line suggests a DNA interaction other than the 
accepted one for carboplatin. This may be an important featm^e in overcoming 
platinum resistance in cancer cell lines which is a common reason for the failure of 
novel drug candidates.
The poor performance of JS7 apparent by the large standard deviations and IC50 
values was disappointing after initially promising results. One possible explanation 
why the good results could not be repeated with the passage of time ( 6  months) is that 
the complex was not stable in DMSO / water solution. However the mono complex 
with the similar substituent (JS6) appears to be stable judging by the test results. 
Another more plausible reason may be that the complex gradually precipitated out of 
solution, being m the cold envhonment of the fi'idge.
Within the constraints of the doctorate, no data was acquired relating to the toxicity of 
the tested complexes, but this would have to be done in the next stage of testing if the 
complexes ar e to progress.
Without the benefit of DNA / complex interaction studies, attempts to rationalise the 
results ar e httle more than speculation. Regar ding the accepted binding mode of Pt-N7 
of guanine, it is easy to see how cisplatin fits into the position whereas the more bulky
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complexes of the JS series would have difficulty. This would explain why cisplatin is 
more active in most cell lines but does not explain why the JS series are more active 
in S W948 colon cancer. If the oxadiazoline is substituted during binding, then the free 
ligand may interact with DNA on its own. The bulky ligands open up the possibility 
of other binding sites apart from Pt. The hydroxy groups could hydr ogen bond or the 
phenyl rings might experience van der WaaPs attraction. There is also the possibility 
of hydrolysis of the oxadiazoline ring producing furlher binding sites. Another aspect 
to consider is the DNA repair mechanism and apoptosis, the cells self destruct 
mechanism. With cisplatin it may be easier for the repah* mechanism to cut out the 
DNA adducts, than for the JS series where the platinum is sterically hindered by the 
bulky ligands. Consequently apoptosis may occm* more readily in cells which have 
DNA bound to a JS complex, whereas in the corresponding cells bound to cisplatin, 
the repair may take place.
Summing up, the complexes selected for testing, with the exception of JS7, proved to 
be more efficacious than carboplatin in all the cell lines tested. JS5 was particularly 
promising bemg comparable m activity to cisplatin. Whilst the solubilities of the JS 
series aie below the deskable levels, the problem can be overcome. The complexes 
aie also acceptably stable in aqueous solution. Witliin the scope of the doctorate, 
biological testing has proceeded as far as possible and fiuther development will 
requke external collaboration. The type of work required is toxicity studies on 
animals and DNA / complex interaction studies.
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6. Ruthenium complexes.
In keeping with the current project, it was decided to attempt to make ruthenium 
nitrile complexes, and use the same method of cycloaddition of nitrile to nitrone to 
make ruthenium oxadiazoline complexes. Having searched Beilstein, only a handful 
of papers on the subject of ruthenium coordinated nitrile complexes were found, and 
all but one tuined out to be electrochemistry experiments using cyclic voltammetry. 
The other paper, by Duff and Heath^^ ,^ although it contained non-electrochemical 
synthesis, had very little characterization of the complexes, however on checking 
some of then references it was decided to mimic their method.
6.1. Ruthenium benzonitrile complexes.
Two coordinated nitrile complexes were attempted, using a modification of a 
synthesis by Dehand and Rose^^ .^ The first was [RuCl3(PhCN)3 ]^ ^^ '^ ^^  of which there 
ai e two possible structures shown in figui e 96. The X-ray structur e of the mer isomer 
has been described^^^.
Cl
C l.
01 Ru
NCPh
NCPh 
NCPh
facial
Cl
Cl
PhCN' Hu:"
NCPh
Cl 
NCPh
meridional
Figme 96. The facial and meridional structures of [RuCl3 (PhCN)3].
This was difficult to isolate without contamination by the product of reduction 
[RuCl2 (PhCN)4 ], so it was decided to make the latter complex instead. The trans 
structme is shown in figme 97 below, which is suggested by only one ON band in 
the IR spectrmn at 2244 cm'*, but no X-ray structure has been published.
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PhCN'
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Cl
'NCPh
Figure 97. The structur e of [RuCl2 (PhCN)4 ].
The two structures of [NBu4 ]‘^ [RuCl4 (PhCN)2 ]‘ shown below in figure 98 are also 
possible but only the trans isomer has been previously reported*^ .^
C l
NCPh 
/C l
cr I Cl
NCPh
or
Cl
C l^ l /NCPh  ^ R u ^  c r  I "NCPh
Cl
Figure 98. Possible structures of [NBu4 ]^[RuCl4 (PhCN)2] ' .
This complex was not attempted as the synthesis involved extra steps and there was 
no spectroscopic evidence for cycloaddition whatsoever with the other ruthenium 
nitrile complexes.
6.2. Ruthenium acetonitrile complexes
The same aqueous method as for platinum acetonitrile was used as already described. 
The two starting materials used were ruthenium trichloride hydrate, and potassium 
hexachlororuthenate. Both turned black and it is likely both were reduced to metallic 
ruthenium or ruthenium oxides. There was no evidence in the infia-red spectra of 
either to suggest a successful ligand exchange, and the ruthenium acetonitrile 
complexes are known to be yellow orange in coloui'.
6.3 Attempted cycloadditions using [Ru(II)(Cl)2(PhCN)4]
Cycloaddition using an analogous method to platinum was attempted using 
chloroform as solvent and A-methy 1-C-phenyl nitrone. A black precipitate was
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produced and proton NMR spectroscopy of the reaction mixture showed no 
appropriate signals present. The most likely explanation is that the ruthenium(II) is 
reduced to metallic ruthenium(0), either by the chloroform used as solvent in the 
reaction, and / or the reaction conditions. The reaction was repeated using benzonitrile 
as solvent. After three days the product was precipitated using ether but again, there 
was no cycloaddition product evident in the proton NMR spectrum.
Cycloaddition was also attempted using microwave irradiation (fifteen minutes at 
60 ”C followed by fifteen minutes at 100 ®C) and the aforementioned starting 
materials, employing DCM as solvent. Proton NMR spectroscopy of the crude 
product indicated no cycloaddition had taken place. The reaction mixture was reduced 
under vacuum and a brown solid precipitated using diethyl ether. Proton NMR 
spectroscopy of the solid revealed no signals in the aromatic region. The remaining 
solute was concentrated and placed in the fi*eezer for two days. Cleai* crystals were 
formed, the proton NMR spectrum and elemental analysis of which were consistent 
with benzamide.
For completeness, cycloadditions were attempted m the NMR tube using other 
nitrones, namely 7V-methyl-C-p-(dimethylamino)phenyl nitrone, and A-methyl-C-p- 
(2-methoxyethoxy)phenyl nitrone, and chloroform as solvent. Although the former 
nitrone did not give the desked cycloaddition product fiom reaction with the bis 
benzonitrile platinum(II) complex, there was an unexpected reaction, this was chosen 
to see if it would behave with ruthenium in the same way. Analyses of the products in 
both cases showed little reaction of any type had taken place, and proton NMR 
spectroscopy suggested they were mainly raw material and a small amount of 
aldehyde.
6.4 One pot synthesis starting with ruthenium trichloride hydrate.
A one pot synthesis using ruthenimn trichloride hydrate, benzonitrile and A-methyl-C- 
phenyl nitrone was also attempted. The reaction mixtuie was heated at 120 for fom* 
days, and turned green. A solid was precipitated using diethyl ether, but proton NMR 
spectroscopy showed no aromatic signals at all. It was concluded that the green colom*
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was simply ruthenium in a different oxidation state. Considering ruthenium’s standard 
reduction potentials*^*:
+ 3e ^  Ru E® (V) =0.758,
Ru^+ + 2e ^  Ru E® (V) =0.600,
Ru^+ + e Ru^* E® (V) = 0.249, 
which are all positive, meanhig the Gibb’s free energy will be negative, reduction is 
favoured.
6.5 Direct addition of an uncoordinated oxadiazoline to ruthenium
Due to the failure of these attempts at cycloaddition it was decided to perform a direct 
addition of an uncoordinated oxadiazoline to ruthenium trichloride hydrate.
The oxadiazoline was attempted according to Heimkens et a lP  using benzonitrile, N- 
methyl-C-phenyl nitrone and toluene as solvent. It was refluxed for ten days and the 
solvent regularly topped up to prevent the mixture becoming increasingly polar. 
Despite at least ten attempts at this reaction, it was not possible to produce the desired 
product, and the main products were breakdown products of the nitrone, namely 
benzaldehyde. Every attempt was made to exclude water from the reaction including 
dried solvents and nitrogen. The reaction was also attempted by microwave 
irradiation, and in a sealed pressure vessel, also without success. The reaction was 
attempted using A-methyl-C-p-(dimethylamino)phenyl nitrone, and this was similarly 
unsuccessful. It was therefore not possible to test if an oxadiazoline could be directly 
added to ruthenium trichloride.
Conclusion
At tlris stage, ratlier than waste more time it was decided to suspend the investigation 
of ruthenium, and concentrate on platinum, and perhaps try other transition metals 
later on. It was concluded that ruthenium does not activate nitriles toward 
cycloaddition in the same way as platinum does. The reasons for this are not known 
for certain but speculatively it might be suggested the coordination sphere of 
ruthenium(III) is more crowded than platinum(II), octahedral versus square planar.
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and this prevents the nitrone attaining a favorable position for reaction. Secondly, the 
ruthenium benzonitrile complex necessarily has benzonitrile ligands in cis position, 
cycloaddition of cw-platinum(II) nitrile complexes is much slower than their trans 
counterparts and the products less stable. Possibly for ruthenium nitriles the rate is so 
slow that no reaction takes place. Both have similar Pauling electronegativity values 
(2.2) so it would not be expected that platinum should activate the nitrile more so than 
ruthenium. The chemistry of ruthenium is different to platinum, ruthenium(III) is able 
to accommodate many neutral ligands and hold a positive chaige in a way that is not 
so common for platinum(II), and cycloaddition, or lack of it, is another example of 
this difference in chemistry.
170
7.1 Future Work
Inevitably when time and money are governing factors there will be aieas of a project 
where it would have been both profitable and interesting to investigate a certain area 
in greater depth. This project is no exception, however a line has to be diawn between 
investigation and obsession and with the main aims of the project in mhid the 
following aieas emerge.
1. A fui'ther look at ruthenium where the results obtained were no reflection of 
the effort put in. Possibly different heterocycles could be synthesized and 
attached to ruthenium.
2. Another look at the reaction of nitrones containing electron deficient 
substituents and platinum nitrile complexes, where it was not possible to 
conclusively assign the products. If any of the proposed structuies could be 
isolated they could well possess anti-tumour activity and biological testing 
might be beneficial.
3. The ligand exchange using mono oxadiazoline platinum(II) and 
triphenylphosphine was perplexing. As they were rapid, they might be 
elucidated by low temperatme NMR spectroscopy.
4. With oral bioavailabilty in mind, further solubility tests of the platinum 
oxadiazoline complexes made and not tested, and likewise further biological 
testing including DNA binding studies.
5. Producing complexes with greater solubility in water possibly starting fiom 
PtCl2(»î,/7-di-OH-C6H4CN)2, or by substitution of the benzonitrile ligand of 
mono oxadiazoline platinum complexes by more hydrophilic ligands.
6. Extending the multinuclear platinum work staiting with the dinitrone made 
fi om terephthladehyde could lead to all sorts of possibilities of exchanges with 
the mono cycloadduct, or bis cycloaddition using different more polar 
nitrones.
The latter three are all intended to extend the present work, and develop
complexes with improved solubility in polai' solvents, improved bioavailability
and elucidate the mechanism of action of the complexes anti-tumoui' effect.
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7.2. Conclusions.
1. The [2+3] cycloaddition of novel platinum nitrile complexes to novel nitrones 
has been canied out successfully, to produce a bank of mono and bis 
oxadiazoline platinum complexes.
2. For the first time, platinum oxadiazoline complexes have been made that are 
soluble in polai' non chlorinated solvents, and the said complexes aie 
compatible with DMSO / water mixtures.
3. For the first time the structure of a mono oxadiazoline platinum(II) complex 
has been determined by X-ray diffraction analysis.
4. Both mono and bis oxadiazoline platinum complexes have been tested 
biologically for anti-tumour effect in vitro, and have been found to be as good 
as, or better than carboplatin, in ovaiian, colonic and testiculai* cancer cell 
lines.
N — Me
X
M e— N
Figure 99. Bis oxadiazoline platinum complexes tested for biological anti 
tumoui' activity, substituents shown in table 18.
Complex no. X Y
45 H OH
49 H Me0 -C2H4 0 -
47 OH H
Table 18. Bis oxadiazoline platinum complexes tested biologically for anti-tumoui* 
effect.
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Figure 100. Mono oxadiazoline platinum complexes tested biologically for anti­
tumour activity, Y = H, X = Me0 -C2H4 0 -.
5. One particular complex JS6, proved to be more cytotoxic in cai'boplatin resistant 
ovarian cancer than the platinum sensitive cell line, and this suggests a different 
mechanism of action than the accepted guanine, N7 binding mode.
6. A significant improvement of the Williamson ether synthesis using microwave 
hradiation has been developed. This is a rapid method for the production of phenyl 
ethers in high yield with good pur ity.
KgCOg
MeOH
Microwave
Scheme 27. The microwave synthesis of phenyl ethers, X= Br or Cl.
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8. Experimental procedure
Materials and Instrumentation. Solvents were obtained from commercial sources 
and used as received. C, H and N elemental analyses were caiTied out on a Leeman 
CE 440 automatic analyser. Infrared spectra (4000-400 cm~ )^ were recorded on 
Perkin Elmer 2000 FTIR in KBr pellets. El, Cl and positive MS-FAB spectra of the 
samples in 3-nitrobenzyl alcohol (NBA) matrices, were obtained on a Thermoquest 
MAT 95XL instrument. and ^^ C ID experiments were acquned on a Bruker 300 
spectrometer unless otherwise stated, and 2D ^H, ^^ C and ID and *^ P^t NMR 
experiments were acquned on a Bruker DRX 500 spectrometer at ambient 
temperatur e, if not indicated otherwise. ^^ P^t NMR chemical shifts are given relative 
to aqueous KiEPtCfr] = -1630 ppm, with half height line widths in parenthesis. 
Moleular models were drawn using the Molekel package and are based on 
information gamed from the X-ray structures which are generated using the Platon 
programme^^^. Details of bond lengths and angles will be published in the 
aforementioned forthcoming publications.
8.1 Preparation of nitrones.
Below is a typical procedure for the production of nitrones, specific conditions vary 
fr om aldehyde to aldehyde and these are summarized in the table below.
8.1.1 iV-Methyl-C"phenyI nitrone
A mixture of A-methyl-hydroxylamine hydrochloride (24 mmol, 2.0 g), NazCOs (24 
mmol, 2.544 g) and benzaldehyde (24 mmol, 2.546 g), dichlorornethane (40 ml) and 
methanol (10 ml) was refluxed with stirring for ca. 4 hours. The solvent was then 
evaporated (rotavapor) and the residue extracted three times with dichloromethane, 20 
ml each time. The solution was then evaporated close to dryness, hexane was added 
and finally, the product was crystallised in the freezer. The final crystals, (white), 
which were obtained were weighted and formd out to be 2.2 g in total.
The yield is 66%.
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RH HONHgMeCI
O Me
R
oa
R = H and ortho- MeO-C2H40, OH, NaSOa, 
m e ta -  M0O-C2H4O, OH, COOH 
para- MeO-C2H4 0 , OH, N(Me)2, N(Me)3'^  MeS0 4 ', COOH. 
Scheme 28. Production of nitrones.
N o. A ldehyde R eaction conditions
1 Benzaldehyde 4 / 1  DCM / MeOH, reflux for 4 hrs, NagCO], evaporate, 
extract with DCM, precipitate with hexane.
2 Salicylaldéhyde 4 /  1 MeCN / EtOH, reflux for 12hrs, NaaCOs, evaporate, 
extract with DCM, precipitate with hexane.
3 3-hydroxybenzaldehyde 4 /1  DCM / MeOH, reflux for 4 hrs, NazCOs, evaporate, 
the resulting oil was recrystallised from methanol in the 
freezer for 4 days.
4 4-hydroxybenzaldehyde 4 /1  EtOH / MeCN, reflux for 20 hrs, NagCO], 
evaporate, the resulting oil was recrystallised from 
methanol in the freezer for 4 days.
5 2-(2-m ethoxyethoxy)- 
benzaldehyde
4 / IMeCN /  EtOH, reflux for 12 hrs, NagCO], 
evaporate, extract with DCM.
6 3 -(2-m ethoxyethoxy)- 
benzaldehyde
4 /1  MeCN / EtOH, reflux for 12 hrs, NajCOs. 
evaporate, extract with DCM.
7 4-(2-m eth oxyeth oxy)- 
benzaldehyde
4 /1  DCM / MeOH, reflux for 36 hrs, Na2C0], 1.5 molar 
excess of N-methyl hydroxylamine added in 2 lots at the 
start and at 18 hours, evaporate, extract with DCM.
8 3-carboxybenzaldehyde 4 /1  DCM / MeOH, reflux for 4 hrs, NazCOs, evaporate, 
recrystallise from hot methanol, disregard the initial ppt 
of fine white powder which is inorganic.
9 4-carboxybenzaldehyde 4 /1  DCM / MeOH, reflux for 20 hrs, NazCO], 
evaporate. The product was insoluble in organic solvents 
and could not be isolated, a proton nmr specfrum was 
acquired of the crude.
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10 Benzaldehyde ortho- sodium 
sulphonate salt
7 /1  MeCN / MeOH, reflux for 4 hrs, NazCO ,^ 
evaporate, extract with hot methanol, disregard the initial 
ppt of fine white powder which is inorganic, reduce soln. 
and precipitate with diethyl ether.
11 4-dimethylamino
benzaldehyde
4 /1  DCM /  MeOH, reflux for 4 hrs, omit NajCOs. 
Precipitate with diethyl ether, filter and wash solid with 
diethyl ether. The product is the hydrochloride salt, if  
NaaCOs is used the free base is the product.
12 4-formyl-phenyl- 
(tiimethylammonium) methyl 
sulphate.
4 /  1 DCM /  MeCN, reflux for 4 hrs, NagCOs, under 
nitrogen. Evaporate and recrystallise from cold methanol 
(having filtered out inorganics) in the freezer for 2 days.
13 terephthaldehyde 4 /1  DCM / MeOH, 2 molar equivs. ofNaaCOg and N- 
methyl hydroxylamine, 18 hrs reflux.
Table 19. Simimaiy of nitrones produced with reaction and work-up conditions.
8.1.1 A^-Methyl-C-phenyl nitrone ( 1 ).
White crystalline solid, yield 6 6 %.
Analytical data:
Formula: C;H,NO, MW 135.17. ‘H NMR spectrum in CDCI3 , S (ppm): 3.81 (s, 3H, 
NMe), 7.35 (s, IH, CH=N), 7.39 (m, 3H, Ph) and 8.20 (2H, 7.9 Hz, Ph(2,6)).
"C  NMR spectrum in CDCI3 , S (ppm): 54.3 (NMe), 128.3, 128.4, 130.3, 135.1 
(CH=N and CH of Ph), 130.4 (C, of Ph). IR (KBr), selected bands, cm ': 3058, 2994, 
2932 w v(C-H), 1595 v(C=N).
8.1.2 W-Methyl-C-o-hydroxyphenyl nitrone (2).
A cream crystalline solid, yield is 85%.
Analytical data:
Foimula CgHpNOa, MW 151.16, Anal, calc.% C: 63.56; H: 6.00; N: 9.27; found, C: 
63.27; H: 6.00, N: 9.26.
NMR spectrum in CDCI3 , 5 (ppm): 3.80 (s, 3H, NMe), 6.82 (t, 7.8 Hz, H, Ai'CH), 
6.91 (d, 7.8 Hz, H, AiCH), 7.01 (d, 7.8 Hz, H, ArCH), 7.34 (t, 7.8 Hz, H, AiCH), 7.49 
(s, H, CH=N) and 12.40 (s, H, OH).
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'^C NMR spectrum in CDCI3 , Ô (ppm): 52.0 (NMe), 116.7 (1C, ArC(3)H), 119.1 and
120.1 (20 ArC(4 and 6 )H), 132.2(10, OH=N), 134.1 (10, ArO(5)H), 142.2 (10, 
ArO(l)), 159.5 (0-0, ArO(2)OH).
IR (KBr), selected bands, cm"': 1587, v(0=N).
Accurate MS-CI, 151.0631, theoretical, 151.0628
8.1.3 iV-Methyl-C-m-hydi-oxyphenyl nitrone (3).
Cream crystalline solid, yield. 30%
Analytical data:
Formula: C8H9NO2 , MW 151.16, Anal, calc.%, C: 63.56; H: 6.00; N: 9.27; found, C: 
62.97; H: 5.92, N: 9.08.
‘H n m r  spectrum in ds-DMSO, ô (ppm): 3.72 (s, 3H, NMe), 6.79 (d, 7.8 Hz, IH, 
AiC(4)H), 7.21 (t, 7.8 Hz, IH, ArC(5)H) and 7.41 (d, IH, ArC(6 )H 7.8 Hz, ), 7.96 (s, 
IH, ArC(2)H), 7.74 (s, H, CH=N), 11.35 (s, OH).
NMR spectrum in de-DMSG, Ô (ppm): 53.9 (NMe), 113.8 (1C, ArC(2)H ), 116.9 
(1C, ArC(4)H ), 119.2 (1C, ArC(6 )H ), 119.8 (ICq, ArC(l) ), 129.1 (1C, ArC(5)H ),
134.5 (CH=N) and 157.0 (1C, ArC(3)0).
IR (KBr), selected band, cni^: 1608 v(C=N).
MS-EI, m/z\ 150, 151 [M, isotopic pattern], 152 [M^], and 137 [M  ^- Me].
Accurate MS-CI, 151.0628, theoretical, 151.0628
8.1.4 iV-Methyl-C-j^-hydi’oxypheny 1 nitrone (4).
Cream crystalline solid, yield 35%.
Analytical data:
Formula: CgH^NOz, MW 151.16, Anal, calc.%, C: 63.56; H: 6.00; N: 9.27; found, C: 
63.16; H: 5.97, N: 9.28.
^H NMR spectrum in de-DMSG, ô (ppm): 3.82 (s, 3H, NMe), 7.98 (d, 8 . 8  Hz, 2H, 
ArC(2,6)), 7.51 (d, 8 . 8  Hz, 2H, ArC(3,5)), 8.31 (s, IH, CH=N), 10.04 (s, GH).
^^ C NMR spectrum in dg-DMSG, Ô (ppm): 53.2 (NMe), 115.2 (2C, ArC(3,5)), 129.7 
(2C, ArC(2,6)), 133.6 (1C, CH=N), 160.1 (1C, ArC(4)G), 121.6 (1C, ArC(l)).
IR (KBr), selected band, cm"^ 1603 v(C=N), 3300 w, 2919 w, v(CH).
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MS-CI, m/z: 151 and 150 [M isotopic pattern], 134 [M -  OH].
Acciuate MS-CI, 151.0628, theoretical, 151.0628
8.1.5 77-Methyl-C-o-(2-methoxyethoxy)phenyl nitrone (5).
A pale brown oil, yield is 90%,
Analytical data:
Formula C11H 15NO3 , MW 209, Anal, calc.%, C: 63.14; H: 7.23; N: 6.69; found, C: 
61.92; H: 7.23, N: 6.78.
‘H n m r  spectrum in de-DMSO, 8  (ppm): 3.83 (s, 3H, NMe), 3.42 (s, 3H, MeO), 
3.72 (t, 4.6 Hz, 2H, CH2 O), 4.18 (t, 4.6 Hz, 2H, OCH2), 7.00 (t, 8.3 Hz, IH, 
ArC(5)H), 7.10 (d, 8.3 Hz, IH, ArC(3)H), 7.36, (t, 8.3 Hz, IH, ArC(4)H), 9.17 (d, 8.3 
Hz, H, ArC(6 )H), 7.87 (s, CH=N)
'^C NMR spectrum in d«-DMSO, 8  (ppm): 54.7 (NMe), 58.2 (MeO), 67.8 (CH2 -O), 
70.23 (O-CH2 ), 119.9 (1C„ Arc (1)), 127.8 (CH=N), 112.0 (ArC(3)H), 120.3 (ArC 
(4)H), 127.2 (ArC(6 )H), 131.1 (AiC(5)H), 155.5 (AiC(2)-0). IR (KBr), selected 
bands, cm'': 1656, v(C=N).
MS-EI, m/z: 209 [M], 210 [M'^  ], 151 [M - HC=N(CH3)0 ], 134 [M -  CH3OC4H4 O]. 
Accurate MS-CI, 209.1046, theoretical, 209.1046.
8.1.6 jV-Methyl-C- m-(2-methoxyethoxy)phenyl nitrone (6 ).
A pale brown oil, the yield was 8 6 %.
Analytical data:
Formula C11H15NO3 , MW 209, pale brown oil, yield 8 6 %, Anal, calc.%, C: 63.14; H: 
7.23; N: 6.69; found, C: 61.41; H: 7.28, N: 6.72.
*H NMR spectrum in d^-DMSG, ô (ppm): 3.79 (s, 3H, MeN), 3.32 (s, 3H, MeG), 
3.67 (t, 4.5 Hz, 2H, CH2 G), 4.10 (t, 4.5 Hz, 2H, GCH2), 7.01 (d, 7.9 Hz, IH, AiC(4)H 
) ,  7.34 (t, 7.9 Hz, IH, ArC(5)H), 7.65 (d, 7.9 Hz, IH, ArC(6 )H), 7.82 (s, CH=N),
8.07 (s, IH, ArC(2)H).
^^ C NMR spectrum in CDCI3 , ô (ppm): 54.3 (NMe), 59.1 (GMe), 70.9 (G-CH2), 67.4 
(CH2 -G), 113.0 (Cq, Arc (1)), 114.3 (Ai€(2)H), 117.7 (ArC(4)H), 121.6 (ArC(6)H),
131.7 (ArC(5)H), 135.2 (CH=N) and 158.6 (AiC(3)-G).
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IR (KBr), selected bands, cni"^ : 1659, v(C=N).
MS-FB, m/z: 209 [M], 210 [M"], 151 [M - HC=N(CH3)0 ], 134 [M -  CH3OC4H4O]. 
Accurate MS-CI, 209.1049, theoretical, 209.1046.
8.1.7 jV-Methyl-C- /?-(2-methoxyethoxy)phenyl nitrone (7).
A pale yellow oil, the yield was 80%
Analytical data:
Formula C11H15NO3 , MW 209, Anal, calc.%, C: 63.14; H: 7.23; N: 6.69; found, C: 
61.80; H: 7.27, N: 6.73.
NMR spectrum in CDCI3, ô (ppm): 3.44 (s, 3H, NMe), 3.76 (s, 3H, MeO), 3.76 
(m 2H, CH2 O), 4.15 (m 2H, OCH2), 6.96 (d, 7.5 Hz, 2H, ArC(3,5)H) , 8.19 (d, 7.5 
Hz, 2H, Ar*C(2,6)H), 7.39 (s, CH=N)
^^ C NMR spectrum in CDCI3 , Ô (ppm): 55.0 (NMe), 59.3 (GMe), 67.7(CH2G), 70.7 
(GCH2 ), and 115.0 (ArC (2,6) H), 123.2 (ArC (1)-CH=N), 130.9 (ArC(3,5)H), 136.3 
(CH=N), 160.7 (ArC(4)-G),
IR (KBr), selected bands, cm’^ 1610, v(C=N).
MS-EI, m/z: 209 [M], 210 [M^], 151 [M - HC=N(CH3)G], 134 [M -  CH3GC4H4G]. 
Accurate MS-CI, 209.1018, theoretical, 209.1046.
8.1.8 N-Methyl-C-/w-carboxyphenyl nitrone (8).
A white solid 1.5 g. Yield. 84%, mpt, 161-163 T .
Analytical data:
Formula: C9H9NG3 , MW 179.17, Anal. calc%, C: 60.33; H: 5.06; N: 7.82; found, C: 
59.48; H: 4.99, N: 7.65.
^H NMR spectrum in de-DMSG, Ô (ppm): 3.77 (s, 3H, NMe), 7.37 (t, 8.3 Hz, IH, 
ArC(5)H), 7.88 (s, IH, CH=N), 7.91 (d, 8.3 Hz, ArC(6)H), 8.43 (d, 8.3 Hz, IH, 
ArC(4)H), and 8.52 (s, IH, ArC(l)H).
^^ C NMR spectrum in dô-DMSG, 8 (ppm): 169.3 (CGGH), possibly 128.3 (ArC(3), C- 
CGGH), possibly 97.0(ArC(l)), 53.8 (NMe), 134.1 (CH=N) 127.3, 128.4, 129.3,
130.4 (ArC (2,4,5,6)H).
IR (KBr), selected band, cm“^ : 1607 v(C=N).
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MS-EI, m/z: 179 [M], 133[M-COOH], 164 [M -M e].
Accurate MS-CI, 179.0562, theoretical, 179.0577.
8.1.9 Y-Methyl-C-p-carboxypheny 1 nitrone (9).
The solid product was filtered off but proved to be too polar and insoluble in organic 
solvents, to be separated from the inorganic starting materials. Proton NMR and 
infrared spectra were obtained fr om the crude.
Formula: C9H9NO3. M.W. 179.16.
'H n m r  spectrum in de-DMSO, S (ppm): 3.77 (s, 3H, NMe), 7.88 (d, 8.2 Hz, 2H, 
ArC(3,5)H), 7.92 (s, CH=N), 8.16 (d, 8.3 Hz, 2H, ArC(2,6)H).
IR (KBr), selected band, cm"': 1595 v(C=N).
8.1.10 A^-Methyl-C- 2-(sodium sulphonate)-phenyl nitrone (10).
White crystalline solid, yield 91.7%, mpt, 270 °C.
Analytical data:
Formula: C8HgN0 4 SNa., MW 237.21, NMR spectrum in dg-DMSO, ô (ppm): 
3.78 (s, 3H, NMe), 7.34(m, 2H, ArC(4,5), 7.84 (d, 8.9 Hz, H, ArC(5)H) and 8.57 (s, 
CH=N), and 9.26 (d, 8.9 Hz, H, ArC(2)H).
'^C NMR spectrum in dô-DMSO, Ô (ppm): 55.1 (NMe), 97.2 (ArC(l)-C-N), 126.8,
126.5 (AiC(6,5)H), 128.6, 128.4 (2C, ArC(3,4)H), 131.9 (CH=N), 169.3(AiC(2)-S). 
IR (KBr), selected bands, cm'^:1656, v(C=N).
MS-EI, m/z: 236 [M], 208 [M -NMe].
Accurate MS-EI, 236.9910, theoretical, 237.0066.
8.1.11. Benzenamine, iV,A^-dimethyl-4-[(methylimino)methyl]-, 7V4-oxide; nitrone 
( 11).
Orange crystalline solid, the yield is approximately 90%.
Analytical data:
Formula: C10H14N2 O, MW 178.23. Anal. calc, for CioHi4N2 0 HCl,%, C: 55.94; H: 
7.04; N: 13.04; found, C: 52.86; H: 7.15, N: 13.37.
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NMR spectrmn in CDCI3 , 6  (ppm): 3.12 (s, 6 H, N(CH3)z), 4.05 (s, 3H, NMe), 
6.75 (d, 9.3 Hz, 2H, AiC(3,5)H), 8.09 (d, 9.3 Hz„ 2H, ArC(2,6)H), 8.45 (s, IH, 
CH=N).
NMR spectrmn in CDCI3 , ô (ppm): not observed(CH=N), not observed (AiC(l)- 
CH=N), 39.7 (NMez), 48.5 (NMe), 111.6 (ArC(3,5)H), 136.4 (ArC(2,6)H),
152.0 (Ai-C(4)-N). IR(KBr), selected bands, cni^; 3004,2923,2832, v(C-H), 1698 
,v(C=N).
MS-EI, m/z\ 177, 178 [M, isotopic pattern], 179 [ M^ ], 163 [M -  Me], 148 [M -  
2Me], 134 [M-(Me)zN].
Accmate MS-CI, 178.1101, theoretical, 178.1101.
8.1.12 Benzenammonium methyl sulphate, jV,#,7V-trimethyl-4- 
[(methylimino)methyl]-, M-oxide; nitrone. ( 1 2 ).
Yellow crystalline solid, the yield is approximately 82%, mpt, 120-122 °C.
Analytical data:
Formula: C12H20N2 O5 S, MW 304.1. Anal, calc.%, C: 47.35; H: 6.62; N: 9.20; found, 
C: 44.06; H: 6.67, N: 9.20.
^H NMR spectrum in dô-DMSO, ô (ppm): 3.38 (s, 3H, MeSO^s 3.63 (s, 9H, 
N(CH3 )3), 3.83 (s, NMe), 8.05 (d, 8.3 Hz, and s, 3H, ArC(3,5)H and CH=N), 8.21 
(d, 8.3 Hz, 2H, ArC(2,6)H).
*^ C NMR spectrum in dô-DMSO, ô (ppm): 52.75 (MeSOT), 54.26 (NMe), 56.15 
(NMc3), 120.7 (ArC(3,5)H), 128.7 (AiC(2,6)H), 132.3 (CH=N), possibly 121.7 or
131.9 (ArC(l)), 161.3 (AiC(4)-N).
IR (KBr), selected bands, cm'^: 1690, v(C=N).
MS-EI, m/z\ 303, 304 [M, isotopic pattern], 289 [M - CH3], 274 [M - 2 CH3], 259 [M - 
3 CH3].
Accmate MS-CI, 303.9900, theoretical, 304.1087.
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8.1.13 N,N^ -dimethyl-p-phenylenedinitrone, iV,AT -( 1,4-phenylenedimethylidyne)bis- 
/V, AT-dioxide 
l,4-di-(CH=N(Me)0)-C6H4 (13).
White crystalline solid, the yield is 77%.
Analytical data:
Formula C10H12N2O2 , MW 304.1, NMR spectrum in d^ -^CDaOD, Ô (ppm): 3.88 (s, 
6H, NMe), 7.86(2H, CH=N), 8.31 (s, 4H, C6 H4 ).
NMR spectrum in d'^-CDsOD, Ô (ppm): 138.7 (CH=N), 133.8 (2C, ArC (1,4)- 
C=N), 130.3 (4C, ArC (2,3,5,6) H), 54.5 (ONMe).
Accurate MS-CI, 192.0892, theoretical, 192.0893.
8.2 Glycol ether substituted precursors.
Typical procedure: A pyiex cylindrical reaction tube adapted to the SmithCreator^^ 
(Personal Chemistry/Biotage) was charged with formylphenol or hydroxybenzonitrile 
(5mmol), anhydmus K2CO3 (5 mmol, 680 mg), 2-haloethylmethylether ( 6  mmol, 0.56 
ml of the bromo-compound or 15 mmol, 1.37 ml of the chloro-compound), 1.5 ml 
methanol and a magnetic stirrer bai*. The tube was septum-sealed and irradiated with 
microwaves at the set temperature and reaction time given in Table 7 (reproduced 
below, table 20). The temperatuie was measured by IR detection and maintained 
constant by modulated iiradiation of 300 W down to 8  W. The reaction mixture was 
cooled to room temperatuie, the solvent was evaporated under reduced pressure and 
the solid residue extracted with hexane (3 x 50 ml). After evaporation of the solvent, 
TLC and NMR-spectroscopy, puie products were obtained the analytical data of 
which aie below.
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X = Br X = C1
Comp. R = pKa"' T fC ] Time [min] Yield [%] T fC ] Time [min] Yield [%]
14 4-CHO 7.61 1 0 0 15 45 140 30 65
15 3-CHO 8.98 1 0 0 15 78 140 30 74
16 2-CHO 8.37 1 0 0 15 81 140 30 76
17 4-C=N 7.97 1 2 0 30 87 140 30 96
18 3-CsN 8.61 1 2 0 30 89 140 30 73
19 2-C=N 6 . 8 6 1 2 0 30 80 140 30 91
2 0 3,4-
OHC6H3CN
160 60 42
Table 20. Reaction conditions and yields.
Analytical data:
8.2.1. 4-(2-methoxyethoxy)benzaldehyde (14).
Clear oil. Formula: C10H 12O3 , MW 180.20, ‘H NMR spectrum in CDCI3 , ô (ppm): 
3.43 (s, 3H, MeO), 3.75 (m, 2H, CH2 -O), 4.17 (m, 2 H, O-CH2), 7.00 (d, 8 . 8  Hz, 2H, 
AiC(3,5)H), 7.95 (d, 8 . 8  Hz, 2H, ArC(2,6)H), and 9.85 (s, CHO).
'^C NMR spectrum in CDCI3 , ô (ppm): 190.8 (CHO), 163.8 (ArC(4)-0), 132.0 
(ArC(2,6)H), 130.1 (ArC (l)-CHO), 114.9 (ArC(3,5)H), 70.7 (CH2 -O), 67.7(0-CH2),
59.3 (OMe).
IR (KBr), selected bands, cm'^1687, v(C=0).
8.2.2. 3-(2-methoxyethoxy)benzaldehyde (15).
Clear oil. Formula: C10H12O3 , MW 180.20, ^H NMR spectrum in CDCI3 , Ô (ppm): 
3.23 (s, 3H, MeO), 3.55 (t, 4.7 Hz, 2H, CH2 O), 3.95 (t, 4.7 Hz, 2H, OCH2), 7.00 (m, 
IH, ArC(4)H), 7.22 (m, 3H, AiCH) and 9.74 (s, CHO).
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13C NMR spectrum in CDCI3 , ô (ppm): 191.9 (CHO), 159.2 (ArC(3)-0), 130.0 
(Ai'C(5)H), 137.7 (ArC(l)-CHO), 123.3 (ArC(6 )H), 121.7 (ArC(4)H), 113.0 
(ArC(2 )H), 70.7 (CH2 -O), 67.7(0-CH2), 59.3 (OMe).
IR (KBr), selected bands, cin ^:1687, v(C=0).
8.2.3. 2-(2-methoxyethoxy)benzaldehyde (16).
Clear oil. Formula: C10H12O3 , MW 180.20, Anal, calc.%, C: 66.65; H: 6.71; found, C: 
65.62; H: 6.63.
^H NMR spectrum in CDCI3 , Ô (ppm): 3.20 (s, 3H, MeO), 3.55 (t, 4.5 Hz, 2H, 
CH2 O), 3.97 (t, 4.5 Hz, 2H, OCH2), 6.76 (overlapped d and t, 8.5 Hz, 2H, Ai'C(3,5)H), 
7.26 (t, 8.5 Hz, IH, ArC(4)H) 7.60 (d, 8.5 Hz, IH, ArC(6)H) and 10.30 (s, CHO).
^^ C NMR spectrum in CDCI3 , ô (ppm): 180.3 (CHO), 161.1 (ArC(2)-0), 135.8 
(ArC(4)H), 127.8 (ArC(6)H), 120.7 (ArC(5)H), 124.9 (ArC(l)-CHO), 112.8 
(ArC(3)H), 70.6 (CH2 -O), 6 8 . 0  (O-CH2), 58.9 (OMe).
IR (KBr), selected bands, cm'^ 1687, v(C=0).
Accurate MS-CI, 181.0864, theoretical, 181.0859.
8.2.4. 4-(2-methoxyethoxy)benzonitrile (17).
Cleai* oil. Formula: CioHn NO2 , MW 177.20, ^H NMR spectiiim in CDCI3 , 
ô (ppm): 3.44 (s, 3H, MeO), 3.76 (t, 4.7 Hz, 2H, OCH2), 4.15 (t, 4.7 Hz, 2H, CH2O), 
6.97 (d, 8.7 Hz, 2H, ArC(3,5)H), 7.57 (d, 8.7 Hz, 2H, ArC(2,6)H).
^^ C NMR spectrum in CDCI3 , ô (ppm): 162.1 (ArC(4)-0), 134.0 (ArC(2,6)H),
118.8 (CWN), 104.1 (AiC(l)-C=N), 115.4 (ArC(3,5)H), 70.7 (CH2 -O), 67.7(0-CH2),
59.3 (OMe).
IR (KBr), selected bands, cm'^: 2216 v(C=N), 1197, 1176 v(C-O).
Accurate MS-EI, 177.0788, theoretical, 177.0784
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8.2.5. 3-(2-methoxyethoxy)benzonitrile (18).
Clear oil. Formula: C i o H u  NO2 , MW 177.20, 'H NMR spectrum in C D C I 3 ,  S (ppm): 
3.31 (s, 3H, MeO), 3.63 (t, 4.7 Hz, 2H, OCH2), 4.00 (t, 4.7 Hz, 2H, CH2 O), 7.03 (m, 
3H, ArC(2,4,6)H), 7.23(m, IH, ArC(5)H).
"C  NMR spectrum in CDCI3 , 5 (ppm): 158.8 (ArC(3)-0), 130.3 (ArC(5)H), 112.9 
(AiC(l)-ON), 124.4 (AiC(6 )H), 119.7 (ArC(4)H), 118.6 (CsN), 117.5 (ArC(2)H),
70.6 (CH2 -O), 67.7 (O-CH2), 58.9 (OMe).
IR (KBr), selected bands, cm'*: 2231, v(CsN), 1059, 1034, v(C-O).
Accurate MS-EI, 177.0784, theoretical, 177.0784
8.2.6. 2-(2-methoxyethoxy)benzonitrile (19).
White solid. Formula: CioHn NO2 , MW 177.20, Anal, calc.%, C: 67.78; H: 6.26; N: 
7.90; found, C: 67.29; H: 6.12, N: 7.87.
'H NMR spectrum in CDCI3 , 8  (ppm): 3.33 (s, 3H, MeO), 3.68 (t, 4.7 Hz, 2H, 
OCH2), 4.12 (t, 4.7 Hz, 2H, CH2 O), 6.91 (m, 2H, ArC(3,5)H), 7.39 (m, 2H, 
ArC(4,6)H).
'^C NMR spectrum in CDCI3 , 8  (ppm): 160.5 (ArC(2)-0), 134.5 (ArC(4)H), 133.6 
(ArC(6 )H), 112.6 (Ai(3)CH), 121.0 (ArC(5)H), 116.5 (O N ), 102.0 (ArC(l)-CsN),
70.6 (CH2-O), 6 8 . 8  (O-CH2), 59.3 (OMe).
IR (KBr), selected bands, cm'*: 2227, v(CsN), 1291, 1262, v(C-O), 1129, 1113, 
v(C-0).
Accurate MS-EI, 177.0782, theoretical, 177.0784
8.2.7. 3,4-di(2-methoxyethoxy)benzonitrile (20).
Colourless oil. Formula: C13H18NO4 , MW 252.29, Anal, calc.%, C: 61.89; H: 7.19; N: 
5.55; found, C: 61.43; H: 6.44, N: 5.95.
R f  0 .33 , 3/1 DCM/ethyl acetate, single spot.
NMR spectrum in CDCI3 , ô (ppm): 3.44 (s, 6 H, 2MeO), 3.77 (m, 4H, (CH2)2), 
4.16 (m, 4H, (CH2)2), 7.14 (d, 9.0 Hz, H, ArC(5)H), 7.39 (d, 9.0 Hz, H, ArC(6 )H), 
7.25 (s, IH, ArC(2)H).
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'^C NMR spectrum in CDCI3 , 8  (ppm): 154.5 (ArC(4)-0), 150.4 (ArC(3)-0),
128.1 (ArC(6 )H), 119.9 (ArC(2)H), 118.1 (O N ), 114.9 (ArC(5)H), 105.0 (ArC(l)- 
O N ), 70.0 (CH2 -0 ), 72.1(0-0%), 59.6 (OMe).
IR (KBr), selected bands, cm'*: 2225, v(CsN), 1050, 1034, v(C-O).
Accurate MS-CI, 252.1225, theoretical mass, 252.123
8.3. Miscellaneous méthylations.
Method of alkylation reproduced from section 5.2.
R
+ -------------------------- Me-
M e - N "  70 "C 1 Hour M e " " /  -S O 4CH3
 ^ MeMe
R= CN (22) or CHO (21)
Scheme 29. Quaternisation of tertiary amines.
The method employs a fourfold excess of the alkylating agent as solvent, mild 
conditions of 1 houi' warming at 70 under a nitrogen atmosphere. Excess of 
dimethyl sulphate is removed with diethyl ether and the product easily pinified by 
washing with successive portions of diethyl ether and DCM.
8.3.1. (4-Formylphenyl)trhnethylammonium methylsulphate (21)
Analytical data:
Yellow solid, yield 75%, mpt, 163-165 ”C.
Formula: C11H 17NO5 S, MW 275.1, Anal, calc.%, C: 47.98; H: 6.22; N: 5.08; found, 
C: 47.77; H: 6.40, N: 5.02.
NMR spectrum in de-DMSO, ô (ppm): 3.38 (s, 3H, MeSO/), 3.67 (s, 9H, 
N(CH3 )3), 8.15 (d, 9.0 Hz, 2H, ArCH), 8.23 (d, 9.0 Hz, 2H, AiCH) and 10.15 (s, 
CHO).
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" c  NMR spectrum, de-DMSO, 5 (ppm); 192.05 (CHO), 152.0 (ArC(4)-N), 137.0 
(ArC (l)-CHO), 130.76 (ArC(2,6)H), 121.63 (AiC(3,5)H), 56.24 (NMes), and 52.74 
(MeSOO
IR (KBr), selected bands, cm'*; 3019, 1700,v(C=0).
MS-EI, ot/z: 275 [M], 164 [M - CHjSO/ ].
Accurate MS-EI, 274.9899, theoretical, 275.0822.
8.3. 2. (4-Cyanophenyl)trhnethylammomum methylsulphate (22).
White solid 1.46 g, yield 54%, mpt, 184-186 ”C.
Formula: C11H 16N2 SO4 , MW 272.3, Anal, calc.%, C: 48.51; H: 5.92; N: 10.29; 
found, C: 48.23; H: 6.00; N: 10.11.
NMR spectrum m dô-DMSO,
Ô (ppm): 3.38 (s, 3H, MeS0 4 ‘), 3.64 (S, 9H, (CH3)N), 8.20 (m, 4H, AiC(2,3,5,6)H). 
"C  NMR spectrum, de-DMSO, Ô (ppm): 150.3 (ArC(4)-N), 134.3 (ArC(2,6)H),
117.3 (CN), 113.1 (Arc (1)-C=N), 122.3 (ArC(3,5)H), 56.3 (NMc3), and 52.6 
(MeSOT)
IR, (KBr), selected band, cm'*: 2230 v(C=N).
MS-FAB, m/z\ 273 [M^], 162 [M - counter ion], 253 [M - 2Me].
8.3.3. Imhie made from aniline and p-dimethylaminobenzaldehyde* (2 3 ) .  
N,N-dimethyl-4-[(methylimino)phenyl]- benzene.
Method. Equimolar quantities (5 mmol) of the stalling material were dissolved in 
DCM (10 ml), a few molecular sieves were added and the mixtuie stirred under reflux 
for 6 horns. The sieves were filtered out and the reaction mixtuie reduced under 
vacuum. The remaming starting material was removed with diethyl ether and the 
product recrystallised from methanol and diethyl ether. No mineral acid was included 
contrary to the reference.
Analytical data:
Yellow crystalline solid, yield is 83%.
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Formula: C15H16N 2, MW: 224.2 *H NMR spectrum in CDCI3, 5 (ppm): 3.11 (s, 
6 H, N(CH3)z), 8.33 (s, IH, HC=N), 7.77 (d, 8.5 Hz, 2H, C- Ph) 7.18 
(overlapped m, 3H, C=N-Ph) 7.37 (d, 7.7 Hz, 2H, =N-Ph) and 6.74 (d, 8.5 Hz, 
2H, C- Ph).
‘^ C NMR spectrnm in CDCI3 , 5 (ppm): 40.7 (2C of (CH3 )2N), 163.3 (C=N), 
132.1, 112.9 (4C OF C a ^ ) , 130.5, 126.7, 122.3 (5C of C«Ha), 124.9 (Cq of 
CaHs), 153.9 or 154.9 (N-C, of CaH4 >, 153.9 or 154.9 (C-C, of CaK,).
8.4. Platiiium(II) bis nitrile complexes.
The three routes used were; (specific conditions are included in table 21 below)
1. A variation on the Hoffinann and Bugge m ethod*used by W alton*and Eysel 
et al., *^ which is an aqueous route stalling with potassium tetrachloroplatinate. 
Dichlorobis(acetonitrile) platinum(II) was used as a stalling point for many of the 
complexes made in this section.
[PtCl2 (MeCN)2 ].
K2 [PtCh] (300 mg) is dissolved in distilled water (10 ml). The solution was pipetted 
off from the insoluble impurities and acetonitrile (0.5 ml) added and shaken. The 
resulting orange solution was sealed in a flask and left at room temperatuie for 7 days 
to exchange. The product appears as yellow crystals as the solution pales to yellow 
and is recovered by filtration. A second crop of paler yellow crystals is precipitated 
after removal of the fti st crop. These are vai ying mixtures of cis and trans isomers.
PtCl2(p-OH-C6H5CN)2
At least a 10 molai' excess of 4-hydroxybenzonitrile (420 mg) was dissolved in 
toluene / chloroform (2 ml, 4/1). [PtCl2 (MeCN)2] (100 mg) was added and the mixture 
stined at 85 for 85 houis. The reaction mixtuie is reduced under vacuum and the
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excess free ligand removed using diethyl ether (3 x 20 ml). The product is 90% tt'ans 
complex with a small amount of cis complex.
2. To produce a predominantly trans product a vaiiation on the Kharasch method of 
diiect ligand attachment to platinum was employed^^’^ ,^ using platinum dihalide 
and the desired ligand.
tr'ans- [PtBi’2 (PhCN)2 ].
Platinum(II) bromide (300 mg) was dissolved in hot (100 °C) benzonitrile (3 ml) and 
the mixtuie stirred at this temperatuie for 30 minutes. By this time the solution had 
tuined yellow. The hot solution was filtered and allowed to cool and a yellow 
precipitate filtered off. A second crop was obtained by the addition of diethyl ether to 
the solution. The product was washed with diethyl ethyl and dried. The product is 
predominantly trans, if pure trans is required chromatography using DCM as eluent is 
caii'ied out the trans isomer running first.
3. The Ramberg and Bugge aqueous route was used to make cis complexes. These 
were made for chaiacterization puiposes as cis complexes aie of limited value for 
cycloaddition reactions.
C/5*-PtCl2(p-OH-C6H5CN)2.
K2 [PtCl4 ] (300 mg) is dissolved in distilled water (10 ml). The solution was pipetted 
off fi'om the insoluble impuidties and saturated with p-hydroxybenzonitrile. The 
excess free ligand is removed by filtration and the solution stoppered in a flask. It is 
left at room temperature for 14 days and the product appears as yellow / green 
crystals. These are isolated by filtration and any free ligand removed with diethyl 
ether.
Specific reaction conditions for all the platinum nitrile complexes made are contained 
in tables 2 1  a-c below.
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Product No Reaction Conditions Result
PtCl2(PhCN)2 24 2  days, 60 °C, CHCh. 
Reduce under vacuum, 
precipitate with diethyl 
ether. Chromatography on 
silica using DCM as eluent.
Mixture of cis and 
trans isomers
PtCl2(o-OH-C6H4-CN)2 25 4 days, 60 "C, CHCI3. 
Reduce under vacuum and 
remove free ligand with 
diethyl ether.
unstable products 
mixture of cis and 
trans isomers.
PtCl2(w-OH-C6H4-CN)2 26 4 days, 60 °C, CHCI3 . Same 
work-up as 25.
mainly trans product
PtCl2(p-OH-C6H4-CN)2 27 2  days, 60 °C, CHCI3* 
same work-up as 25.
high yield mainly cis
PtCl20?-Me3N^ -C6H4-CN)2 n/a 1 0  days, 60 T ,  
CHCh/MeCN 4/1
no product isolated
PtCl2(p-C02H-C6H4-CN)2 n/a 4 days, 60 “C, THF no product isolated
PtCl2(w-MeOC2H40-H-C6H4-CN)2 28 10 days, 90 °C, no solvent product unstable in 
solution
PtCl2(p-Me0C2H40-H-C6H4-CN)2 29 10 days, 90 “C, no solvent. 
Chromatography on silica 
using DCM/EA, 5/1
trans product
PtCl2(o-]VIeOC2H40-H-C6H4-CN)2 n/a 10 days, 90 “C, no solvent no product isolated
PtCl2(3,4-di-(Me0C2H40)-H-C6H4-CN)2 30 14 days 90 °C, no solvent. 
Same work-up as 29
trans product
PtCl2(p-Me2N-C6H4-CN)2 35 7 days, 60 “C, CHCI3 
Same work-up as 25.
low yield, coordination 
via Mc2N
PtCl2(m,p-di-OH-C6H4-CN)2 36 10 days, 90 °C, 
same work-up as 25.
poor yield
PtCl2(p-N0 2 -C6H4-CN)2 37 7 days, 60 °C, CHCI3 , same 
work-up as 25
low yield, used for 
characterisation only
* optimum conditions, 45 houis in 4/1 toluene /chloroform at 85 °C 
Table 21 (a). Method 1.
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Product No Reaction Conditions Result
PtCl2(PhCN)2 24 1 hr, 110 “C, precipitated with pet. 
ether and filter. Chromatography 
on silica, eluent DCM.
mainly trans product
PtCl2(m-OH-C6H4-CN)2 26 0,5 hr, 85 “C, remove free ligand 
with diethyl ether.
mainly trans product
PtCl2(p-OH-C6H4-CN)2 27 0.5 hr, 120 °C, remove free ligand 
with diethyl ether.
high yield mainly trans 
but contaminated with 
a suspected polymeric 
impurity. Impossible to 
purify.
PtCl2(p-Me0C2H40-H-C6H4-CN)2 29 2 hrs 100 °C, chromatography on 
silica, DCM/EA, 5/1 as eluent.
trans product isolated
PtBr2(PhCN)2 31 1 hr, 110 “C, same work-up as 24 high yield trans 
product
PtBr2(m-OH-C6H4-CN)2 32 0.5 hr, 85 °C, remove free ligand 
with diethyl ether.
high yield trans 
product
PtBi'2(p-OH-C6H4-CN)2 33 0.5 hr, 120 °C, remove free ligand 
with diethyl ether.
high yield trans 
product, contaminated 
with a polymeric 
impurity.
Ptl2(PhCN)2 34 1 hr, 110 ®C, same work-up as 24 low yield unstable 
trans product
PtCl2(p-N02-C6H4-CN)2 37 7 days toluene 90 °C, remove free 
ligand with diethyl ether
low yield, used for 
characterisation only
Table 21(b) Method 2.
191
Product No Reaction Conditions Result
PtCl2(o-OH-C6H4-CN)2 25 10 days, RT, water filter out crystals 
and remove free ligand with diethyl 
ether.
poor yield cis isomer
PtCl2(m-OH-C6H4-CN)2 26 14 days, RT, water, same work-up as 
25
mixture of cis and 
trans isomers.
PtCl2(p-OH-C6H4-CN)2 27 10 days, RT, water, same work-up as 
25
low yield cis product
PtCl2(p-C02H-C6H4-CN)2 n/a 10 days RT, water no product isolated, for 
characterisation only.
PtBr2(PhCN)2 31* 10 days, RT, water, solvent extraction 
with DCM.
low yield trans product
PtBr2(m-0H-CgH4-CN)2 32* 14 days, RT, water. no product isolated
PtBr2(p-OH-C6H4-CN)2 33* 10 days, RT, water. low yield trans product
Ptl2(PhCN)2 34* 10 days, RT, water. no product isolated.
PtCl2(m./)-di-OH-CgH4-CN)2 36 10 days, RT, water. no product isolated
PtCl2(p-N02-C6H4-CN)2 37 10 days, RT, water, no work-up. low yield, used for 
characterisation only
* a seven fold molar excess oi■ KI or KBr was also added as appropriate.
Table 21(c). Method 3.
8.4.1. [PtCl2 (PhCN)2 ] (24).
Formula: Ci4 HioN2 Cl2Pt, MW 472.23
*H NMR (500 MHz, C D C I3)  ô(ppm): 7.57 (t, 7.9 Hz, 4H), 7.74 (t, 7.7 Hz, 2H) an d
7.79 (d , 7.4 Hz, 4H)(Ph).
NMR*^  ^ in CDCI3 5 (ppm): tr'ans\ 109.0 (ArC(l), Cq), 133.7 (AiC(2,6)H), 129.5 
(AiC(3,5)H), 135.4 (ArC(4)H), 116.8 (C=N).
cis\ 109.1 (ArC(l), Cq), 133.7 (ArC(2,6)H), 129.6 (ArC(3,5)H), 135.2 (ArC(4)H),
115.3 (CWN).
IR spectrum (selected bands), cm~*: 2285 {cis), 2289 (trans) v(C=N).
*^ P^t NMR*"*** spectrum in d^-acetone ô (ppm): -2350.0 (trans), 2284.0 (cis).
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8.4.2. Formula: [PtCl2 (o-HO-C6H4 -CN)2] (25).
Formula: Ci4HioN202Cl2Pt, MW 504.23, yellow crystals, yield 42%.(Unstable)
*H NMR spectrum in de-acetone ô (ppm): 7.10 (m, 2H, ArCH), 7.17 (m, 2H, ArCH), 
7.63 (m, 2H, ArCH), 7.72 (m, 2H, ArCH).
*^ C NMR spectrum in de-acetone ô (ppm): 162.3 (ArC-O), 137.4, 126.1,117.2 116.3 
(Ai'CH), 115.4 (C=N), not seen, possibly 96.5 (ArC(l)-C=N).
IR, (KBr), selected band, cm'*: 2280 (cis), 2288 (trans), v(C=N).
*^ P^t NMR spectrum in de-acetone ô (ppm): -2332.8 (trans) (1610 Hz).
8.4.3. [PtC l2(m -H O -C eH 4-C N )2] (26).
Formula: Ci4HioN202Cl2Pt, MW 504.23, yellow crystals, yield 81%. Anal, calc.%, C: 
33.36; H: 1.98; N: 5.56; found, C: 35.25; H: 1.90, N: 5.55.
*H NMR spectrum in de-acetone (trans) ô (ppm): 7.35 (t, 8.0 Hz, 2H, ArC(5)H), 7.42 
(s, 2H, ArC(2)H), 7.52 (overlapped m, 4H, ArC(4,6)H), 9.46 (s, 2H, OH).
(cis) Ô: 7.35 (t, 8.0 Hz, 2H, ArC(5)H), 7.40 (s, 2H, ArC(2)H), 7.55 (overlapped m, 
4H, ArC(4,6)H), 9.51 (s, 2H, OH).
*^ C NMR spectrum (mixture of isomers, mainly trans in de-acetone Ô (ppm):
158.0 (ArC-0), 132.1, 126.0, 124.1, 120.3 (ArCH), 118.5 (C=N), 110.2 (ArC (1)- 
C^N).
MS-FAB, m/z: 504 [M"], 527 [M + Na], 468.4 [M -  Cl], 433 [M -2C1], 485 [M - 1 
ligand], 470.4 [M - 20H], 353.5 [M - Cl and 1 ligand].
IR, (KBr), selected band, cm'*: 2292 (cis), 2316 (trans) v(C=N).
*^ P^t NMR spectrum in de-acetone ô (ppm): -2369.0(1075 Hz)(/ra«5), 2275.1(1200 
Hz)(cfy)
8.4.4. [P tC l2(p-H O -C eH 4-C N )2] (27).
Formula: Ci4HioN202Cl2Pt, MW 504.23, yellow crystals, yield 88%.
Anal, calc.%, C: 33.36; H: 1.98; N: 5.56; found, C: 33.75; H: 1.97, N: 5.32.
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*H NMR spectrum in de-acetone (trans), ô (ppm): 7.13 (d, 8.7 Hz, 4H, ArC(3,5)H), 
7.87 (d, 8.7 Hz, 4H, AiC(2,6)H), 9.99 (s, 2H, OH).
(cis) 8 : 7.00 (d, 8.7 Hz, 4H, ArC(3,5)H), 7.62 (d, 8.7 Hz, 4H, ArC(2,6)H), 9.99 (s, 
2H, OH).).
NMR spectrum in de-acetone (trans), 8  (ppm): 162.2 (ArC-O), 120.0 (C=N),
135.0, 117.3 (ArC(2,6 or 3,5)H), 101.6 (ArC (1)-C=N).
*^CNMR spectrum in de-acetone (cis), 8  (ppm): 164.4 (AiC-O), 117.0 (C=N), 137.1,
117.7 (ArC(2,6 or 3,5)H), 99.5 (ArC (l)-C^N).
MS-FAB, m/z: 504 [M^, 527 [M + Na], 468.5 [M -  Cl], 433 [M - 2C1], 485 [M - 1 
ligand], 470.4 [M - 20H], 353.5 [M - Cl and 1 ligand].
IR, (KBr), selected band, cm'*: 2287 v(C=N).
*^ P^t NMR spectrum in de-acetone 8  (ppm): cis, -2244.3, trans -2339.4 (1075 Hz).
8.4.5. /ram-[PtCl2(m-Me0C2H40-CeH4-CN)2] (28)
Formula: C2oCl2 H2 2N2 0 4 Pt, MW 620.4, yellow solid, 48 mg, yield 55%, Anal, calc.%, 
C: 38.72; H: 3.57; N: 4.52; found, C: 38.12; H: 3.50, N: 4.23.
*H NMR spectrum in CDCI3 8  (ppm): 7.31 (overlapped m, 8 H, CeHt), 4.15 (m, 4H, 
OCH2), 3.78 (m, 4H, CH2 O), 3.45 (s, 6 H, MeO).
*^ C NMR spectrum in CDCI3 8  (ppm): 159.0 (AiC(3)-0), II9.9(C=N), 130.9
(ArCH), 126.4 (ArCH), 123.1 (ArCH), 118.3 (ArCH), not seen (ArC (1)-C=N), 70.6 
(CH2 -O), 6 8 .KO-CH2 ), 59.3 (OMe).
MS-FAB, m/z: 621 [M*], 583 [M-HCl],
IR, (KBr), selected band, cm'*: 2292 v(C^N).
*^^PtNMR spectrum in CDCI3 8  (ppm): -2345.8 (535).
8.4.6. /rfl«5-[PtCl2(p-Me0C2H40-C6H4-CN)2] (29).
Foimula: C2oCl2H2 2N2 0 4 Pt, MW 620.4, yellow solid, 55 mg, yield 62%.
Anal, calcd for C2 oH2 2 Cl2N2 0 4 Pt:%, C, 38.72; H, 3.57; N, 4.52. Found: C, 38.27; H, 
3.54; N, 4.26.
194
*H NMR spectrum in CDCI3 5 (ppm): 7.70 (d, 7.5 Hz, 4H, ArC(2,6 or 3,5)H), 7.03 
(d, 7.5 Hz, 4H, ArC(3,5 or 4,6)H), 4.20 (t, 4H, OCH2 , 4.5 Hz), 3.77 (t, 4H, CH2 0 ,4.5 
Hz), 3.44 (s, 6 H, OMe).
'^C NMR spectrum in CDCI3 8  (ppm): 164.2 (AiC-0 ),l 17.0 (O N ), 135.8
(2 AiCH), 115.8 (2ArCH), 100.2 (ArC (l)-O N ), 70.5 (CH2-O), 6 8 .0 (O-CH2), 59.3 
(OMe).
MS-FAB, m/T. 620.7[ M+|, 584.8 [M-HCl],
IR, (KBr), selected band, cm"': 2291 v(CsN).
'®^ Pt NMR spectrum in CDCI3 8  (ppm): -2313.3 (802 Hz).
8.4.7. frans-[PtCl2(m,/)-di(Me0C2H40)-C6H4-CN)2] (30).
Formula C26Cl2H34N20sPt, MW 768.4, yellow solid, yield 48%
Rf 0.18, single spot in TLC, 4/1 DCM/ethyl acetate as eluent.
‘H NMR spectrum in CDCI3 8  (ppm): 7.4 (m, 2H, C6H3), 7.19 (m, 2H, C6H3), 6 . 8 8  
(m, 2H, CsHa), 4.15 (m, 4H, ArCq(4 )OCH2  ), 4.23 (m, 4H, ArCq(3 )0 CH2  ), 3.78 (m, 
8 H,CH2  of McOCH2), 3.44 (s, 12H, MeO).
‘^C NMR spectrum, C D C I3 8  (ppm): 155.1, 149. l(ArCO), 129.2 (ArCH),
117.3(ON), 117.2 (ArCH), 113.2 (ArCH), 100.1 (ArC (1)-C=N), 70.0 (CH2 -O), 
7 2 .KO-CH2), 59.3, 59.4 (OMe).
MS-FAB, m/z\ 767.0[M*], 791.1 [M+Na], 763.0 [M-Me], 731 [M-HCl].
IR, (KBr), selected band, cm"*: 2284 v(ON).
'’’PtNMR spectrum in CDCI3 8  (ppm): -2315.5 (1075 Hz).
8.4.8. /rans-[PtBr2 (PhCN)2] (31).
Analytical data: Orange / yellow solid, formula: Ci4 HioN2Br2Pt, yield is 8 6 %. MW
561.13.
Anal, calcd for Ci4 HioBr2N2Pt:%, C, 29.97; H, 1.80; N, 4.99. Found: C, 29.83; H, 
1.68; N, 4.81.
'H NMR (500 MHz, CDCI3) 8 (ppm) 7.57 (t, 7.9 Hz, 4H), 7.74 (t, 7.7 Hz, 2H) and
7.79 (d, 7.4 Hz, 4H)(Ph). "C  NMR (125.7 MHz, CDCI3) 8 (ppm) 119.1 (CsN), 109.4 
(Cq), 129.7, 133.9 and 135.5 (IOC, Ph).
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MS-FAB*, m/z: 561.8 [M]*, 480.9 [M -  H B rf, 400 [M -  2 HBr]*, 459 [M -  PhCN]*. 
Accurate MS-FAB*, m/z: 558.56 for Ci4Hio” Br2N2Pt, theoretical 558.8853.
IR spectrum (selected bands), cm"'; 2288 v(C=N).
‘^^Pt NMR (107.3 MHz, CDCI3) S(ppm) -2860 (750 Hz).
8.4.9. frans-[PtBr2 (»»-HO-C6H4-CN)2] (32).
MW 593.128, yellow crystals, yield 73%, formula: CwHioOzBriNiPt,
Anal, calcd for CMHioOzBrzNzPt: %, C, 28.34; H, 1.68; N, 4.72. Found: C, 28.33; H, 
1.65; N, 4.58.
*H NMR spectrum in de-acetone ô (ppm): 7.37 (m, 2H, ArCH), 7.39 (m, 2H, ArCH), 
7.46 (m, 2H, ArCH), 7.56 (s, 2H, ArCH), 9.48(s, 2H, OH).
" c  NMR (75 MHz, ds-acetone) 8 (ppm) 119.2 (C=N), 110.2 (Cq), 120.3, 124.2, 125.9 
and 132.1 (CH)(ArCH), 158.8 (ArC-O).
‘®’Pt NMR (107.3 MHz, CDCI3) 5(ppm) -2860 (750 Hz). ‘” Pt NMR spectrum in ds-
acetone Ô: -2872.7, (535 Hz).
MS-FAB^ m/z: 593 [M \\ 513 [M -H B rf, 431 [M -2Bif.
IR, (KBr), selected band, cm"*: 2292 (cis) 2316 (trans) v(C=N).
8.4.10. /r««5-[PtBr2(p-HO-C6H4-CN)2] (33).
MW 593.128, yellow crystals, yield 80%, formula: CwHioOzBrzNzPt.
Anal, calcd for Ci4 Hio0 2 Bi2N2Pt:%, C, 28.34; H, 1.68; N, 4.72. Found: C, 27.91; H, 
1.40; N, 4.40.
*H NMR spectrum in de-acetone ô (ppm): 7.13 (d, 8.5Hz, 4H, ArC(3,5)H), 7.84 (d,
8.5 Hz, 4H, Ai*C(2.6)H), not seen (s, 2H, OH).
*^ C NMR (125.7 MHz, de-acetone) 0(ppm) 99.3 (Cq), 117.2 (C=N), 117.8 and 137.0 
(CH)(ArCH), 164.6 (C ArC-0).
MS-FAB^ m/z: 593.7 [M ]\ 512 [M -H B rf, 431 [M-2HBr]-F.
IR, (KBr), selected band, cm'*: 2287 v(C=N).
*^ P^t NMR spectrum in de-acetone ô: -2832.9, (1075 Hz).
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8.4.11. /ra«.s-[Ptl2 (PhCN)2 ] (34).
Formula: Ci4 Hiol2N2 Pt, MW 655.13, orange yellow solid, (unstable), yield is 56%. 
Anal, calcd for Ci4 Hiol2N2Pt:%, C, 25.67; H, 1.54 ; N, 4.28 . Found: C, 25.17; H, 
1.36; N, 4.08.
‘H NMR (300 MHz, CDCI3) S(ppm) 7.57 (t, 7.95 Hz, 4H), 7.73 (t, 7.8 Hz, 2H) and 
7.78 (d, 7.2 Hz, 4H)(Ph). '^C NMR (75 MHz, CDCI3) S(ppm) 109.4 (Cq), 122.8 
(CsN), 129.5, 133.5 and 135.2 (CH)(Ph).
MS-FAB* »i/z: 655.6 [M]^ 526.8 [M -  HI]*, 551.9 [M-PhCN]*.
IR spectrum (selected bands), cm"’: 2287 v(CWN).
‘“ Pt NMR (107.3 MHz, C D C I3)  S(ppm) -3934.7 (750 Hz).
8.4.12. [PtCk(4-Me2N)-C6H4-CN)2] (35)
Formula: PtCl2N4 CieH2o, MW 559.4, pale yellow powder, 87% (impute, product not 
isolated.
*H NMR (300 MHz, de-acetone) ô(ppm); 2.95 (s, 6 H, Me), 7.96 (ni, 2,6 or 3,5, 4H), 
7.61 (m, 2,6 or 3,5,4H)(ArCH).
MS-FAB'*', w/z: 558.9 [M f, 485.0[M-2HC1]
IR spectrum (selected bands), cm"*: 2244 v(C=N).
*^ P^t NMR (107.3 MHz, de-acetone) ô(ppm) -2124.7 (400 Hz)(diamine), -2135.3 
(possibly Pt(II) monoamine/MeCN).
8.4.13. [PtCl2 (4 -C0 2 H-CeH4 -CN)2 ] (possibly hydrolysed to the amide, product not 
isolated).
*H NMR (300 MHz, de-acetone) ô(ppm) 7.91 (m, 4H ArCH), 7.82 (m, 4H(ArCH).
IR spectrum (selected bands), cm"*: 2236 (CsN of free ligand), 1595 v(NH2 C=0 ). 
*^ P^t NMR (107.3 MHz, de-acetone) 5(ppm) -2034.2 (535 Hz)
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8.4.14. Formula: [PtCl2 (w,p-di-HO-C6H4 -CN)2] (36).
Formula: PtCl2 Ci4HioN2 0 4 , MW 536.2, yellow crystals, yield <20%.
*H NMR spectrum in de-acetone (trans), ô (ppm): 7.10 (s, 2H, ArC(2)H), 7.03 (d,
10.0 Hz, 2H, ArC(2 or 3)H), 7.38 (d, 10.0 Hz, 2H, ArC(2 or 3)H).
NMR spectrum in de-acetone (trans), 6 (ppm): 147.1,155.1 (2 ArC-O),
128.6, 120.1, 117.3 (3ArCH), 98.6 (ArC(l)-C^N), 119.0 (C=N).
MS-FAB, m/z: 536.8 [M"], 559.9 [M + Na], 499.8 [M -  HCl], 463.8 [M -  2HC1].
IR, (KBr), selected band, cm'*: 2341 Br. v(C=N).
*^ P^t NMR spectrum in de-acetone Ô (ppm): trans -2303.3 (750 Hz), much smaller 
signal at -2270 (cis), also at -2214 ppm.
8.4.15. [PtCl2(4-N02-CeH4-CN)2] (37). Product not isolated.
*H NMR (300 MHz, de-acetone) ô(ppm) (thermal method) 8.55 (d, 10.0 Hz, 4H), 8.27 
(d, 10.0 Hz, 4H)(Ai*CH). (Aqueous method) 8.41 (d, 9.0 Hz, 4H), 8.02 (d, 9.0 Hz, 
4H)(ArCH).
Possible hydrolysis product; 7.70 (m, 2H), 7.02 (d, 9.0 Hz, 2H)(ArCH), 9.79 (br. s, 
NHz).
IR spectrum (selected bands), cm"*: 2284 (thermal), 2288 (aqueous) v(C=N).
*^ P^t NMR (107.3 MHz, de-acetone) ô(ppm) (aqueous), -2300.7 (1075 Hz), (thermal) 
-2269.6 (270 Hz), -2240 ppm, possibly a hydrolysis product (amide).
8.5 //*a/i5-platinum(U) mono oxadiazoline complexes with hydroxy-substituents.
Below is a typical procedme for the manufacture of a mono oxadiazoline platinum 
complex. Specific conditions are included in table 22 below.
Reaction of [PtCl2 (CeH5 CN)2 ] with;?-HO-CeH4CH=NOMe 
/ram-[PtCl2(PhCN){N=C(Ph)-O-N(Me)-CH(p-HO-CeH4)}](40).
Platinum bis-benzonitrile (47.2 mg, 0.1 mmol) and nitrone (16.1 mg, 0.1 mmol) were
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placed in a flask with 1 ml of chlorofoim This was placed in a sand bath at 25 
under nitrogen and stirred vigorously. The progress of the reaction is monitored by 
proton NMR and stopped at the fiist appearance of bis oxadiazoline signals at 8.80 
ppm (approximately 3 days). The product is purified by chromatography using firstly 
DCM to remove the nitrile complex, then DCM/ethyl acetate 10/1 as eluent to recover 
the platinum oxadiazoline complex. Great care should be taken if working at room 
temperature over 35 “C that the bis compound is not formed.
Prod. No. Reaction Conditions Work-Up Conditions
38 Equimolar ratio, acetone, 48hrs, 30°C Chromatography / DCM/EA, 10/1 as eluent
39 Equimolar ratio, chloroform, 72hrs, 30°C Chromatography/DCM/EA, 10/1, as eluent
40 Equimolar ratio, chloroform, 72hrs, 25”C Chromatography / DCM/EA, 10/1,as eluent
41 Equimolar ratio, chloroform, 7 days, 25“C Chromatography / DCM/EA, 4/1 as eluent
42 Equimolar ratio, chloroform, 48hrs, 30°C Chromatography / DCM/EA, 4/1 as eluent
43 Equimolar ratio, chloroform, 1 Odays, 30”C Chromatography / DCM/EA, 4/1 as eluent
51 Equimolar ratio, chloroform, 25“C 48 hrs Chromatography / DCM, as eluent
54 Equimolar ratio, chloroform, 25°C 48 hrs Chromatography / DCM as eluent
Table 22. The reaction conditions and work-up procedures for the syntheses of mono 
oxadiazoline platinum complexes, (chromatography on silica).
8.5.1. Reaction of/ra«5 -[PtCl2 (/w-HO-C4 H6 CN)2 ] with PhCH=NOMe 
/rfl/7.s-[PtCl2(w-HO-C6H4){N=C(m-HO-C6H4)-0-N(Me)-CH(Ph)}](38)
Analytical data:
Yellow solid, yield is 60%.
Formula: C2 2Hi9Cl2N3 0 3 Pt, MW 639.39. Anal, calc.%, C, 41.33; H, 3.00; N, 6.57. 
Found: C, 41.54 ; H, 2.88; N, 6.32.
*H NMR spectrum in de-acetone, ô (ppm): 3.09 (sharp s, 3H, NMe), 6.08 (s, IH of 
NCH), 7.68 (m, 2H of Ph.), 7.47 (m, 3H of Ph.), 7.25 (overlapped m, ArC(4)H of 
C6 H4 CN), 7.27 (overlapped m, ArC(2,6)H of C6H4 CN), 7.51 (overlapped m, 
ArC(3,5)H ofCgH^C^N), 7.38 (d, 7.7 Hz, ArC(4)H, CeH4 C=N.), 7.44 (overlapped m, 
ArC(5)H, CeH4 -C=N), 8.36 (d, 7.7 Hz, ArC(6)H, CeH4 C=N), 8.47 (s, AiC(2)H, 
CeH4 C=N), 9.19, 9.37 ( s, 2H, OH).
*^ C NMR spectrum in de-acetone, ô (ppm): 46.0 (NMe), 94.9 (NCHN), 117.3 (CsN),
117.4 (ArC(2) of CeH4 C=N), 123.0 (ArC(6) of CeH4 C=N), 130.0 {meta ArC(5) of
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C(îH4 C=N), 125.2 (ArC(4) of C6 H4 O N ), 128.7, 128.8 (ArC(2,6 and 3,5) of Ph.), 
130.1(ArC(4) of Ph), 109.5 (ArC(l)CsN), 130.5 (ArC(5) of Ce^CsN), 125.2 (either 
6  or 4 ArC of C6H4 CSN), 119.5 (Ai-C(l) of C6H4 O N ), 122.5 (either 6  or 4 ArC of 
C6H4 CSN) 156.0,156.1 (2 AiC(3)-0), 122.5(Cq, N=C-C6H4), 164.5 (C=N),
135.2 (Cq,Ph)
*®^Pt NMR spectrum in d^-acetone, 6  (ppm): -2237.1 (750 Hz).
IR, (KBr), selected band, cm"’: 2283 v(CsN), 1596 v(C=N).
MS-FAB, m/z: 639.0 [M]*, 662.3 [M+Na]*, 603.0 [M-HCl], 566.0 [M-2HC1], 537.0 
[M-PhCN].
8.5.2. Reaction of frans-[PtCl2 (C6 H5 CN)2] with m-HO-C6H4 CH=NOMc 
h-ans-[PtCl2(PhCN){N=C(Ph)-0-N(Mc)-CH(m-H0-C6H4)}](39).
YeUow crystalline solid, yield is 74%.
Formula: C2 2Hi,Cl2N3 0 2 Pt, MW 623.389. Anal, calc.%, C, 42.39; H, 3.07 ; N, 6.44 . 
Found: C, 42.45; H, 2.85; N, 6.71.
’H NMR spectnun in CDCI3 , 8  (ppm): 3.09 (sharp s, 3H, NMe), 5.93 (s, IH of 
NCHN), 6.09 ( s, H, OH), 8.98 (d, 7.5 Hz, ArC(2,6)H of PhC=N), 7.59 (overlapped 
m, ArC(3,5)H of PhC=N), 7.68 (overlapped m, ArC(4)H of PhC=N), 7.26 
(overlapped m, 3H ArC(2,4,5)H of CcHt), 6.90 (d, 7.6 Hz, ArC(6 )H of C6H4), 7.47 (t,
7.5 Hz, Ai-C(3,5)H ofPhCN), 7.63 (m, ArC(4)H of PhCN), 7.67 (m, ArC(2,6)H of 
PhCN).
‘^ C NMR specti-um in CDCI3 , 8  (ppm): 46.3 (NMe), 94.7 (N-C(C6H4 -0 )HN), 117.1 
(O N ), 130.8 (ArC(2,6) o fP hO N ), 129.2 (ArC(3,5) of PhC=N), 128.8 (ArC(4) of 
PhC=N), 116.0 (2 or 4), 117.3 (4 or 2), 120.9 (6 ), 130.0 (5) (4 ArC of m-OH-CsH,),
134.8 (ArC(2,6) of PhCN), 134.2 (ArC(3,5) of PhCN), 133.9 (ArC(4) of PhCN),
109.5 (ArC(l)C=N), 156.5 (ArC(3)-0), 164.9 C=N(of oxa), 122.1 (CqAiC(l) of 
N=C-Ph), 136.8 ( CqArC(l), CsH4 ofoxa).
'^^Pt NMR spectrum in ds-acetone, 8  (ppm): -2225.6 (775 Hz).
IR, (KBr), selected band, cm"’: 2289 v(O N ), 1597 v(C=N).
MS-FAB, m/z: 623.8 [M]*, 646 [M+Na]*, 586.8 [M-HCl], 550.9 [M-2HC1], 520.9 
[M-PhCN].
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8.5.3. Reaction of /ra«5'-[PtCl2 (C6H5CN)2] with j?-HO-CeH4 CH=NOMe 
/r««5-[PtCl2(PhCN)(N=C(Ph)-O-N(Me)-CH(p-HO-C6H4)}](40).
Yellow crystalline solid, yield is 71%.
Formula: C2 2Hi9Cl2N3 0 2 Pt, MW 623.389. Anal, calc.%, C, 42.39; H, 3.07 ; N, 6.44 . 
Found: C, 42.10; H, 2.95; N, 6.42.
*H NMR spectiimi in de-acetone, Ô (ppm): 3.02 (shai'p s, 3H, NMe), 5.89 (s, IH of 
NCH), 8.57 ( s, H, OH), 8.98 (d, 7.2 Hz, ArC(2,6)H of PhC=N ), 7.69 (overlapped m, 
ArC(3,5)H of PhC=N), 7.85 (t, 7.0 Hz, ArC(4)H of PhC=N), 7.53 (d, 8.5 Hz, 
ArC(2,6)H of j?-0 H-CeH4 ), 6.90 (d, 8.5 Hz, ArC(3,5)H of p-OH-CeH4 ), 7.69 
(overlapped multiplet, ArC(3,5)H of PhCN), 7.81(m, ArC(4)H of PhCN), 7.92 (d, 7.2 
Hz, ArC(2,6)H of PhCN).
*^ C NMR spectrum in de-acetone, ô (ppm): 46.0 (NMe), 94.8 (NCHN), 116.0 (C=N),
130.6, 130.7 (4 ArC 2,6 and 3,5 C of PhC=N), 128.6 (ArC(4) of PhC=N), 115.7 
(3,5), 129.3 (2,6), (4 ArC ofj9 -OH-CeH4 ), 134.7, 134.1, 133.6, (5 C of PhCN), 109.7 
(ArC(l)CsN), 157.5 (AiC(4)-0), 163.1 (C=N of oxa), 122.3 (Cq AiC(l) ofN=C-Ph),
132.2 ( Cq Ai'C(l) of CeH4  of oxa).
*^ P^t NMR spectrum in de-acetone, ô (ppm): -2220.1 (1075 Hz).
IR, (KBr), selected band, cm'*: 2288 v(C=N), 1596 v(C=N).
MS-FAB, m/z: 623.9 [M ]\ 645.9 [M+Na]^, 587.0 [M-HCl], 551 [M-2 HCl], 520.9 
[M-PhCN], 418 [M-2 PhCN].
8.6 Platinum(Il) mono oxadiazoline complexes with glycol ether substituents.
Specific reaction conditions and work-up proceduies are contained in table 23.
8.6.1. Reaction of /raM^-[PtCl2 (p-Me0 C2H4 0 -CeH4 CN)2 ] with PhCH=NOMe
/ra«5-[PtCl2(p-Me0C2H40-CeH4CN){N=C(p-Me0C2H40-C6H4)-0-N(Me)-
CH(Ph)}](41).
Analytical data:
Formula: C2 8H3 iCl2N3 0 5 Pt, pale yellow solid. MW 755.546, yield is 67%.
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Rf 0.24, single spot, 3/1 DCM/ethyl acetate. Anal calc.%, C, 44.50; H, 4.10 ; N, 5.56 . 
Found: C,42.96; H, 3.87; N, 5.44.
*H NMR spectrum in CDCI3 , ô (ppm): 3.05 (s, 3H, NMe), 3.77 (m, 4H, CH% of O- 
CH2 -OCH3), 4.2 (m, 4H, CH2  of C(q)-0 -CH2 ), 3.46 (m, 6 H, MeO), 5.94 (S, IH of 
NCH), 6.98 (d, 8.5 Hz, AiC(3,5)H, CgHj-O of nitrile ligand), 7.63 (d, 5.8 Hz, 
AiC(2,6)H, C6 H4 -O of nitrile ligand), 7.45 (m, 3 ArCH, Ph of oxadiazoline ligand)
7.70 (d, 6 . 8  Hz, 2AiCH, Ph of oxadiazoline ligand) 7.09 (d, 8.5 Hz, ArC(3,5)H, of 
N=C-CeH4 -0 . of oxadiazoline ligand), 9.04 (d, 8.5 Hz, 2ArC(2,6)H of N=C-C6H4 -0 , 
of oxadiazoline ligand).
" c  NMR spectrum in CDCI3 , 8  (ppm): 163.7,163.9(20, ArC(4)-0), 133.1 
(ArC(2,6) C6H4-O of oxadiazoline ligand ), 128.7, 128.6, 129.9, (50, ArOH, Ph of 
oxadiazoline ligand), 114.6 (ArC(3,5), ArC of C6H4 -O of oxadiazolme ligand), 
115.5(3,5), 135.5(2,6) (4AiC of nitrile ligand), 70.8 (CH2 -O), 67.9 (0-CH2), 59.5 
(OMe), 46.8 (NMe), 94.7 (NCHN of heterocycle), 163.2 (C=N of heterocycle), 134.2 
(Cq, Ph), possibly 128.9 (Cq, ArC(l), O-C6H4-C=N),101.3 (Cq, C-C=N), 117.3 
(C^N).
‘“ Pt NMR spectr um in O D O I3 , 8  (ppm): -2216 (790 Hz).
IR, (KBr), selected band, cm"’: 2281 v(0=N), 1603 v(0=N).
MS-FAB, m/z: 756.2 [M]* 778.5 [M+Na], 718.9 [M-HOl], 682.9 [M-2H01], 652.9 
[M-PhON], 549.0 [M-2PhON].
8.6.2. Reaction o f tram -[Pt0 l2 (0 sH5 0 N)2] with p-MeO-0 2 HiO-0 6 H4 0 H=NOMe 
tran5 -[Pt0 l2 (Ph0 N){N=0 (Ph)-O-N(Me)-0 H(p-MeO-0 2 H4 O-0 6 H4)}](4 2 ).
Analytical data:
Formula: C2 5H2 5Cl2N3 0 3 Pt, MW 681.488. Yellow crystalline solid, yield 71%. Anal. 
calc.%, C, 44.05; H, 3.70 ; N, 6.16 . Found: C, 43.91; H, 3.55; N, 6.10.
*H NMR spectrum in CDCI3 , ô (ppm): 3.04 (s, 3H, NMe), 3.76 (m, 2H, (CH2 )i), 4.13 
(m, 2H, (CH2 )2 ), 3.46 (m, 3H, MeO), 5.93 (s, IH of NCH), 7.00 (d, 7.5 Hz, 
Ai’C(3,5)H of C6H4 O-), 7.72 (overlapped multiplet, AiC(2,6)H of C6H4 O-), 7.49 (t,
7.2 Hz, ArC(3,5)H of PhCN), 7.67 (overlapped m, 3C, ArC(2,4,6)H of PhCN), 7.56 
and 7.59(overlapped m, 3C, ArC(3,4,5)H of PhC=N), 8.99 (d, 8.0 Hz, ArC(2,6)H, 
PhC=N). *^ C NMR spectrum in CDCI3 , 5 (ppm): 46.0 (NMe), 59.4 (OMe), 67.2 (O-
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CH2), 71.2 (CHa-O), 94.6 (NCHN), 128.8 (3,5), 129.5 (4), 130.9 (2,6) (5C ArC 
(PhC=N)), 114.7 (3,5), 133.7 (2,6) (4C ofCgHtO), 134.0 (4), 134.3, 135.0 (5C of 
PhCN), 160.1 (ArC(4)-0), 164.4 (C=N of oxadiazoline ring), 116.8 (CW4), 109.9 
(ArC(l), PhCN), 129.8 (ArC(l) O-CeH,-), 122.5 (ArC(l) PhC=N), Cq.
'®^ Pt NMR spectrum in CDCI3 , 5 (ppm): -2230.1 (1070 Hz).
IR, (KBr), selected band, cm ’: 2288v (C=N) 1601 v (C=N).
MS-FAB, m/z: 681.9 [M]*. 704.8 [M+Na], 644.9 [M-HCl], 608.9 [M-2HC1], 579.9 
[M-PhCN].
Reaction of cis -[PtCl2 (CgH;CN)2] with p-MeO-CaHtO-CqHtCH^NOMe 
cw-[PtCl2(PhCN){N=C(Ph)-0 -N(Me)-CH(p-Me0 -C2H4 0 -C6H4)>](4 3 ).
(Complex is unstable, so only a partial characterisation was obtained)
Analytical data:
Formula: CasHasClaNsOaPt, MW: 681.488 ’H NMR spectrum in CDCI3 , 5 (ppm):
3.05 (s, 3H, NMe), 3.70 (m, 2H, CHaO), 3.97 (m, 2H, OCHa), 3.40 (m, 3H, MeO),
6.06 (s, IH of NCH), 6 . 8 8  (d, 7.5 Hz, ArC(3,5)H of CgHtO-) 7.66 (overlapped 
multiplet (ArC(2,6)H of C6H4 O-), 7.65 (overlapped multiplet ArC(3,5)H of PhC=N), 
7.67 (m, AiC(4)H of PhC=N), 9.07 (d, 7.0 Hz, ArC(2,6)H, PhC=N), 7.19 (d, 7.75 Hz, 
ArC(2,6)H of PhCN), 7.41 (t, 7.75 Hz, ArC(3,5)H of PhCN), 7.48 ( t, 7.75 Hz, 
ArC(4)H of PhCN).
’’C NMR spectrum in CDCI3 , 8  (ppm): 46.8 (NMe), 59.2 (OMe), 67.3 (CH2-0), 70.8 
(O-CHa), 94.0 (NCHN), 8 : 129.3, 130.3 (3C, ArC(3,4,5) of PhC=N), 134.4 (2 
ArC(2,6) of (PhC=N)), 114.8 (3,5), 129.0 (2,6) (4C of C6H4O), 133.0 (ArC(2,6) of 
PhCN), 130.0 (ArC(3,5) of PhCN), possibly 129.3 (overlapped, ArC(4) of PhCN),
159.7 (ArC(4)-0), 163.4 (C=N of oxadiazoline ring), 133.5 (ArC(l) PhC=N), 121.8 
(ArC(l), O-C6H4-), 116.0 (CN), 101.0 (C-CN), (Cq).
'®^ Pt NMR spectrum in CDCI3 , 8  (ppm): -2225.4 (1070 Hz).
IR, (KBr), selected band, cm"’: 2280v (CsN), 1602v (C=N).
MS-FAB, m/z: 682.0 [M]*, 703.9 [M+Na], 608.1 [M-2HC1], 475.0 [M-2PhCN].
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8.6.3 Reaction of /ra«5 -[PtCl2 (3 ,4 -di(MeOC2H4 0 -)C6H4 CN)2 ] with PhCH=NOMe 
/?’a«5-[P tC l2 (3 ,4 -d i(M e0C 2H 40-)C 6H 4C N )(N = C (3 ,4 -d i(M e0C 2H 40-)C 6H 4)-0 -  
N(Me)-CH(Ph)}](44).
Analytical data:
Formula: C3 4H4 3Cl2N3 0 9 Pt, pale yellow solid. MW 903.70, yield is 59%. Anal 
calc.%, C, 45.19; H, 4.80 ; N, 4.65 . It was not possible to obtain an elemental 
analysis as the product was waxy and impossible to scrape off the sides of the flask. 
Even when precipitated from solution with hexane and dried on a Schlenk line the 
powder sheared when the spatula attempted to scoop it up. Rf, eluent 3/1 DCM/ethyl 
acetate, 0.05.
*H NMR spectrum in CDCI3 , 6  (ppm): 3.04 (s, 3H, NMe), 3.78 (overlapped m, 8 H, 
CH2 of CH2 -O), 4.21 (overlapped m, 8 H, CH2  of O-CH2), 3.47 (overlapped m, 12H, 
MeO), 5.93 (s, IH of NCH), 6.92 (d, 8.5 Hz, ArC(6 )H, CgHaCN), 7.31 (d, 8.5 Hz, 
Ai*C(5)H, C6H3CN), 7.13 (s, ArC(2)H, CgHaCN), 7.70 (d, 6.7 Hz, 2AiCH, Ph of 
oxadiazoline ligand), 7.45 (m, 3Ai*CH, Ph of oxadiazoline ligand), 7.05 (d, 8.5 Hz, 
Ai*C(5)H, of N=C-C6H3 of oxadiazoline ligand), 8.58 (d, 2.0 Hz, ArC(6 )H of
N=C-CôH3 of oxadiazoline ligand, 8.5 Hz), 8.79 (s,"' '^"J 2.0 Hz, 1 ArC(2)H ofN=C- 
C6H3 of oxadiazoline ligand ).
" c  NMR spectrnm in CDCI3 , 8 (ppm): 46.2 (NMe), 70.5, 70.6, 70.7, 70.8 (4C of O- 
CHa), 6 8 .6 , 68.7, 68.9, 69.0 (4C of CHa-O), 59.38, 59.33, 59.27, 59.20 (4C of OMe),
154.9,154.1 (2C, AiC(4)-0), 149.2,148.4 (2C, ArC(3)-0), 116.0 (ArC(2)H, CsHj of 
oxadiazoline ligand ), 112.9 (ArC(5)H, CgHs of oxadiazoline ligand), 125.7 
(ArC(6 )H, CgH3 of oxadiazoline ligand ), 128.7, 128.6 (overlapped signals) (5C, 
Ai'CH, Ph of oxadiazoline ligand), 117.1 (Ai*C(6 )H of nitrile ligand), 113.1 (AiC(2)H 
of nitrile ligand), 129.8 (ArC(3)H of nitrile ligand), 94.8 (NCHN of heterocycle),
117.3 (CN), possibly 114.2 (ArC(l) of nitrile ligand), not seen (C=N), possibly 123.4 
(ArC(l), CôH3 of oxadiazoline ligand), possibly 130.0 (Cq, Ai'C(l) of Ph).
‘®’Pt NMR spectrum in CDCI3 , 8  (ppm): -2217.4 (1320 Hz).
IR, (KBr), selected band, cm ': 2284v(teN), 1594v(C=N).
MS-FAB, m/r. 903.9 [M]* 925.9 [M+Na], 830.1 [M-2HC1],
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8.7 Trans platinum(ll) bis oxadiazolme complexes with hydroxy groups.
Below is a typical procedme for the manufactm'e of a platmum(H) bis oxadiazoline 
complex. Specific conditions are included in table 23 below.
Preparation of ^ i*fl«s-[PtBr2{N=C(Ph)-0“N(Me)-CH(Ph)}2].
rraK5 -PtBr2 (PhCN) 2  (28 mg, 0.05 mmol) and C-phenyl-W-methyl-nitrone (15.6 mg, 
0 . 1 2  mmol) were dissolved in deuterated chloroform ( 1  ml) and placed in a vial with 
magnetic stirrer bar and fitted with an airtight lid. This was placed m a sand bath at 60 
for 48 horns. The reaction was monitored periodically by proton NMR, observing 
the disappeaiance of a doublet at 9.00 ppm which represents the ortho phenyl protons 
of the mono oxadiazoline platinum, and the appearance of signals between 8.60 and
8.80 ppm which correspond to the ortho phenyl protons of the deshed bis 
oxadiazoline platinum. The product is purified by column chromatography using 
DCM as eluent.
Prod. No. Reaction Conditions Work-Up Conditions
45 2.2/1 molar ratio, acetone, 7 days, 50°C Reduce under vacuum, wash with ether.
46 2.2/1 molar ratio, acetone, 7 days, 50”C Chromatography/DCM/EA, 10/1, as eluent
47 2 .2 /1  molar ratio, acetone/CHCb 1/1, 7 
days, 50°C
Insoluble diastereoisomer recovered by 
filtration and washed witli ether. 
Remaining solution underwent 
chromatography / DCM/EA, 4/1,as eluent
48 2.2/1 molar ratio, acetone/CHCb 1/1, 7 
days, 50“C
Insoluble diastereoisomer recovered by 
filti'ation and washed with ether. 
Remaining solution underwent 
chromatography / DCM/EA, 4/1,as eluent
49 2.2/1 molar ratio, CHCb, 7-10 days, 50°C Chromatography / DCM/EA, 4/1 as eluent
50 2.2/1 molar ratio, CHCI3, 7-10 days, 50°C Chromatography / DCM/EA, 4/1 as eluent
52 2.2/1 molar ratio, chloroform, 60“C,72 hrs Chromatography / DCM, as eluent
53 2.2/1 molar ratio, acetone, 60°C, 5days Reduce under vacuum. Chromatography/ 
ether as eluent
55 2.2/1 molar ratio, chloroform, 60°C,72 hrs Chromatography / DCM as eluent
Table 23. Reaction conditions and work-up procedures of bis oxadiazoline platinum 
complexes.
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8.7.1. Reaction of [PtClzfy^-HO-Cgff^CN)!] with PhCH=NOMe 
/ra«^-[PtCl2{N=C(p-H0-C6H4)-0-N(Me)-CH(Ph)}2](45).
Analytical data;
Yellow cream solid, yield is 55%. 2 diastereoisomers in 55/45 proportion.
Formula: C3oH2 sCl2N4 0 4 Pt, MW 774.4. Anal, calc.%, C, 46.51; H, 3.64 ; N, 7.20 . 
Found: C, 46.02; H, 3.62; N, 7.46.
*H NMR spectrum in de-acetone, 500 MHz,
1®* diastereoisomer; d (ppm): 2.94 (broad s, 6H, NMe), 5.92 (br. s, 2H of NCH), 6.88 
(d, 8.5 Hz, 4H, ArC(3,5)H)(CeH4), 8.82 (br. d, 4H, unresolved, ArC(2,6)H)(CeH4), 
7.45 (br. m, 6H, Ph), 7.60 (br. m, 4H, Ph), 9.50 (s, 2H, OH).
*^ P^t NMR spectrum in de-acetone / D2 O / Na2 C0 3 , ô (ppm): -2027.3 (1075 Hz), de­
acetone, 2120.6.
2"^  diastereoisomer (mixture with H*); 6: 2.95 (broad s, 6H, NMe), 5.95 (br. s, 2H of 
NCH), 7.00 (br. d umesolved, 4H, ArC(3,5)H)(CeH4), 8.78 (br. d unresolved, 
ArC(2,6)H)(CeH4), 7.43 (br. m, 6H, Ph), 7.66 (br. m, 4H, Ph). *^ P^t NMR spectrum in 
de-acetone / D2 O /N a 2 C0 3 , -2048.8 (1075 Hz), in de-acetone 2141.2.
*^ C NMR spectrum in de- acetone, 10% D2 O, Na2 C0 3 , 6 (ppm): 45.6 (NMe), 94.2 
(NCHN), 104.3 (ArC(l), CeH4 , Cq), 119.6 (3,5), 133.3 and 133.4 (2,6, 2 
diastereoisomers)(8 ArCH of CeH^), 128.5 (2,6 or 3,5), 128.6 (3,5 or 2,6), 129.0 (4) 
(10 ArCH, Ph), 163.3 (C=N of oxadiazoline ring), 164.3 (ArC(4)-0), 137.3 Cq of Ph. 
IR, (KBr), selected band, cm"*: 1607 v(C=N).
MS-FAB, m/z: 774.7 [M]\ at 703.8 [M - 2HC1] ,^ 798 [M + Na]% 814 [M + K ]\
8.7.2. Reaction of /raw5-[PtCl2»2-HO-C4HeCN)2] with PhCH=NOMe 
/ra«5--[PtCl2{N=C(w-H0-CeH4)-0-N(Me)-CH(Ph)}2](46).
(unstable in soln. de-acetone)
Analytical data:
Yellow cream solid, yield is 43%. 2 diastereoisomers in roughly 50/50 proportion. 
Foimula: C3oH28Cl2N404Pt, M 774.4. Anal, calc.%, C, 46.51; H, 3.64 ; N, 7.20 . 
Found: C, 44.16; H, 3.75; N, 6.40.
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*H NMR spectrum in de-acetone, 6  (ppm): 2.97 (sharp s, 6 H, NMe), 5.91, 5.99 (2 
diastereoisomers)(s, 2H of NCH), 7.21, 7.18 (2 diastereoisomers, multiplets, 2 
ArC(4)H of CeH4 -C=N), 7.43, 7.38 (2 diastereoisomers, overlapped multiplets, 2 
ArC(5)H, CeH4 -C=N), 7.43, 7.38 (2 diastereoisomers, overlapped multiplets, 6  Ai*C(4 
and 2,6)H, of Ph.), 7.59, 7.65 (2 diastereoisomers, overlapped multiplets, 4 
Ai‘C(3,5)H, of Ph.), 7.89, 7.94 (2 diastereoisomers, broad pah of singlets, 2ArC(2)H, 
CôH4 -C=N), 8.62, 8.72 (2 diastereoisomers, pair of doublets, 7,5 Hz, 2AiC(2)H, 
C6H4 -C=N), 8.95 ( s, 2H, OH).
*^ C NMR spectrum in de-acetone, Ô (ppm): 46.5 (NMe), 95.5 (NCHN), 117.4, 117.5 
(2 diastereoisomers) (Ai*C(2)H of CeH4 -C=N), 122.9, 123.1 (2 diastereoisomers) ( 
ArC(6 )H of CeH4 -C=N), 121.6 (ArC(4)H of CeH4 -C=N), 129.43, 129.39 (2 
diastereoisomers, Ai*C(5)H of CgH4 -C=N), 122.9 (ArC(l), Cq of CeH4 -C=N ), 129.0 
(ArC(3,5)H of Ph), 129.9 (ArC(2,6)H of Ph), 130.59, 130.64 (2 diastereoisomers, 
ArC(4)H of Ph), 158.0 (Ai’C(3)-0), 164.3 (C=N of oxadiazoline ring), 135.2 (Cq, Ph). 
*^ P^t NMR spectrum in de-acetone, ô (ppm): -2133.6 (1075 Hz)..
IR, (KBr), selected band, cm"*: 1605 v(C=N).
MS-FAB, m/z: 774.0 [M \\ at 701.1 [M - 2HC1], 798.0 [M + Na], 672.1 [M-PhCN],
568.0 [M-2PhCN].
8.7.3. Reaction of/ra«^-[PtCl2 (CeH5 CN)2 ] with/7-HO-CeH4 CH=NOMe 
P-a«5 -[PtCl2 {N=C(Ph)-0 -N(Me)-CH(p-H0 -CeH4)}2 ](4 7 ).
Pale yellow solid, the yield is 48%. 2 diastereoisomers in roughly 5/2 proportion 
Formula: C3oH2 8Cl2N4 0 4 Pt, MW 774.4. Anal, calc.% C: 46.51; H; 3.64; N: 7.23; 
found, C: 45.97; H: 3.61, N: 7.46.
*H NMR spectrum in de-DMSO, Ô (ppm): 2,88 (s, 6 H, NMe), 5.86 (s, 2H of NCH), 
6.84 (d, 8 . 6  Hz, 4H(3,5), C6H4), 7.41 (d, 8 . 6  Hz, 4H(2,6), CeH4), 7.57 (t, 8.0 Hz, 4H, 
ArC(3,5)H, PhC=N), 7.81 (t, 8.0 Hz, 2H, ArC(4)H, PhC=N), 8.74 (d 8.0 Hz, 4H, 
AiC(2,6)H, PhC=N), 9.69 ( s, H, OH).
*^ C NMR spectrum in de-DMSO, Ô (ppm): 45.5 (NMe), 93.6 (NCHN), 114.9 (3,5),
129.8 (2,6) ( 8  ArCH, CeH4), 133.8 (2C, ArC(4)H of Ph), 128.4 (4C, ArC(3,5)H of 
Ph), 129.9 (4C, ArC(2,6)H of Ph), 123.5 (C q, ArC(l) of N=CPh), not seen (C q, 
ArC(l) of C6H4), 158.3 (ArC(4)0), 162.5(C=N).
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'’^Pt NMR spectrum in de-acetone, ô (ppm): -2118.8, possibly -2115.0 (1075Hz).
IR, (KBr), selected band, cm *: 1604 v(C=N).
MS-FAB*, m/z: 775.1 [M]*, 701.9 [M-2HC1], 737.1 [M -H C l], 797.2 [M + Na].
8.7.4. Reaction o f /rans-[PtCl2(C6H5CN)2] with m-HO-CeHeCH^NOMe 
poHs-[PtCl2{N=C(Ph)-0-N(Me)-CH(m-H0-C6H4)}2](48).
Pale yellow solid, the yield is 51%. 2 diastereoisomers one of which precipitates. 
Precipitated diastereoisomer.
Formula: C3oH2 8 Cl2N4 0 4 Pt, MW 774.4. Anal. calc.(for mixture of diastereoisomers) 
C, 46.51; H, 3.64 ;N, 7.20 . Found: C, 45.02; H, 3.78; N, 6.46.
'H NMR spectrum in d«-acetone, 8  (ppm): 2.97 (s, 6 H, NMe), 8.74 (s, 2H of OH), 
5.94 (s, 2H ofNCH),.6.95(d, 9.1 Hz, 2H, ArC(2 or 4)H of CsHr-CH-N, ), 7.08 (s, 2 H, 
ArC(2 or 4)H of CeHt-CH-N), 7.15 (d, 9.1 Hz, 2H, ArC(6 )H of C6H4 -CH-N), 7.30 (t,
9.1 Hz, 2H, AiC(5)H of C«H,-CH-N), 7.49 (t, 8.5 Hz, 4H, ArC(3,5)H of PhC=N),
7.71 (m, 2H, ArC(4)H of PhC=N), 8.62 (d, 8.5 Hz, 4H, ArC(2,6)H, Ph of PhC=N).
"C  NMR spectrum in d^-acetone, 5 (ppm): 46.1 (NMe), 94.9 (NCHN), 115.6 
(ArC(2 or 4)H of CoHt-CH-N), 116.5 (ArC(4 or 2)H ofC«H4-CH-N), 120.2 (ArC(6)H 
ofCgHt-CH-N), 129.3 (ArC(5)H of C6H4 -CH-N), 128.9 (2C, ArC(3,5) of PhO N  ),
130.5 (2C, ArC(2,6) of PhO N ), and 133.8 (1C, ArC(4) of PhC=N), not seen (Cq, 
N=CPh), not seen (C q, C 6H 4) ,  not seen (O N ), 159.0 ArC(3)-0.
Soluble diastereoisomer.
Formula: C3oH28Cl2N404Pt, MW 774.4. *H NMR spectrum in de-acetone, 8 (ppm): 
2.99 (s, 6H, NMe), 8.50 (s, 2H of OH), 5.95 (s, 2H of NCH), 6.96 (d, 9.5 Hz, 2H, 
ArC(4)H of CeHt-CH-N), 7.09 (s, 2H, AiC(2)H of CeHe-CH-N), 7.16 (d, 9.5 Hz,2H, 
ArC(6)H of CeHe-CH-N), 7.31 (t, 9.5 Hz, 2H, AiC(5)H of CeHe-CH-N), 7.48 (m, 4H, 
AiC(3,5)H of PhC=N ), 7.72 (m, 2H, ArC(4)H of PhC=N), 8.87 (d, 8.1 Hz, 4H, 
ArC(2,6)H, PhofPhC=N).
'^C NMR spectrum in de-acetone, 8 (ppm): 45.8 (NMe), 94.9 (NCHN), 115.4 
(ArC(2 or 4)H of CeHq-CH-N), 116.3 (ArC(2 or 4)H of CeHi-CH-N), 120.0 (ArC(6)H 
ofCeHe-CH-N), 130.5 (ArC(5)H of CeHe-CH-N), 128.5 (ArC(3,5) ofPhC=N ), 130.5 
(ArC(2,6) of PhC=N), and 133.7 (ArC(4) of PhC=N), possibly 122.8 (C q , N=CPh),
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127.5 (Cq, C6H4 ), 157.6 (ArC(3)0), possibly 160.9 (C=N).
NMR spectrum in de-acetone, ô (ppm): -2148.9 (1075 Hz), one isomer seen.
IR, (KBr), selected band, cm'*: 1601 v(C=N).
MS-FAB, m/z\ 775.1 [M ]\ 701.9 [M - 2HC1], 737.1 [M -  HCl], 797 [M + Na] . 
oxadiazoline free ligand at 255.
8.8. Platinum(II) bis oxadiazoline complexes with glycol ether substituents.
Specific reaction conditions and work-up procedures are contained in table 23.
8 .8 .I.Reactionof /r««5 -[PtCl2 (p-Me0 C2H4 0 -C4H6 CN)2 ] with PhCH=NOMe 
/rfl«5 -[PtCl2 {N=C(p-Me0 -C2H4 0 -CeH4)-0 -N(Me)-CH(Ph)}2](4 9 ).
NMR showed a mixture of diastereoisomers, roughly 50/50 proportions.
Yellow solid 40 mg, yield approximately 45%.
Analytical data:
Formula: C36H4 oCl2N4 0 6 Pt, MW 890.7. Anal, calc.% C: 48.54; H: 4.52; N: 6.29; 
found, C: 47.28; H: 4.53, N: 6.29.
*H NMR specti-um in CDCI3 , 2 diastereoisomers 50/50, ô (ppm): 2.91, 2.94 (s, 6 H, 
NMe), 3.79 (m, 4H, CH2 O), 4.19 (m, 4H, OCH2 ), 3.47 (m, 6 H, OMe), 5,88 (s, 2H of 
NCH), 6.82 (m, 4H, ArC(3,5)H, of C6H4 O), 7.48 (m, 6 H, of Ph), 7.60 (m, 4H, of Ph),
8 . 6 6  (d, 8.5 Hz, 2H, AiC(2,6)H, CelHO), 8.82 ( br. m, 2H, ArC(2,6)H, C6H4 O). (The 
last 2 signals equivalent to 4 protons and indicative of 2 diastereoisomers).
*^ C NMR spectrum in CDCI3 , ô (ppm): 162.9 (ArC(4)-0), 133.0, 132.7 
(2 diastereoisomers), 114.3 (4C AiCH (2,6 and 3,5 of C6H4 O)), 129.6 (AiC (1)-C=N),
136.4 (ArC (l)-C-N of Ph.), 128.5, 128.6 and 129.5 (5C, AiCH of Ph), 70.8 (CH2 -O),
67.6 (0-CH2), 59.3 (OMe), 46.3 (NMe), 94.7 (NCHN), 163.0 (C=N of oxadiazolme 
ring).
*^ P^t NMR spectrum in CDCI3 , 8  (ppm): -2106.8 (775 Hz) and -2124.2 (775 Hz), 2 
diastereoisomers in roughly equal proportion.
IR, (KBr), selected band, cm'*: 1605v (C=N).
MS-FAB, m/z: 891.2 [M]^ 913.1 [M+Na], 854.2 [M-HCl], 817.3 [M-2HC1], 788.2 
[M-PhCN].
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8.8.2. Reaction of/raw5 -[PtCl2 (C6H5 CN)2 ] withp-Me0 -C2H4 0 -C6H4 CH=N0 Me 
/ra«^-[PtCl2{N=C(Ph)-O-N(Me)-CH(p-MeO-C2H4O-C6H4)}2](50).
NMR showed a mixture of diastereoisomers in roughly 60/40 proportion. 
Yellow/brown solid 40 mg, yield approximately 41%.
Analytical data:
Formula: C36H4oCl2N4 0 6 Pt, MW 890.7. Anal, calc.% C: 48.54; H: 4.52; N: 6.29; C: 
46.86; H: 4.50; N: 6.30.
NMR spectrum in CDCI3 , 2 diastereoisomers 60/40, 6  (ppm): 2.91, 2.94 (s, 6 H, 
NMe), 3.78 (m, 4H, CH2 O), 4.18 (m, 4H, OCH2  ), 3.46 (m, 6 H, MeO), 5.85 (s, 2H of 
NCH), 7.39 (m, 4H, Ai*C(3,5)H, of PhC=N), 7.65 (overlapped multiplet, possibly 
2H, ArC(4)H of PhC=N), 7.49 (overlapped m, 4H, of C6H4 O), 7.01 (d, 4H, 
ArC(3,5)H of C6H4 O, 8.0 Hz), 8 . 6 6  (d, 8.0 Hz, ArC(2,6)H, PhC=N, ), 8.77 ( broad 
multiplet, ArC(2,6)H, PhC=N). (The last 2 signals equivalent to 4 protons and 
indicative of 2  diastereoisomers).
" c  NMR spectrum in CDCI3 , 8  (ppm): 159.9 (ArC(4)-0), 130.6,130.5, 130.2 (5C 
ArCH (PhC=N)), 114.6 (3,5), 128.3 (2,6) (4C o f  Q H 4O ), 71.0 (CH2-O), 67.3 (O- 
CH2), 59.3 (OMe), 46.1 (NMe), 94.5 (NCHN), 163.9 (C=N o f  oxadiazoline ring),
132.3 (Cq, CHPh), 125.8, (C q o fC « H 4 0 ) .
'’^Pt NMR spectrum in CDCI3 , 8  (ppm): -2103.4 (775 Hz) and -2120.3 (1075 Hz), 2 
diastereoisomers in roughly 60/40 proportion.
IR, (KBr), selected band, cm'^: 1605v (C=N).
MS-FAB, m/z: 891.0 [M]\ 854.2 [M-HCl], 817.0 [M-2HC1], 788.9 [M-PhCN].
8.9 PIatinum(lI) dibromo oxadiazoline complexes.
Specific reaction conditions and work-up procedures are contained in table 22 (mono 
cycloadduct), and table 23 ( bis cycloadduct).
8.9.1. Preparation of ^ raw.y-[PtBr2(PhCN){N=C(Ph)-0-N(Me)-CH(Ph)}](51). 
Analytical data:
Formula: C2 2Hi9Br2N3 0 pt, yellow orange solid, the yield is 73%.
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Anal, calcd for CiiHigBraNsOPt; MW 696.29,%, C, 37.95; H, 2.75; N, 6.03. Found: 
C, 38.22; H, 2.71 ;N, 5.86.
'H NMR (500 MHz, CDCI3) S (ppm): 3.08 (s, 3H, NMe), 6.00 (s, IH, N-CH-N), 7.45 
(m, 3H) and 7.73 (d, 7.4 Hz, 2H)(CH-Ph), 7.59 (t, 7.7 Hz, 2H), 7.66 (m, IH) and 9.00 
(d, 8.1 Hz, 2H)(N=C-Ph), 7.50 (t, 7.7 Hz, 2H), 7.66 (m, IH) and 7.69 (m, 
2H)(NsCPh).
"C  NMR ( 1 2 5 .7  MHz, C D C I3)  5 (ppm): 4 6 .4  (NMe), 9 5 .6  ( N - C H - N ) ,  1 1 0 .2  (Q,, 
N s C P h ) ,  1 1 8 .5  (O N ), 1 2 2 .5  ( C q ,N = C P h ) ,  1 2 8 .7 ,  1 2 8 .8 ,1 3 0 .1  ( 5 C , ArCH of C H P h ) ,
1 2 9 .4 ,  1 3 3 .7 , 1 3 4 .2  (5 C , ArCH of PhCN), 1 2 9 .3 ,  1 3 1 .1 ,  1 3 4 .9  (5 C . AiCH ofN=CPh),
1 3 5 .6  (C q , C H P h ), 1 6 4 .4  (O N ).
*” Pt NMR (107.3 MHz, CDCI3) 8  (ppm): -2693 (750 Hz).
IR spectrum (selected hands), cm"': 2291 w v(O N ), 1622 w v(C=N).
MS-FAB*, m/z: 696.8 [M]*. 615.9 [M -  H B rf, 535 [M -  2 H B rf, [M -  PhCN]*, 
432.2 [M -  2 HBr -  PhCN]*.
Accurate MS-FAB*, m/z: 694.5350 for C2 2Hi9Br*'BrN3 0 '^‘'Pt, theoretical 694.96.
8.9.2. Preparation of /r«n^-[PtBr2{N=C(Ph)-0-N(Me)-CH(Ph)}2](52).
Analytical data:
Formula: C3oH2 8Br2N4 0 2 Pt, yellow orange solid, the yield is 71%.
Anal, calcd for C3oH2 sBr2N4 0 2 Pt: MW 831.46,%, C, 43.34; H, 3.39; N, 6.74. Found: 
C, 42.91; H, 3.26; N, 6 .6 8 .
NMR (500 MHz, CDCI3) ô (ppm): Fii*st diastereoisomer, 2.99 (s, 6 H, NMe), 5.98 
(broad s, 2H, N-CH-N), 7.62 (m, 2H, ArC(4)H, C=NPh), 7.40 (m, 4H, ArC(3,5)H, 
C=NPh) and 8 . 6 8  (d, 7.8 Hz, 4H, ArC(2,6)H, N=C-Ph), 7.57 (m, 4H, ArC(2,6 or 
3,5)H, CHPh), 7.43, 7.47 (m, 6 H, ArC(4, and 2,6 or 3,5)H of CHPh)).
Second diastereoisomer (mixture with first diastereoisomer). 2,99 (s, 6 H, NMe),
5.81 (broad) (s, 2H, N-CH-N), 7.51 (overlapped m, 6 H, ArC(4 and 3,5)H of N=CPh 
and 4H, ArC(3,5 or 2,6)H of CHPh), and 7.59 (broad m, 6 H, ArC(4 and 3,5 or 2,6)H 
of CHPh), and 8.83 (broad m, 4H, ArC(2,6)H, N-C-Ph).
^^ C NMR (125.7 MHz, CDCI3) 6  (ppm): mixture of diastereoisomers, 46.5 (NMe),
95.8 (N-CH-N), 123.0 (C q, N = C P h ) ,  136.2 (C q of CHPh), 131.0 (2C, ArC(2,6)H of
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C=NPh), 130.9 (2C, ArC(3,5)H of C=NPh), 133.4 (C, ArC(4)H of C=NPh), 129.3, 
128.5,130.0 and 129.9 (5C, ArCH of CHPh), 163.5, 164.8 (C=N),
^^^tNMR (107.3 MHz, CDCI3) Ô (ppm): -2523 (1500 Hz).
IR spectrum (selected bands), cm~ :^ 1628s v(C=N).
MS-FAB^ m/z: 831.8[M^], 750.9 [M -  H Brf, 670.0 [M -  2 HBrf, 464.0 [M -  2 HBr 
-2PhC N ]\
Accurate MS-FAB^, m/z: 831.426 for C3 0H2 8B1' BrN4 0 2 Pt, theorectical 831.0201. 
8.9.3. Preparation of /rârw^-[PtBr2 {N=C(j!7-0 H-C6H4 -)-0 -N(Me)“CH(Ph)}](5 3 ). 
(Impur e, contains possibly a dimeric platinum oxadiazoline complex)
Impurity data (obtained by comparison with the spectra of similar products):
^H NMR spectrum in de-acetone, ô (ppm ): 2.75, (broad s, 6 H, NMe), 6.10 (broad s, 
2H, NCH), 8.87 (broad rn, 4H, ArC(2,6)H of /?-OH-C6H4-C=N), 6.95 (broad m, 4H, 
ArC(3,5)H of p-0H-C6H4-C=N), 7.45 (broad overlapped multiplet, lOArCH of 
PhCN), 9.60 (s, OH).
*^ C NMR spectrum in de-acetone, ô (ppm): 40.6 (NMe), 95.2 (NCHN) from HMQC, 
N=C-CeH4  and CHPh carbons between 125.0 and 135.0.
^^ P^t NMR spectrum in de-acetone, Ô (ppm): -2538.5 broad; (1500 Hz).
Proposed structure;
oxa ^Br Br
Analytical data: (desired product).
Yellow orange solid, yield is 49%, 2 diastereoisomers.
Formula: C3oH2 8Br2N4 0 4 Pt, MW: 863.45. Anal, calcd for C3oH2 8Br2N4 0 4 Pt:%, C, 
41.73; H, 2.84; N, 6.49. Found: C, 42.33; H, 3.17; N, 6.50. ^H NMR spectrum in de­
acetone, Ô (ppm): 3.00 (broad s, 6 H, NMe), 6.05, 5.91 (broad s, 2H of NCH), 7.40, 
7.46, 7.70, (broad multiplets, lOH of PhCN), 8.65, 8.80, (broad m, 4H, ArC(2,6)H of 
p-OH-CeH4 C=N), 7.07 (m, 4H, AiC(3,5)H ofp-OH-CeH4 -C=N, 8 . 6  Hz), 9.65 (broad 
s, OH).
^^ C NMR spectrum in de-acetone, ô (ppm): 45.6 (NMe), 94.2 (NCHN), 104.3 (Cq, 
ArC(l), C=NCeH4 -0 ), 134.0 (2,6), 116.0 (3,5)(4C, ArCH of ;?-OH-CeH4 -C=N),
130.1, 128.9, 129.9 (5C of Ph), 131.0 (Cq, ArC(l), CHPh), 163.2 (C=N of
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oxadiazoline ring), 163.0 (AiC(4)-0).
NMR spectrum in de-acetone, ô (ppm): -2518.0 broad; -2518.5 sharp (535 Hz). 
IR, (KBr), selected band, cm"\ 1608 v(C=N).
MS-FAB, m/z\ 863.7 [M]\ at 782.8 [M - HBr], 701.9 [M - 2HBr], 8 8 6 . 8  [M + Na].
8.10. Platmum(n) diiodo oxadiazoline complexes.
Specific reaction conditions and work-up procedures aie contained in table 22 (mono 
cycloadduct), and table 23 ( bis cycloadduct).
8.10.1. Prepaiation of ?ran5 -[Ptl2 (PhCN){N=C(Ph)-0 -N(Me)-CH(Ph)}](5 4 ).
Analytical data:
Pale brown solid, the yield is 76%.
Anal, calcd for C2 2Hi9l2N3 0 Pt: MW 790.29, C, 33.44 ; H, 2.42; N, 5.32 . Found: C, 
33.30; H, 2.38; N, 5.08.
'H NMR (500 MHz, CDCI3) 5 (ppm); 3.11 (s, 3H, NMe), 6.07 (s, IH, N-CH-N), 7.51 
(3,5), 7.68, 7.70 (2,6 and 4), (PhCN), 8.93 (d, 8.0 Hz, ArC(2,6)H)(N=C-Ph), 7.57 
(overlapped m, 3H)(N=CPh), 7.46 (2,6 or 3,5), 7.76 (3,5 or 2,6),
7.77 (AiC(4)H)(overlapped multiplets, CHPh).
^^ C NMR (75 MHz, CDCI3) Ô (ppm): 46.1 (NMe), 96.4 (N-CH-N), 110.2 (C q, 
N^CPh), 121.9 (N=C), 122.6 (C q , N=CPh), 134.7, 131.0, 128.6 (5C, ArCH of 
N=CPh), 133.9, 133.3,129.3 (5C, ArCH of PhCN), 128.4, 129.6,130.1 (5C, ArCH of 
CHPh), 133.5 (C q, CHPh), 164.4 (C=N).
^^^PtNMR (107.3 MHz, CDCI3) Ô (ppm): -3695.4 (750 Hz)
IR spectrum (selected bands), cnf^: 2290 v(C=N), 1622 v(C=N).
MS-FAB+, m/z\ 790.9 [M]f 661.9 [M -  H lf , 533.9 [M -  2 H lf , 431.0[M -  2 HI -  
PhCN]\
8.10.2. Preparation of/raw-[Ptl2 {N=C(Ph)-0 -N(Me)-CH(Ph)}2](5 5 ).
Analytical data:
Pale brown solid, the yield is 6 8 %.
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Anal, calcd for C3oH2 «l2N4 0 2 Pt: MW 925.46, C, 38.93; H, 3.05; N, 6.05. Found: C, 
38.42; H, 3.02; N, 5.75.
Due to many of the signals of the two diastereoisomers being distinct and fully 
assignable, the results are presented in tabular form for claiity.
1^ * diastereoisomer, yield 45% 2"*' diastereoisomer, yield 55%
Nucleus ppm H ppm ppm H ppm
C=NPh, ortho 133.24"'' d, 7.3 Hz, 8.74 133.16 d, 7.3 Hz, 8.59
C=NPh, meta 128.6 m, 7.46 128.4 t, 8.0 Hz, 7.30
C=NPh, para 129.84 m, 7.64 
o/lapped
129.76 m, 7.65 
o/lapped
CqC=NPh 122.7 Na 123.1 Na
C=N (oxa) 164.2 Na 163.5 Na
NMe 46.3 Br s, 3.03 46.1 Br s, 3.00
CHPh 97.2 Br s, 5.81 96.4 Br s, 6.18
CHPh, ortho 128.1 7.45, 7.49, 
7.64 o/lapped
128.2 7.48, 7.66 
o/lappedCHPh, meta 130.8 130.7
CHPh, para 129.6 129.6
CqCHPh 135.7 or 136.0 Na 136.0 or 135.7 Na
li b. Where carbon signals have been gi\en to two decimal places it is to differentiate from anotlier 
close signal.
Table 24. The proton and "C NMR of trans-[Ptl2 {N=C(Ph)-0 -N(Me)-CH(Ph)}2]
*®^Pt NMR (107.3 MHz, CDCI3) 8  (ppm): 2 diastereoisomers, -3445, -3458 ( Hz).
IR spectrum (selected hands), cm"': 1635s v(C=N).
MS- FAB*, m/z: 925.8[M*], [M -  HI]*, [ M - 2  HI]*, [M -  2 HI -  2PhCN]*.
8.11. Mono cycloadditions using the dinitrone of terephthaldeliyde.
Reaction of /r«w5’-[PtCl2 (PhCN)2 ] with 1,4- di(HC=N(Me)0 )-C6H4
Preparation of/ra«5 ,/ran^-[l,4 -di{PtCl2 (PhCN)(N=C(Ph)-0 -N(Me)-CH)}-(C6H4 ]
(56).
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specific reaction conditions and work-up procedures are contained in table 2 0 . 
Formula Pt2 Cl4N6 0 2 C3 8H3 2 , MW 1136.67, yellow crystalline solid, yield 71% Anal. 
calcd:%, C, 40.15; H, 2.84; N, 7.39. Found: C, 40.15; H, 2.97; N, 7.50.
2 diastereoisomers in roughly 60/40 proportion.
NMR (500 MHz, CDCI3) Ô (ppm): 3.05 (s, 6 H, NMe), 6.07, 6.04 (s, 2H, N-CH- 
N), 7.80 (d, 4 Ai*C(2,6)H, 7.5 Hz)(PhCN), 7.57 (overlapped m ArC(3,5)H)(PhCN), 
7.75 (m, Ai’C(4)H,)(PhCN), 7.60 (overlapped m, AiC(3,5)H)(N=C-Ph), 7,68 
(overlapped m, ArC(4)H)(N=C-Ph), 8.98 (overlapped m, AiC(2,6)H)(N=C-Ph), 
7.88, 7.90 (s, 4 H)(N-C-C6H4 -C-N).
NMR (75 MHz, CDCI3) Ô (ppm): 46.0 (NMe), 94.2 (N-CH-N), 121.6 (2C)(Cq, 
PhN=C), 130.8 (4C, Ai-CH(2,6))(PhC=N), 129.3 (4C, ArCH(3,5))(PhC=N), 134.7 
(2C, ArCH(4))(PhC=N), 134.1 (4 C(2 ,3 ,5 ,6 )(CôH4), 129.1 (2C)(Cq, C6H4-CHN)
133.8 (4 C , ArCH(2,6)(PhCN), 128.6 (4 C ,  ArCH(3,5)(PhCN), 135.3 (2C, 
A iC H ( 4 ) ( P h C N ) ,  109.8 (2C, C q )(P h C N ), 116.6 (2C, C N )( P h C N ) , 165.0, 165.8 
(2C)(C=N).
^^ P^t NMR, CDCI3) Ô (ppm): -2246.1 (1070 Hz).
IR, (KBr), selected band, cm ^ 2286 v(C=N), 1601 v(C=N).
MS-FAB, m/z\ 1136.9 [M]\ 1100.0 [M-HCl], 1063.0 [M-2HC1], 1032.8 [M-PhCN],
929.8 [M-2PhCN].
Reaction of cz^-[PtCl2 (PhCN)2 ] with 1,4- di(HC=N(Me)0 )-C6H4  
Preparation of cw,m -[l,4 -di{PtCl2 (PhCN)(N=C(Ph)-0 -N(Me)-CH)}-(C6H4 ].
This complex was unstable turning green as the reaction progressed, so only a partial 
characterisation is provided. The product was not isolated.
‘H NMR (500 MHz, CDCI3 ) 8  (ppm): 3.11 (s, 6 H, NMe), 6.25 (s, 2H, N-CH-N),
7.82 (d, 4 ArC(2,6)H, 7.7 Hz)(PhCN), 7.59 (overlapped m ArC(3,5)H)(PhCN), 7.74 
(m, ArC(4)H,)(PhCN), 7.57 (overlapped m, ArC(3,5)H)(N=C-Ph), 7.67 (overlapped 
m, ArC(4)H)(N=C-Ph), 9.03(br), 9.09 (overlapped m, ArC(2,6)H)(N=C-Ph), 7.88, 
7.90 (s, 4 H)(N-C-C6H4 -C-N).
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8.12. Platiniim(IV) oxadiazoline complexes; oxidative additions reactions.
A typical procedure for the oxidation reactions is shown below.
Preparation of /rfl«5 -[PtCl4 (PhCN)(oxa)].
/ra«5 -[PtCl2 (PhCN){N=C(Ph)-0 -N(Me)-CH(Ph)}] (30 rag, 0.05 mmol) were 
dissolved in deuterated chloroform (0.5 ml) in an NMR tube and dry chlorine gas 
bubbled through the solution using an NMR tube pipette (in the case of bromuration, 
an equimolar amount of bromine dissolved in deuterated chloroform was used). When 
a colour change is observed from cold yellow to warm yellow n.b. (approximately 30 
seconds depending on the flow rate), proton NMR is performed to monitor the 
progress of the reaction. The disappearance of the broad singlet at 5.90 ppm and 
appear ance of a sharp singlet at 6.72 ppm is indicative of a complete reaction. The 
product is precipitated with petroleum ether and washed with diethyl ether and dried 
in vacuo. N.b stated coloiu' change is for the chlorination only, for the brornination 
proton NMR is used to monitor the reaction and more bromine added if required.
8.12.1. Bromination of fran^-[PtCl2 (PhCN){N=C(Ph)-0 -N(Me)-CH(Ph)}](5 7 ).
Formula: PtBr2 Cl2N3 0 C2 2Hi9 , MW 767.197,
'H NMR (500 MHz, CDCI3) Ô (ppm): 3.26 (s, 3H, NMe), 6.84 (s, IH, N-CH-N), 7.80 
(d, 7.4 Hz, ArC(2,6)H), 7.57 (m, ArC(3,5)H), 7.42 (m, ArC(4)H)(PhCN or PhCHN), 
7.43, 7.55 (m, ArC(2,6 or 3,5)H), 7.57 (m, ArC(4)H)(PhCN or PhCHN), 7.55 (m, 
ArC(3,5)H), 7.69 (t, 7.5Hz, ArC(4)H), 8.32 (d, 7.5 Hz, Ar€(2,6)H)(N=C-Ph).
*^ C NMR (125.7 MHz, CDCI3) Ô (ppm) 46.8 (NMe), 93.8 (N-CH-N), 107.6 (C q, 
N=CPh), 118.1 (N=C), 123.2 (C q, N=CPh), 126.2 (CH), 127.9 (CH), 128.5 (CH),
129.1 (CH), 129.6 (CH), 134.3(CH), 136.4 (CH), (CHPh, N-CPh and N=CPh), 132.0 
(ArC(2,6)(N=CPh), 134.8(ArC(4)H), 137.7 (C q , CHPh), 173.8 (C=N).
^^ P^t NMR (107.3 MHz, CDCI3) Ô (ppm): -  649.0, (1000 Hz).
IR spectrmn (selected bands), cm“ :^ 2316 v(C=N), 1625, v(C=N).
MS-FABf w/z: 604.9 [M-2HBr], 568.9 [M-2HBr-HCl].
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8.12.2. Brornination of/r««^-[PtBr2(PhCN){N=C(Ph)-0-N(Me)-CH(Pli)}](58).
Formula: PtBr4N3 0 C2 2Hi9 , MW 856.100, Anal. calc, for C2 2 Hi9Br4N3 0 Pt:, C, 30.86; 
H, 2.22; N, 4.91. Found: C, 30.58; H, 2.21; N, 4.95. (red residue from the 
bromination of the chloro complex is a good fit for C2 2Hi9 Br4N3 0 Pt).
(initial product)
‘H NMR (500 MHz, CDCI3) S (ppm): 3.29 (s, 3H, NMe), 7.01 (s, IH, N-CH-N), 7.46 
(m, 3H), 7.39 (m, IH), 7.73 (m, IH), 7.80 (d, 8.0 Hz, 2H), 7.55 (overlapped m, 4H, 
(2H, ArC(3,5)H of N=C-Ph), 7.67 (overlapped m, 2H, (IH, ArC(4)H of N=C-Ph), 
8.35 (d, 7.5 Hz, 2H, ArC(2,6)H of N=C-Ph).
'^C NMR (125.7 MHz, CDCI3) 8  (ppm): 47.1 (NMe), not seen, possibly 93.0 (N-CH- 
N), not seen, possibly 111.0 (Cq, NsCPh), not seen, possibly 113.0 (NsC), not seen 
(Cq, N=CPh), 128.5 (CH), 128.8 (CH), 129.3 (CH), 129.7 (CH), 131.0 (ArC(2,6)H),
133.6 (CH), 135.7 (CH), ( N=CPh and N=CPh, CHPh), and not seen (C=N). 
' ” PtNMR (107.3 MHz, CDCI3) 8  (ppm): -  1649.1 (214 Hz).
(final product after precipitation of red residue, thought to be PhC(H)=NMe).
'H NMR (500 MHz, CDCI3) 8 (ppm), 4.16 (s, NMe), 7.55 (t, 7.4 Hz, (AiC(3,5)H),
7.67 (t, 7.4 Hz, (ArC(4)H), 8.24 (d, 7.4 Hz, ArC(2,6)H), 8.27 (s, HC=N),
‘^ C NMR (125.7 MHz, CDCI3) 8  (ppm): 52.03 (NMe), 150.6 (HC=N), 133.6 
(ArC(2,6)H), 135.7 (ArC(4)H), 129.7 (ArC(3,5)H).
Small signals also seen for bis bromo platinum oxadiazoline complex.
Red residue:
IR spectrum (selected bands), cm"' : 2315 v(C=N), 1627, v(C=N).
Anal. Calcd for CjiHiçBrqNsOPt: M.W. 856.1, C, 30.86; H, 2.22; N, 4.91. Found: C, 
24.88; H, 1.67; N, 4.18.
8.12.3. Chlorination of P-ans-[PtCl2 (PhCN){N=C(Ph)-0 -N(Me)-CH(Ph)}](5 9 ). 
Formula: PtCl,N3 0 C2 2H](), MW 678.29,
‘H NMR (500 MHz, CDCI3) 8  (ppm): 3.19 (s, 3H, NMe), 6 . 6 8  (s, IH, N-CH-N), 
7.36(t, 7.2 Hz, ArC(4)H), 7.40 (t, 7.2 Hz, ArC(3,5 or 2,6)H), 7.54 (overlapped m, 
ArC(2,6 or 3,5)H)(PhCH-N); 7.87 (d, 8.0 Hz, ArC(2,6)H)(PhCN), 7.56 (overlapped 
m, ArC(3,5)H)(PhCN), 7.42 (t, 8.0 Hz. ArC(4)H)(PhCN); 7.67 (t, 8.4 Hz,
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ArC(4)H)(N=C-Ph), 7.52 (overlapped m, ArC(3,5) H)(N=C-Ph), and 8.27 (d, 8.4 Hz, 
ArC(2,6)H)(N=C-Ph).
‘^ C NMR (125.7 MHz, CDCI3) 8  (ppm); 46.9 (NMe), 92.8 (N-CH-N), 107.8 (C q, 
NsCPh), 117.2 (NsC), 123.2 (C q, N=CPh), 126.4, 128.2, 128.7 (ArC)(PhCH-N);
129.8 (C(3,5)H), 134.6 (C(2,6)H), 136.7 (C(4)H),(PhCN); 135.0 (C(4)H), 127.9
(C(2,4)H), 132.3 (C(1,6)H), (CHPh, N=CPh); 137.3, 138.1 (C q , CHPh), 173.2 (C=N). 
‘’’Pt NMR (107.3 MHz, CDCI3) 8  (ppm): -340.7 (750 Hz).
IR spectrum (selected bands), cm ': 2314 v(C=N), 1629, v(C=N).
MS-FAB, mJr. 676, [M]*, 639.5, [M-HCl], 572.0 [M-PhCN], 469 [M-2PhCN].
Anal. Calcd. for CizHigClqNsOPt: MW 678.29, C, 38.94; H, 2.82; N, 6.19. Found: C, 
33.95; H, 2.59; N, 5.18.
8.12.4. Chlorination of trnM5'-[PtCl2(4 -(2 -Me0 -C2H4 0 )-C6H4CN){N—C(4-(2-MeO-
C2H4O)-C6H4)-O-N(Me)-CH(Ph)}](60).
Characterisation is incomplete due to decomposition of the complex.
Formula: PtCltN3 0 3 C2 gH3 2 , M.W. 827.46,
'H NMR (500 MHz, CDCI3) 8  (ppm): 3.17 (s, 3H)(NMe), 3.46 (ovelapped m, 6 H)( 
MeO), 3.78 (overlapped m, 4 H)(OCH2), 4.17 (overlapped m, 4 H)(OCH2), 6 . 6 6  (s, 
1 H)(N-CH-N), 7.86 (d, 8.5 Hz, 2H)(PhCH-N), 7.35, 7.38, (overlapped m, 3H)(PhCH- 
N); 7.02(overlapped m, 2 H)(RO-C6H4 CN), 7.76,(d, 8.5 Hz, 2 H)(RO-CaH4 CN), 7.11 
(d, 8.4 Hz, 2 meta H)(N=C-C6H4 0 R) and 8.35 (d, 8.4 Hz, 2 ortho H)(N=C- 
CôHqOR).
'^C NMR (125.7 MHz, CDCh) 8  (ppm): 46.8 (NMe), 59.32 (MeO), 68.12, 70.42 
(OCH2), 92.7 (N-CH-N), 117.3 (NsC), 123.2 (Cq, N=CPh), 126.3, 136.8 (5C, 
ArCH)(PhCH-N), 138.5, 116.3 (4C, ArCH)(RO-C(iH4-CN), 117.3 (
ArC(3,5)H)(N=CC6H4-OR), 134.9 (ArC(2,6)H)(N=CC6H,-OR); 138.1 (C q , CHPh),
166.8 (C=N).
"”Pt NMR (107.3 MHz, CDCI3) 8  (ppm) -289.8 (750 Hz).
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8.13. Substitution reactions of [PtCl2 (PhCN){N=C(Pli)-0 -N(Me)-CH(Ph)}].
(These were carried out as described in the results and discussion)
A typical procedure for this reaction is;
[PtCl2 (PhCN){N=C(Ph)-0 -N(Me)-CH(Ph)}] (15 mg, 0.025 mmol) and dry pyridine 
(1.975 mg, 0.025 mmol) were placed in a NMR tube and solvated with dry deuterated 
chloroform (0.05 ml). This was left for four days at room temperature and then the 
proton NMR checked. This was consistent with the desired product. Over the next 48 
hours the product crystallised out in the tube, and X-ray diffraction confirmed the 
product.
8.13.1. Reaction of pyridine with rr<3 «5'-[PtCl2 (PhCN){N=C(Ph)-0 -N(Me)-CH(Ph)}].
?raw5-[PtCl2(Pyr'){N=C(Ph)-0-N(Me)-CH(Ph)}](61).
Analytical data:
Pale yellow crystalline solid, the yield is 77%.
Formula: PtCl2N3 0 C2oHi9 , MW 583.368.
'H NMR (500 MHz, CDCI3) ô (ppm): 3.07 (s, 3H, NMe), 6.03 (s, IH, N-CH-N), 7.67 
(m, ArC(4)H)(PhC=N), 7,59 (t, ArC(3,5)H)(N=C-Ph), 9.05 (d, 8.5 Hz, ArC(2,6) 
H)(N=C-Ph), 8.74 (d, 6 . 6  Hz, ArC(2,6)H)(pyr), 7.22 (t, 6 . 6  Hz, ArC(3,5)H )(pyr.), 
7.71 (m, ArC(4)H)(pyr), 7.45 (m, 3H )( PhCH-N) and 7.76 (d, 7.1 Hz, ArC(2,6)H) 
(PhCH-N).
‘^ C NMR (125.7 MHz, CDCI3) Ô (ppm): 46.4 (NMe), 95.0 ( N - C H - N ) ,  153.8 (2C of 
pyr.), 125.3 (2C of pyr.), 138.1 (ArC(4) of pyr.), 133.8 (ArC(4) of PhC=N), 128.8 
(ArC(3,5) of PhC=N), 130.9 (ArC(2,6) of PhC=N), 128.7 (ArC(2,6) of Ph), 129.8,
128.9 (3C of Ph), 122.8 (C q, ArC(l), N=C-Ph), 136.3 (C q , ArC(l), Ph), not seen 
(C = N ) .
'^^Pt NMR (107.3 MHz, CDCI3) Ô (ppm): -2023.1 (1070 Hz).
IR spectrum (selected bands), cm“ :^ 1450, 1348,1118, 692.5, 1625 v(C=N). 
MS-FABf m/r. 584.0 [M]f 547.0 [M -  HCljf 510.1 [ M - 2  H Clf, 481.1 [M -  
PhCN]\
X- ray crystal structure figure 76.
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8.13.2. Reaction of 4-dimethylaminopyridine (DMAP) with 
Zr««.y-[PtCl2 (PhCN){N=C(Ph)-0 -N(Me)-CH(Ph)}]. 
[PtCl2(DMAP)(N=C(Ph)-0-N(Me)-CH(Ph)}](62).
The procedme for this reaction is the same as for the pyridine substitution. The 
reaction mixture then undergoes column chromatography on silica using DCM as 
eluent which removes the main product as part of a mixture. The column is then 
eluted with DCM / methanol, 4/1 which renders the product below.
Analytical data;
Pale yellow crystalline solid, the yield is 27%.
Formula: PtCl2N4 0 C2 2H2 4 , MW 626.44
'H NMR (500 MHz, de-acetone) 6  (ppm): 2.95 (s, 6 H, N(Me)2), 3.05 (s, 3H, NMe), 
6.22 (s, IH, N-CH-N), 7.81 (t, 7.0 Hz, ArC(4)H)(N=C-Ph), 7.72 (t, 7.0 Hz, 
ArC(3,5)H)(N=C-Ph), 9,15 (d, 7.0 Hz, ArC(2,6)H)(N=C-Ph), 7.13 (d, 7.5 Hz, 
2H)(DMAP), 6.06 (d, 7.5 Hz, 2H )(DMAP), 7.37 (m, 3H )( PhCH-N) and 7.64 (d, 6.5 
Hz, ArC(2,6)H)(PhCH-N).
^^ C NMR (125.7 MHz, CDCI3) 6  (ppm): 47.0 (NMe), 39.0 (NMez), 95.2 (N-CH-N),
108.1 (2C of DMAP), 151.4 (2C of DMAP), 134.7 (ArC(4) of PhC=N), 128.0 
(ArC(3,5) of PhC=N), 129.8 (ArC(2,6) of PhC=N), 128.9 (ArC(2,6) of Ph), 130.16, 
130.18 (ArC(3,4,5) of Ph), possibly 134.9 (Cq, ArC(l) CHPh), 157.5 or 158.9 
possibly (C q  of DMAP) 162.6 (C=N), not seen (C q , ArC(l) N=CPh).
‘^ ^PtNMR (107.3 MHz, CDCI3) 6  (ppm): -2035.6.
IR spectrum (selected bands), cm~*: 1622 v(C=N), 1542, 1448, 1390, 1338, 1223, 
1205, 1162, 1121,1065, 1028.
MS-FAB^, m/z: 590.0 [M - HCl]f 553.0 [ M - 2  HCljf 547.0 [M - CsHsN]^ 523.0 
[M-PhCN], 503.0 [M-DMAP].
8.13.3. Reaction of DMSO with P’an5 -[PtCl2 (PhCN)(N=C(Ph)-0 -N(Me)-CH(Ph)}].
[PtCl2(PhCN)(N=C(Ph)-O-N(Me)-CH(Ph)}](30 mg, 0.05 mmol) and DMSO (3.8 mg,
0.05 mmol) were placed in an NMR tube with one drop of deuterated chloroform to 
solvate it, and left for four days at room temperature. After this time proton NMR and 
TLC showed a mixture of products. Column chromatography was carried out using
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initially DCM to remove the benzonitrile and unreacted mono oxadiazoline platinum 
complex. Then DCM / ethyl acetate in a 3/1 ratio was used to elute the products.
c/^-[PtCl2(DMS0){N=C(Ph)-0-N(Me)-CH(Ph)}](63).
Formula: CnHioNzOzSPtCb, MW 582.4. White crystalline solid, yield 71%,
‘H NMR (300 MHz, CDCI3) 5(ppm): 2.55, 2.75 (s+d, J^h-pi 20 Hz, 6 H, DMSO), 3.11 
(s, 3H, NMe), 6.10 (s, IH, N-CH-N), 7.50 (m, 3H)(PhCH-N), 7.61 (t, 7 . 8  Hz, 
ArC(4)H)(N=C-Ph), 7.70 (t, 7.2 Hz, AiC(3,5)H)(N=C-Ph), 7.86 (m,
ArC(2,6)H)(PhCH-N) and 8.72 (d, 7.8 Hz, ArC(2,6)H)(N=C-Ph),
»C NMR (125.7 MHz, CDCI3) 5 (ppm): 46.5 (NMe), 94.3 (N-CH-N), 123.7 (Cq. 
ArC(l))(N=CPh), 129.9, 130.3 and 134.1 (ArCH)(N=CPh), 128.8, 128.9 and 129.0 
(ArCH)(CHPh), 136.5 (ArC(l))(CHPh).
‘"^Pt NMR (107.3 MHz, CDCI3) B (ppm): -2967.1 (750 Hz).
IR spectrum (selected bands), cm"': 1633 v(C=N), 1494, 1450, 1406, 1353, 1313, 
1147, 1024, 777, 697.3,440.5.
MS-FAB*, m/z: 582.9 [M+H]*, 604.9 [M+Na]*, 546.0 [M-HCl]*, 510.0 [M-2HC1]*. 
P*an5-[PtCl2(d6-DMS0){N=C(Ph)-0-N(Me)-CH(Ph)}](64). This characterisation was 
obtained from experiment 1 in the results and discussion, where de-DMSO was used 
as solvent.
White crystalline solid, yield <10%. (not isolated)
NMR (300 MHz, CDCI3) ô (ppm): {(CD3 not seen, dg-DMSO), 3.09 (s, 3H, NMe), 
5.99 (s, IH, N-CH-N), 7.45 (m, 3H)(PhCH-N), 7.58 (m, ArC(4)H)(N=C-Ph), 7.70 
(rn, ArC(3,5)H)(N=C-Ph), 7.98 (m, ArC(2,6)H)(PhCH-N) and 8.69 (m, 2 ortho 
H)(N=C-Ph),
^^^PtNMR (107.3 MHz, CDCI3) 5 (ppm): -3058.3 (350Hz).
8.13.4. Reaction of triphenylphosphine with Pnm-[PtCl2 (PhCN)(N=C(Ph)-0-N(Me)- 
CH(Ph)}].
A typical procedure for this reaction is;
[PtCl2 (PhCN){N=C(Ph)-0 -N(Me)-CH(Ph)}] (15 mg, 0.025 mmol) and 
triphenylphosphine (6.55 mg, 0.025 mmol) were placed in a NMR tube and solvated 
with deuterated chloroform (0.05 ml). This was left for 10 minutes at room
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temperature and then the proton NMR checked. The desired product was not isolated 
due to further ligand exchange.
[PtCl2(P(Ph)3){N=C(Ph)-0-N(Me)-CH(Ph)}](65).
The initial product reaches maximum concentration in approximately 30 minutes. 
Exchanges then take place resulting in numerous products.
Analytical data:
Product not isolated
Formula: PtCl2N20PC33H29, MW 766.56
‘H NMR (500 MHz, CDCI3) 8  (ppm): 3.06 (s. 3H, NMe), 6.17 (s, IH, N-CH-N), 7.48 
(m, 3H)(CH-Ph), 7.78 (m, H)(CH-Ph), 7.06 (d, 7.5 Hz, AiC(2,6)H)(CH-Ph), 7.39 
(m, 6ArC(2,6 or 3,5)H of P(Ph)3), 6.95 (m, 6ArC(3,5, or 2,6)H of P(Ph)3), 7.59 (t, 7.0 
Hz, 3ArC(4)H of P(Ph)3), 7.72 (m, lH)(PhC=N), 7.55 (t, 7.3 Hz, AiC(3,5)H)(N=C- 
Ph) and 8.30 (d, 7.3 Hz, ArC(2,6)H)(PhC=N).
‘^ C NMR (125.7 MHz, CDCI3) 8  (ppm): 46.36 (NMe), 94.97 (N-CH-N), 153.8 (2C 
of tpp.), 125.3 (2C of P(Ph)3), 128.9 (1C ofP(Ph)3), 138.3 (ArC(4) ofPhC=N), 128.8 
(ArC(3,5) of PhC=N), 130.9 (ArC(2,6) of PhC=N), 128.7 (ArC(2,6) of PhCN),
129.8, 128.9 (3C of PhCN), 130.7,128.5, 132.4 (C,).
"^PtNMR (107.3 MHz. CDCI3) 8 (ppm): doublet, -3598, 'j'^^Pt-^'P, 3450 Hz, -2919 
and -3390, possibly PtC12(oxa)( P(Ph)3).
^‘P NMR (202.46 MHz, CDCI3) 8 (ppm): singlet, 3.83, doublet 3.83, ‘/ ‘P -"¥ t, 3450 
Hz, (cis complex, trans P(Ph)3 -Pt-Cl bond) 20.1, singlet, 20.1 doublet, P-'^^Pt, 
2632 Hz, (tra«s-PtCl2(P(Ph)3)2), singlet, 14.31, doublet 14.31, 'f'P-'^^Pt, 3665 Hz,
IR spectrum (selected bands), cm“^ 2229 v(CN)(free PhCN is 2232), 1664, 1436, 
1098, 910.1, 729.3, 692.1, 542.7, 515.7 and 499.6.
MS-FAB^, m/z\ 833.9 [PtCl(PhCN)(oxa)(P(Ph)3) ] \
8.13.5 Reaction of PtCl2 (oxa)(PhCN) with 2 -amino-1-methylimidazole.
Reaction did not go to completion and no product was isolated. The same procedure 
as the previous triphenylphosphine reaction was adopted.
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Figure 101. The proton NMR spectrum of the reaction of 2-amino-1 -methylimidazole 
with PtCl2(oxa)(PhCN).
8.14. Ruthenium benzonitrile complexes
8.14.1. Formula; [Ru(Cl) 2  (PhCN)4 ] (66).
Ruthenium trichloride hydrate (0.60 g, 2.3 mmol) was heated at 125 C in a mixture 
of methanol (2.5 cm^) and benzonitrile (10 cm^) for 42 hours. The yellow crystalline 
product can be filtered out and a second crop precipitated on addition of diethyl ether 
(30 ml).
Formula [C2 8 H2 0CI2N4 RU], MW 584.46, Yellow crystals 1.41g, yield 98%.
'H NMR spectrum in CDCI3 , ô (ppm): 7.97 (d, 7.2 Hz, 2H, PhCN), 7.57 (t, 7.2 Hz, 
H, PhCN), 7.47 (m, 7.2 Hz, 2H, PhCN).
IR, (KBr), selected band, cm'’ : 2242, v(CN).
MS-FAB, m/z: 585[M]% 548 [M- HC1]\ 445 [M- HCl-PhCN]\
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Appendix 1. Variable temperature N M R  spectra o f  PtBr2(oxa )2  
show ing sharpening o f  signals but no conformational change.
Pt Br2(oxa)2, 1H spectrum at 298K
\
PtBr2 (oxa)2  at 328K
PPM
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PtBr2(oxa) 2  at 403K
\
TT5T7TT PPM
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Appendix 2. The Mass FAB spectra of product 47 and the 
speculative product PtCI4N4O2C16H20
m s .;/ü tü ae# .-10 RT: 0.66-0 /6 AV; 4 NL. Z.OOLÙ 
T: + c FAB Full ms ( 199.50-2000.50)
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Figure 59. The MS-FAB spectrum of [PtCl2 {N=C(Ph)-0 -N(Me)-CH(p-H0 - 
C 6H 4)}2](47) .
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Figure 64. Mass spectrum of the reaction between rra«5 -[PtCl2 (PhCN)2 ] 
protonated derivative of 1 1 .
and the
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111 II 11 ! Il
5 5 0
Figm-e 102. A comparison of the isotopic pattern of two significant peaks from figures 
59 and 64 respectively, which contain the PtCl2N4 0 2  isotopic contribution.
Table 25. Comparison of the ^^ ^Pt NMR shifts and half height line-widths of various 
PtX2N2  complexes. (Ref. K2PtCU)
Complex Shift (ppm) Line-width (Hz)
r^a?25-PtCl2(nitrile)2* -2320 to -2370 500 - 1500
/ra«5-PtBr2(PhCN)2 -2860 750
/ra«5-Ptl2(PhCN)2 -3935 750
/ram-PtCl2 (nitrile)(oxa)^ -2210 to -2240 770 - 1300
trans-PtBr2(PhCN)(oxa) -2693 750
fr««.y-Ptl2 (PhCN)(oxa) -3695 750
v^3M.y-PtCl2(oxa)2* -2027 to -2140 775- 1100
/ra«5-PtBr2(oxa)2 -2523 1500
[Pt(NH3)4F -2575 1500
^Varying phenyl ring substituent.
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-2400 ppm
’Pt NMR spectrum (CDCI3 ) of the reaction of PtCl2 (PhCN )2  / 4-(Me)2N-C6H4-CH=N(Me)0
24002350230022002 1 0 02350
^^^Pt NMR spectrum (D2 O) of the reaction of PtCl2 (PhCN )2  / 4-(Me)3N"^-C6H4-CH=N(Me)0
As can be seen from the table, varying phenyl ring substituents can have a large effect 
of line-width whereas being coordinated to different halogens does not necessarily 
have an effect. Being coordinated to different nitrogen environments does not 
necessarily affect the line-width as can be seen for the ammonia complex compared to 
the others. Therefore there is no easy correlation between ligand and line-width.
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1Appendix 3. Plots testing for first and second order kinetics in DMSO 
substitution experiment 3.
An expansion of the kink in figure 74 (a) shows that over the first eight hours the 
reaction is not first order (figure 74 (b)), log A falling exponentially.
First eight hours of expL 3
1.99 
1.98 
<  1.97 
O 1.96 
-  1.95 
1.94 
1.93 
1.92
^ L o g  A
Time (hrs)
Figure 74 (b). DMSO expt. 3, plot of log A against time, first 8  hours.
To test for second order kinetics a plot of the reciprocal of the concentration of 
starting platinum complex against time was generated. To satisfy the requirement for 
second order, the plot should be a straight line. However this was found not to be the 
case as can be seen in figure 74 (c). Most likely what is going on is a mixture of 
mechanisms and the equimolar reaction does not solely follow first or second order 
kinetics. As the trans complex is only made when DMSO is in large excess, it can be 
concluded that the reaction producing this complex follows a first order type 
mechanism.
Expt.3: Requirement for second order kinetics.
♦0.011 - ♦ 1/C
0.0105 -
D 100 200 300 400 500 
Time (minutes)
Figure 74(c). Expt. 3: Plot of 1/C against time to test the requirement for second order 
kinetics.
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Appendix 4. The proposed hydrolysis product from the attempted 
substitution o f  PtC12(PhCN)(oxa) w ith pyridine.
PtCI2(PhCN)(oxa) / Pyridine substitution, proton NMR spectrum.
T 2PPM45670
= PtCh(pyr)(oxa) = PtCl2(oxa)(C6H 5C{OH)=NH)
The major product is possibly the structure on the right, but not excluding other 
solutions.
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